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1 General Introduction
1
 
Multidrug resistance (MDR) in cancer cells is the development of resistance to a variety of 
structurally and functionally non-related anticancer drugs. This phenomenon has become 
a major obstacle to cancer chemotherapy seriously affecting the clinical outcome. MDR is 
associated with increased drug efflux from cells mediated by an energy-dependent 
mechanism involving the ATP-binding cassette (ABC) transporters, mainly P-glycoprotein 
(P-gp, ABCB1), the multidrug resistance-associated protein-1 (MRP1, ABCC1) and the 
breast cancer resistance protein (BCRP, ABCG2). The first two transporters have been 
widely studied already and ABCG2 is subject of intense study since its discovery as its 
overexpression has been detected in resistant cell lines in numerous types of human 
cancers. To date, a long list of modulators of ABCG2 exists and continues to increase. 
However, little is known about the clinical consequences of ABCG2 modulation. This fact 
makes the design of novel, potent and non-toxic modulators of this efflux protein a major 
challenge to reverse multidrug resistance and thereby increase the success of 
chemotherapy. The aim of the present chapter is to describe and highlight specific 
ABCG2 modulators reported to date based on the selectivity of the compounds, as many 
of them are effective against one or more ABC transport proteins. 
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2 New Analogs of tariquidar 
 
 
 
1.1 Multidrug resistance phenomenon 
Chemotherapy is one of the most important cancer treatments. Unfortunately, most 
cancers are either resistant to chemotherapy or acquire resistance during treatment,1 
these phenomenon is known as multidrug resistance (MDR), defined as the cross-
resistance or insensitivity of cancer cells to numerous drugs which are often structurally or 
functionally unrelated (Figure 1-1).2,3 MDR is often the ultimate cause of failure of 
cytotoxic drugs in cancer chemotherapy. Many mechanisms of drug resistance, such as 
activation of detoxifying systems, evasion of the apoptotic control, changes in cellular 
repair mechanisms or activation of drug efflux pumps have been identified.4 Based on this 
knowledge, strategies to overcome drug resistance and to increase the efficacy of cancer 
chemotherapy have been developed. Thereby, the inhibition or modulation of cellular 
efflux pumps to reverse drug resistance has been subject of research for decades. 
Stimulated by the identification of the MDR1 gene,5 initially many clinical trials in cancer 
therapy focused on the ABCB1 transporter. P-gp expression was considered to be solely 
responsible for the phenomenon of MDR. However, during the last two decades it 
became clear that ABCB1 is not the only member of the ABC transporter family which is 
involved in the resistance against clinically relevant chemotherapeutics. After the 
discovery of MRP1 (ABCC1) and its affiliation to the ABC transporter family,6 additional 
proteins contributing to chemoresistance were identified, including the Breast Cancer 
Resistance Protein. 
MDR in cancer is caused by multiple mechanisms that operate either independently or in 
unison. Overexpression of drug transporters is just one of the many ways that cancer 
cells have adapted in order to survive the diversity of agents used in cancer 
chemotherapy.7 
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Figure 1-1 Multidrug Resistance Phenomenon. A. Schematic presentation of anticancer 
drug entry into a cancer cell via membrane. B Schematic presentation of the phenomenon 
of MDR in cancer cells (Adapted from Ullah, M. 20083) 
 
1.2 ABC transporter superfamily 
The ATP-binding cassette (ABC) transporter superfamily contains membrane-embedded 
proteins that are involved in the transport of a wide variety of substrates, such as 
cholesterol, peptides, drugs, toxins, bile salt, organic anions, nucleosides, iron, chloride 
ion and sterols across extra- and intracellular membranes.8,9 The intracellular 
concentration of endo- and exogenous substrates is limited by their active efflux through 
ATP binding and hydrolysis as supplier of energy. To date, 49 human ABC transporter 
members are known and classified into seven subfamilies (ABC-A to ABC-G). 
The ABC efflux pumps use the energy of ATP hydrolysis to transport a huge variety of 
molecules against the concentration gradient across biological membranes.10 In our 
cellular defense system, the location of ABC transporters in the gastrointestinal tract 
represents the first defense mechanism against numerous ingested xenobiotics. As this 
also includes numerous orally administered drugs, ABC proteins, especially P-gp, play a 
4 New Analogs of tariquidar 
 
 
 
major role in limiting the uptake and, thus, the bioavailability of drugs.11 ABC transporters 
are furthermore involved in limiting the access of various compounds to sensitive tissues 
like the testes, the placenta or the brain, thereby protecting these organs from toxic 
agents. Classically exemplified by ABCB1, ABCC1 and ABCG2, respectively, it became 
clear that these plasma membrane proteins are key players in protecting the organism 
from xenobiotics and toxins by preventing their uptake and procuring their elimination. 
From all the identified transporters, three are associated with multidrug resistance (MDR): 
P-glycoprotein (P-gp, ABCB1), the multidrug resistance-associated protein-1 (MRP-1, 
ABCC1) and the breast cancer resistance protein (BCRP, ABCG2) (Figure 1-2). 12-14 
 
Figure 1-2 Topology and domain arrangement of the ABC transporters ABCC1 (A), 
ABCG2 (B) and ABCB1 (C) (Adapted from Vautier et al.15) 
ABC transporters are considered as therapeutic targets to overcome MDR in tumor 
therapy16 and many efforts have been made to identify and develop modulators. Several 
reviews concerning the biochemical, and pharmacological aspects,14,17-20 as well as 
computational methods and models used to predict substrate properties of drug-like 
compounds21 and the discovery of reversal agents22-26 for ABCB1 and ABCC1 proteins 
have been published. In the last decade ABCG2/BCRP emerged as an important protein 
involved in multidrug resistance and the focus of MDR studies shifted to this protein. 
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1.3 Breast Cancer Resistance Protein (ABCG2) 
ABCG2 (ATP-binding cassette sub-family G member 2) was simultaneously discovered 
by three different groups in 1998, and is therefore known as ABCP for its identification in 
human placenta, BCRP for its isolation from the breast cancer cell line MCF-7/AdrVp and 
MXR for its identification in the mitoxantrone-resistant colon carcinoma cell line S1-M1-
80.12 The human ABCG2 protein is a half-transporter composed of 665 amino acids with a 
molecular weight of 72 kDa. Unlike other ABC transporters, ABCG2 is a half-transporter 
with a single nucleotide binding domain (NBD) and one membrane spanning domain 
(MSD) containing six transmembrane segments, which is supposed to form homodimers 
or homomultimers to become functional. Despite intensive research a high-resolution 
crystal structure has not been reported limiting a deeper insight into precise transport 
mechanisms.13,27-29 
Multiple physiological functions have been considered for ABCG2, but in general its tissue 
localization appears to play a protective role against various xenobiotics limiting their oral 
absorption.30-32 Studies have indicated that ABCG2 is a key player in preventing the 
absorption of toxic compounds from the gut, increase their hepatobiliary clearance, and 
protect the maternal–fetus, blood–brain and blood–testis barriers.33 High ABCG2 
expression has been found especially in the placenta and intestine, but also in the brain 
endothelium, prostate, testes, ovaries, liver, adrenal gland, uterus, and central nervous 
system.34 
Several evidences suggest that when the ABCG2 is overexpressed in cancer lines, 
contains a mutation in the glicine482 and this is a dominant factor for the resistance to 
various cytostatic agents, as many studies have demonstrated that this position is critical 
for the recognition of substrates by protein.35,1  
Functional characterization has demonstrated that ABCG2 transports a highly diverse 
range of substrates including methotrexate (MTX), mitoxantrone (MX) and many tyrosine 
kinase modulators, which were reported both as substrates and inhibitors of ABCG2. 
Furthermore, ABCG2 recognizes a broad variety of positively and negatively charged 
substances and is resistant to most topoisomerase I or II inhibitors such as topotecan or 
doxorubicin explaining failures of cancer therapy (Figure 1-3).36,37 
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Figure 1-3 Schematic molecular mechanism of substrate binding and ATP hydrolysis by 
ABC transporters  
1.4 ABCG2 modulators 
A modulator may be a compound that can act as an activator/substrate, an inhibitor, or 
both. Therefore, the term modulator will be used throughout the text instead of the term 
inhibitor, even though in some publications the term inhibitor was used. The term inhibitor 
should only be used when a compound was proven by a suitable assay, such as ATPase 
assay to act as a real inhibitor and is not transported itself. 
High overexpression of ABCG2 is observed in many tumor types, e.g. in melanoma, 
making it one of the major obstacles in the treatment of cancer.38 One of the main 
approaches avoiding MDR during chemotherapy is blocking of the functions of this ABC 
transporter. Suitable modulators for the transporter have been developed.32,39 However, it 
should be kept in mind that the mutual blocking of ABCG2 transporter function in 
malignant cells and of endogenous ABCG2 in healthy cells can lead to side effects such 
as increased toxicity caused by ABCG2 substrates.30,40 In addition, as ABC transporters 
play a major role as a detoxification and protection system for the human body, blocking 
of the efflux function has the risk of provoking serious side effects, as the inhibition will not 
only occur in cancer cells but also in tissues where a normal ABC function is desired. In 
severe diseases like glioblastoma side effects of an effective therapy may be acceptable, 
in other cases however, the use and risks must be considered carefully. Moreover, 
inhibition of an ABC transporter will not only impede the efflux of its substrate drugs, but 
also alter their distribution. This may cause drug-drug interactions. 
New Analogs of tariquidar 7 
 
The main clinical implications of specific ABCG2 modulators are their potential to act as 
multidrug reversal agents affecting the ADME (absorption, distribution, metabolism, 
excretion) properties of its substrates.41 The ideal ABCG2 modulator should antagonize 
the drug efflux activity even at nanomolar concentrations, be completely selective for 
ABCG2 with no or little inherent toxicity. Furthermore, selective modulators are of 
importance as pharmacological tools to identify possible binding sites and examine the 
ABCG2 mediated MDR at a molecular level. The mechanism of transport is not 
completely understood until now. Modulators may alter the efflux activity in many different 
ways, e.g. through specific interactions with the protein or by behaving as a "poor", very 
slowly transported substrate blocking the efflux function for other substrates. Other 
possibilities are the interaction with the ATP-binding site affecting the binding of ATP 
depending on intracellular ATP levels. Interaction with the the membrane phospholipids 
can increase the membrane permeability for ions reducing the activity of the transporter. 
Several types of ABCG2 modulators, such as chemotherapy drugs, tyrosine kinase 
inhibitors, antivirals, carcinogens and flavonoids were reported recently. Unfortunately, 
very few compounds have shown promising results in preclinical trials.28,42-45 The aim of 
the present chapter is to describe and highlight specific ABCG2 modulators reported to 
date based on the selectivity of the compounds, as many of them are effective against 
one or more ABC transport proteins. 
1.4.1 Acrylonitriles 
 
In 2011, two acrylonitriles, YHO-13177 (1) and its water-soluble diethylaminoacetate 
prodrug YHO-13351 (2) were reported as reversal agents of ABCG2-mediated drug 
resistance, both in vitro (1) and in vivo (2, Figure 1-4).46 Acrylonitrile 1 was able to reverse 
resistance to the ABCG2 substrates SN-38, which is the active metabolite of irinotecan, 
mitoxantrone (MX) and topotecan in ABCG2-transduced cells HCT116/ABCG2 and cells 
that acquired resistance to SN-38 mediated by ABCG2 (A549/SN4), whereas little or no 
effect was observed in the parental cells. The concentration of 1 producing a half-maximal 
reversal of the drug resistance was within a range of 0.01 to 0.1 µM. No effect on ABCB1-
mediated resistance to paclitaxel in ABCB1-transduced K562 cells and ABCC1-mediated 
resistance to doxorubicin in ABCC1-transfected KB-3-1 cells was observed. Also, a 
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cytotoxic effect of 1 itself on the cancer cells was not observed. The authors investigated 
the underlying mechanism of reversal of drug resistance and suggested that 1 is involved 
in a posttranscriptional downregulation of ABCG2 and inhibits the drug transport function. 
However, further studies are needed for elucidating the exact mode of action. The water-
soluble prodrug 2 was used for in vivo studies in mice. Co-administration of irinotecan 
(30 mg/kg) with 100 or 200 mg/kg of 2 significantly increased the survival time in a dose-
dependent manner. In a pharmacokinetic study, co-administration of 30 mg/kg of 2 (i.v.) in 
mice increased AUC0-∞ (total drug exposure over time) values of irinotecan in 1.4-fold and 
for SN-38 in 1.6-fold compared with 45 mg/kg irinotecan (in vivo) alone. 
 
Figure 1-4 Acrylonitriles 
 
1.4.2 Anti HIV-Based Modulators 
Human immunodeficiency virus (HIV) can be controlled by the administration of three to 
four antiretroviral drugs from different classes acting on different viral targets. This is 
known as highly active antiretroviral therapy (HAART). The antiretroviral agents are HIV-
protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase 
inhibitors (NtRTIs).47 Some investigations indicated that drugs used for the treatment of 
human immunodeficiency virus (HIV) might also interact with ABCG248,49 as shown by Kis 
et al.50 This study, performed with HIV-negative healthy volunteers, ART-naïve HIV+, and 
HIV+ subjects receiving ART, showed that a lower expression of ABCC2 was found in 
ART-naïve subjects compared to control, while CYP3A4 and ABCG2 showed a trend 
towards decreased expression. In addition, the protein expression of ABCC2 and ABCG2 
was also significantly lower in HIV+ naïve group compared to control and was partially 
restored to baseline levels in HIV+ subjects receiving ART. 
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In 2007, Weiss et al. evaluated the influence of several anti-HIV drugs on ABCG2 activity 
in vitro. ABCG2 inhibition was estimated by measuring the increase of the ABCG2 
substrate pheophorbide A (PhA) accumulation in MDCKII-ABCG2 cells using 
fumitremorgin C (FTC, 82, 10 µM) as reference compound (IC50 0.47 µM). The PIs 
lopinavir (3), nelfinavir (4), delavirdine (5), efavirenz (6) and saquinavir (7, Figure 1-5) 
showed potent ABCG2 inhibitory activity with values of 7.66 µM, 13.5 µM, 18.7 µM, 
20.6 µM and 27.4 µM, respectively. The NNRTI nevirapine and NRTI/NtRTI zidovudine 
showed low inhibition whereas PI indinavir and NRTIs/NtRTIs didanosine, emtricitabine, 
lamivudine, stavudine, tenofovir and zalcitabine had no inhibitory effect.47 Also, Peroni et 
al. investigated how the intestinal permeability of efavirenz (6) was modulated by ABCG2. 
Antiretroviral 6 was shown to be transported by ABCG2, but not by ABCB1. Moreover, 
after repeated oral administration increasing protein levels of ABCG2 were found in the 
intestinal epithelium.49 A study by Neumanova et al. in 2016 investigated the influence of 
MDR-associated transporters on the distribution of zidovudine and lamuvidine by an in 
vitro bidirectional transport study and concentration equilibrium assays on cell 
monolayers.51 The established MDCKII cell line was used with overexpressing ABCG2, 
ABCB1, ABCC2 or ABCC5. Consistent with the study performed by Weiss et al., 
lamuvidine was found to have zero interactions with these transporters. In contrast to the 
previous study, zidovudine (8, Figure 1-5), also known as zidothymidine (AZT), was 
reported to be a substrate of both ABCB1 and ABCG2, but not ABCC2 or ABCC5 and its 
transport was shown to be blocked upon addition of the dual ABCB1/ABCG2 modulator 
elacridar (129, 2 µM).  
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Figure 1-5 Anti HIV-based modulators 
1.4.3 Flavonoids and Chromone Derivatives 
Flavonoids comprise a large class of polyphenolic compounds, and are integral 
components in our common diet as they are ubiquitously present in plants. Several 
studies have indicated that flavonoids may play a protective role in the prevention of 
cancer, coronary heart diseases, bone loss and also have anti-allergic, antioxidant,52,53 
antibacterial,54 antiviral55 and anti-inflammatory56 properties.57 Due to the health beneficial 
activities and low toxicity, hundreds of herbal preparations containing flavonoids are 
available as dietary supplements. The consumption of these products is becoming more 
and more widespread, along with the burgeoning public interest in alternative medicine 
and in disease prevention. Therefore, their interaction with ABCG2 has to be taken into 
consideration as pharmacokinetics of drugs being ABCG2 substrates may be drastically 
altered. On the other hand, flavonoids may have potential as multidrug reversal agents. 
1.4.3.1 Aurones 
Aurones are flavonoid-type heterocyclic compounds found in plants and contribute to the 
pigmentation of some flowers and fruits. As aurones are structurally related to flavones it 
does not come as a surprise that this compound class is now increasingly investigated by 
researchers for their therapeutic values.58,59 
A series of 4,6-dimethoxyaurones was evaluated for their potential to modulate ABCG2 by 
increasing the accumulation of mitoxantrone in MDA-MB-231 cells transfected with 
ABCG2. Ten aurones (9–18, Figure 1-6) were effective at a concentration of 0.5 µM 
compared to the reference compound FTC (82) at 10 µM. The effect of the same 
compounds at higher concentration (10 µM) on the accumulation of calcein-AM in 
MDCKII/ABCB1 cells was also investigated and none of the aurones were considerably 
better than the ABCB1 modulator verapamil, which shows a preference of the studied 
compounds for ABCG2 inhibition.60,61 In a more recent report the same authors identified 
three new derivatives: trimethoxyaurone (19), indanone (20), and azaaurone (21, Figure 
1-6), which were clearly selective for ABCG2. These compounds exhibited EC50PhA values 
(test compound concentration required to increase the accumulation of PhA to 50% of 
maximum levels obtained with 10 µM FTC, 82) of 5.42 ± 0.24 µM, 1.76±0.19 µM and 
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4.61±0.25 µM, respectively in the PhA accumulation assay using ABCG2-overexpressing 
MDA-MB-231 cells.62 
 
Figure 1-6 Aurones 
1.4.3.2 Chalcones 
Different types of chalcones, which are intermediates of flavonoid biosynthesis in plants, 
are modulators of the multidrug resistance-associated transporter ABCB1.63,64 Han et al. 
investigated 17 non-basic chalcone analogues for their ABCG2-modulating properties.65 
Chalcones 22–24 (Figure 1-7) with 2,4-dimethoxy groups or 2,4-dihydroxyl groups on ring 
A were found to increase mitoxantrone accumulation to a greater extent than FTC (82, 
10 µM) at a concentration of 5 µM with no significant effect on ABCB1. However, the 
authors stated that ABCC1 and ABCC2 may be possible targets of these compound 
classes, which has to be further investigated. It was clearly observed that among all 
chalcones, compounds with 2,4-dimethoxy substituents at ring A were most active. 
Different substituents on the A-ring appeared to be required for inhibiting ABCG2, but the 
inhibition was rather low due to inadequate substitutions in both rings A and B. 
In 2012 a series of 44 chalcones and 1,3-diarylpropenones was investigated for inhibition 
of ABCG2-mediated mitoxantrone transport. Elacridar (129, 5 µM) was used as a control 
(100% inhibition). The best compounds were 25 (2 µM, 130.7%) and 26 (2 µM, 103.5%, 
Figure 1-7), showing potent inhibition of ABCG2 and low toxicity. In general, methoxy 
groups at positions 3, 4, and 5 of the ring B increase the cytotoxicity markedly and  should 
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be therefore avoided. Chalcones and indoylphenylpropenones are promising leads as 
modulators of ABCG2. The easy chemical syntheis of such compounds and their high 
activity and specificity are important prerequisites for preclinical trials.66 Wiese et al. 
investigated in 2012 chalcones and benzochalcones with different substituents on ring A 
and B using the Hoechst 33342 accumulation assay. The inhibitory activity was tested in 
MCF-7/MX and MDCK/ABCG2-expressing cells. The authors also tested the compounds 
for inhibition of ABCB1 and ABCC1. Substituents at position 2´ and 4´ on ring A were 
found to be crucial for the activity, whereas substituents on ring B were changing the 
activity. 3,4-Dimethoxy substitution on ring B and to a smaller extent, 2-and 4-chloro 
substitution improve ABCG2 inhibition. Compounds 27 (IC50 0.85 µM) and 28 (IC50 
0.53 µM, Figure 1-7) were found to be most potent with an activity threefold smaller 
compared to the reference compound Ko143 (85, IC50 0.26 µM).
67 
Two years later, a series of quinoxaline-substituted chalcones as modulators of ABCG2-
mediated mitoxantrone efflux was designed, synthesized and evaluated. The IC50 values 
were determined comparing each quinoxaline-containing compound with the 
corresponding compounds containing either a 2-naphthyl or a 3,4-methylenedioxyphenyl 
moiety. Compounds 29–34 (Figure 1-7) have a quinoxaline attached to ring B of the 
chalcone and showed the smallest IC50 values, 1.7, 1.9, 1.4, 2.2, 1.4, 2.1 µM, 
respectively, in comparison to compounds 35–40 (Figure 1-7) with 2-naphtyl attached to 
ring B (IC50 17.0, 4.1, 11.2, 2.5, 23.3 µM, respectively) and compounds 41–46 (Figure 
1-7) with 3,4-methylenedioxyphenyl substituent (IC50 5.6, 3.5, 6.1, 0.94 µM, respectively). 
This allowed the identification of three characteristic structure–activity relationship (SAR) 
parameters for ABCG2 drug-efflux activity. First, the high efficiency of the new 
quinoxaline- and 1-naphthyl derivatives compared to that of 3,4-methylenedioxyphenyl- 
and 2-naphthyl-containing chalcones at the B-ring position; second, at least two methoxy 
groups on the phenyl A-ring (through both electrostatic and steric contributions) are 
required, while a bicyclic unit occupying the B-ring position provides maximal inhibition 
and third, a higher potency can be reached by shifting the bicyclic unit to the A-ring and 
methoxy substituents to the phenyl B-ring.68,69  
In 2016 Wiese et al. reported heterodimeric modulators of ABCG2 by combining chalcone 
and quinazoline scaffolds, which were both found to be inhibitors of ABCG2. A series of 
22 compounds was synthesized and tested for inhibition, specificity and cytotoxicity.70 The 
most potent compound of the series (47, Figure 1-7) has a IC50 value of 0.19 µM, low 
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cytotoxicity and is almost ABCG2 selective, whereas other compounds were dual 
ABCB1/ABCG2 modulators or even less active at ABCG2 than ABCB1.70 
 
Figure 1-7 Chalcones 
1.4.3.3 Chromones 
Chromones (1,4-benzopyrones) are natural compounds with a partial structure of 
flavonoids. Since flavonoids were earlier described as modulators with poor selectivity 
toward ABCG2, it was hypothesized that higher potency and selectivity could be achieved 
by maintaining the chromone skeleton and replacing the B-ring of flavonoids with a 
chemical motif found in other ABCG2 modulators.28 
In 2005, 14 benzopyrane (chromone) derivatives were evaluated for their effect on the 
accumulation and the cytotoxicity of the anticancer drug mitoxantrone. At 10 µM, 
phenylalkylamine linked chromones 48 and 49 (Figure 1-8) increased both intracellular 
accumulation and cytotoxicity of mitoxantrone in HCT116/R cells with a comparable rate 
as FTC (82) and imatinib mesylate (160) used as reference compounds. Lack of 
cytotoxicity as well as their interesting chemosensitizing properties make these 
compounds good candidates for in vivo studies.71 
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In 2012, Valdameri et al. synthesized a series of 13 substituted chromones and analyzed 
them for their ability to inhibit ABCG2-mediated mitoxantrone efflux from transfected 
HEK293 cells. The percentage of inhibition was determined by flow cytometry, relative to 
elacridar (129, 5 µM) as a control. The best compounds of this series were compound 50 
(IC50 0.11 µM, Figure 1-8), 51 (IC50 0.16 µM, Figure 1-8) and 52 (IC50 0.17 µM, Figure 
1-8).72,73 Compound 52 was also synthesized by another group as a reference compound 
due to its structural similarity to flavonoid derivatives being selective ABCC1 modulators.74 
Interestingly, the potency of compound 52 determined with MCF-7/Topo cells (IC50 
1.8 µM, Imax 108%, Hoechst 33342 assay, FTC, 82 was used as reference at 10 µM) was 
tenfold lower than reported for the transfected HEK293 cells. The authors stated that the 
compound is selective for ABCG2, but mentioned that compound 52 stimulates ABCB1 
mediated drug efflux activity at high concentrations. The results demonstrate that the data 
for potency of some modulators may dependent on the assay system and the reference 
compounds used, complicating direct comparison. 
 
Figure 1-8 Chromones 
1.4.3.4 Flavones, Isoflavones, Flavanones, Flavonols and 
Rotenoids 
A first study on the ABCG2-mediated transport performed with five flavonoids (quercetin, 
hesperetin, silymarin and daidzein, and the stilbenoid resveratrol) showed that all 
polyphenols (each at 30 µM) significantly increased the accumulation of the ABCG2 
substrates mitoxantrone and bodipy-FL-prazosin in the ABCG2-overexpressing cell lines 
MCF7/MR and K562/BCRP as measured by flow cytometry. Hesperetin (69) exhibited the 
highest ABCG2 inhibitory activity (30 µM, Figure 1-9), and was comparable to that 
produced by the reference ABCG2 modulator Ko143 (85) at 10 µM.57 In the same year, 
the effect of 20 flavonoids on the accumulation and cytotoxicity of mitoxantrone in 
ABCG2-overexpressing human breast cancer cells (MCF-7/MX100) and large cell lung 
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carcinoma cells (NCI-H460 MX20) were investigated. The flavonoids apigenin (53), 
biochanin A (65), chrysin (55), genistein (64), hesperetin (69), kaempferol (72), naringenin 
(67), and silymarin (each at 50 µM, Figure 1-9) were shown to modulate ABCG2 in such a 
manner, that a threefold increase in accumulation of mitoxantrone was observed in both 
cell lines. The effect was similar to FTC (82) at 10 µM. The flavonoids daidzein (66), 
fisetin (70, Figure 1-9), phloretin, quercetin and silibin were able to produce a twofold 
increase. Chrysin (55) and biochanin A (65) were the most potent modulators producing 
significant increases in mitoxantrone accumulation at concentrations as low as 0.5 or 
1.0 µM and in mitoxantrone cytotoxicity at a concentration as low as 2.5 µM.75 However, 
oral co-administration of neither chrysin nor 7,8-benzoflavone had a significant effect on 
the accumulation of the ABCG2 substrate topotecan in rats or in mdr1a/1b (‒/‒) mice. The 
authors attributed this in vitro - in vivo discrepancy to the poor inhibition activity of the 
investigated flavonoids against mouse or rat ABCG2 (Abcg2).76 
The analysis of the combined effects of apigenin (53), biochanin A (65), chrysin (55), 
genistein (64), kaempferol (72), hesperetin (69), naringenin (67), and silymarin on the 
mitoxantrone accumulation in MCF-7/MX100 cells overexpressing ABCG2 indicated that 
the ABCG2 inhibition is additive when different flavonoid combinations with equimolar 
concentrations are given.77 Imai et al. evaluated the effects of phytoestrogens, which are 
similar to estrogen in their structure and/or function and other flavonoids in ABCG2-
mediated MDR.78 It was found that genistein (64) and naringenin (67, Figure 1-9) are 
potent ABCG2 modulators at a concentration of 3 µM on drug resistant K562/ABCG2 
cells and the cytotoxicity of anticancer drugs SN-38 and mitoxantrone was potentiated. 
This effect was also observed with acacetin (54) and kaempferol (72) while some 
glycosylated flavonoids displayed moderate reversal activity. Naringenin-7-glucoside (68) 
and luteolin-4’-O-glucoside (59, Figure 1-9) were the most potent glycosylated flavonoids 
and might be useful due to their high water solubility. Studies of transcellular transport of 
[3H]-genistein using LLC/ABCG2 cells suggest that the inhibition by genistein (64) is 
caused by competitive transport of this compound by ABCG2. 
Structure–activity relationship (SAR) and quantitative–structure activity relationship 
(QSAR) studies of 25 flavonoids were performed by Zhang and co-workers in order to 
derive a model for flavonoid-ABCG2 interaction.79 The presence of a 2,3-double bond in 
ring C, attachment of ring B to position 2, hydroxylation at position 5, lack of hydroxylation 
at position 3 and hydrophobic substituents at positions 6, 7, 8 or 4´ appear to be the 
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structural requirements for inhibiting ABCG2. A planar conformation may improve the 
binding of the respective flavonoid to ABCG2. In the same year a flavonoid SAR study led 
to the identification of 6-prenylchrysin (60) and tectochrysin (61, Figure 1-9) as potent and 
specific modulators of ABCG2.80 Comparison between flavonoids containing three 
hydroxyl groups using ABCG2-transfected wild-type HEK293-R482 and mutant HEK293-
T482 cells indicated that the flavone apigenin (53) was more efficient (IC50 16 µM) than 
the flavonol galangin (71, IC50 19 µM) and isoflavone genistein (64, IC50 24 µM). The least 
efficient compound was the flavanone naringenin (63, IC50 37 µM). As apigenin (53) was 
the most active compound, the effect produced by the position of hydroxyl groups and 
hydrophobic substituents on the flavone skeleton was evaluated An OH group at position 
5 and C-isoprenylation at position 6 yields the most active compound. The potency of 6-
prenylchrysin was comparable with that of GF120918/elacridar (129, IC50 0.3 µM). 
In a more recent study the interactions between ABCG2 and 56 dietary phytochemicals, 
including 33 flavonoids were examined using cell- and membrane-based methods. In the 
first assay, test compounds at a concentration of 50 µM were investigated for their ability 
to diminish the efflux of mitoxantrone using HEK293/ABCG2 cells, and except for 
anthocyanins (cyanidin 3-glucoside, cyanidin 3-rutinoside, delphinidin 3-glucoside, 
delphinidin 3-rutinoside), flavanols (+)-catechin and (‒)-epicatechin, hesperidin, morin, 
myricetin and tricetin, all of the tested flavonoids showed increased values of 
mitoxantrone accumulation. Next, the effect of the phytochemicals on the transport of the 
tritiated ABCG2 substrate methotrexate (MTX-3H) into Sf9/ABCG2 membrane vesicles at 
5 and 50 µM was evaluated. Consistent with the cell-based mitoxantrone accumulation 
assay most flavonoids inhibited the transport of methotrexate at both concentrations. (+)-
Catechin showed no effect at both concentrations, while the anthocyanins and (‒)-
epicatechin were only effective at 50 µM. The effect of many flavonoids at 50 µM was 
comparable to 1 µM Ko143 (85). IC50 values were determined for compounds exhibiting a 
significant inhibition of methotrexate transport, and seven flavonoids (apigenin (53), 
chrysoeriol (56), diosmetin (57), kaempferol (72), myricetin 3’,4’,5’-trimethylether (76), 
tamarixetin (78) and tricetin 3’,4’,5’-trimethylether (63, Figure 1-9), were found to have 
IC50 values below 0.1 µM and in the same range as the reference compound Ko143 
(0.026 ± 0.003 µM). Compounds acacetin (54), chrysin (55), kaempferide (73), laricitrin 
(74), luteolin (58), myricetin (75), quercetin (77), tricetin (62, Figure 1-9) showed IC50 
values below 0.5 µM.81 
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Figure 1-9 Flavonoids 
Inhibition of the ABCG2-mediated efflux by rotenoids isolated from roots of Boerhaavia 
diffusa (Nyctaginaceae) was investigated by flow cytometry using ABCG2-transfected 
HEK293-R482 cells.82 From the eleven isoflavonoid derivatives studied, boeravinones G 
(79) and H (80, Figure 1-10) efficiently inhibit the efflux of mitoxantrone at a concentration 
of 5 µM with IC50 values of 0.7 ± 0.07 µM and 2.5 ± 0.47 µM, respectively. The effect of 
boeravinone G was comparable to elacridar (129, 5 µM). The other nine rotenoid 
derivatives were less effective and higher concentrations were needed to achieve 
inhibition. A SAR study performed with these compounds showed the positive effect of a 
methoxy group at position 6, a double bond between ring B and C (6a and 12a positions) 
and the absence of substituents at position 10. Tetrasubstitution of ring D and contraction 
of ring B are unfavourable. 
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Figure 1-10 Rotenoids 
In 2011 Pick et al. analyzed a structurally diverse set of flavonoids.83 The activities of 31 
compounds were evaluated by structure‒activity relationships based on 2D and 3D-
QSAR analyses revealing the influence of the different substituents at the various 
positions. The authors were able to identify some structural features positively 
contributing to the inhibition of ABCG2: a hydroxyl group in position 5, a double bond 
between 2 and 3 and a methoxy moiety in position 3, whereas an OH-group in the same 
position diminished the inhibitory activity, which indicates the importance of a hydrogen 
bond acceptor in this position (Figure 1-11). 
 
Figure 1-11 Overview of structural features influencing the inhibition of ABCG2 by 
flavonoids (green illustrates a positive contribution, red a negative contribution to the 
inhibitory potency) 
Two years later, Juvale et al. synthesized a series of flavones, 7,8-benzoflavones and 5,6 
benzoflavones with varying substituents at positions 3,3′ and 4′.84 The synthesized 
(benzo)flavones were evaluated for their ABCG2 inhibition properties in both Hoechst 
33342 and PhA accumulation assays and further screened for their inhibitory activity 
towards ABCB1 and ABCB1 by a calcein AM accumulation assay. Compound 81 was 
found to be the most potent of this series (Figure 1-12). 
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Figure 1-12 Flavones, 7,8-benzoflavones and 5,6-benzoflavones 
1.4.4 Fumitremorgin C (FTC) Analogues 
Fumitremorgin C (FTC, 82, Figure 1-13) is a prenylated indole alkaloid isolated from 
Aspergillus fumigates, which has been described as a potent and selective ABCG2 
modulator. However, its adverse neurotoxic effects including tremors and convulsion in 
mice, prevent its safe use in patients.85-87 
To improve the specificity and selectivity of 82 while eliminating the potential for toxicity, a 
panel of 42 mixtures of diastereoisomers was screened for ABCG2 inhibitory activity on 
mitoxantrone accumulation and compared with elacridar (129). To demonstrate the 
functional comparability of human ABCG2 and mouse homologue Abcg2, assays were 
performed on the T6400 mouse as well as the human T8 cell line. The purified 
diastereoisomers (3S, 6S configuration) Ko132 (83) and Ko134 (84, Figure 1-13) showed 
a mitoxantrone accumulation (at a concentration of 1 µM) in T6400 cell line comparable to 
elacridar (129) and therefore constitute interesting leads for further development.88 
In 2002, Schinkel et al. evaluated a new tetracyclic analogue of FTC (Ko143, 85, Figure 
1-13) as a modulator of ABCG2. The diketopiperazine analogue was compared with two 
FTC derivatives (83 and 84) and elacridar (129) by increased cellular mitoxantrone 
accumulation in the mouse MEF3.8/T6400 fibroblast cell line. Ko143 (EC90 23 nM) is a 
more specific inhibitor of ABCG2 than other known inhibitors of ABCG2 such as elacridar 
(129, EC90 51 nM). More importantly, Ko143 is nontoxic at effective in vitro and in vivo 
concentrations, which makes it one of the most promising compounds for the 
development of clinical modulators of ABCG2-mediated efflux and appears to be the most 
potent ABCG2 inhibitor known thus far.89,90 However, it was recently reported that Ko143 
is also targeting ABCB1 and ABCC1 at concentrations higher than 1 µM. An ATPase 
20 New Analogs of tariquidar 
 
 
 
assay was used to monitor the activity of ABCG2 and ABCB1 ATPase in the presence of 
Ko143. The ATPase activity of ABCG2 was found to be lower in presence of Ko143, while 
the ATPase activity of ABCB1 was stimulated. Moreover, the compound lacks stability in 
rat plasma due to the rapid hydrolysis of the tert-butyl ester moiety. When Ko143 was 
incubated together with NaF acting as an esterase inhibitor, no metabolism product was 
detected. The authors also investigated the inhibition properties of the synthesized 
hydrolysis product of Ko143 (86, Figure 1-13) showing that the inhibitory effect is only 
induced by Ko143 and not by its hydrolytic metabolite. 91 
In 2007, Wu et al. reported a new class of FTC analogues with simplified structure. 
Doxorubicin was used as ABCG2 substrate to evaluate the effect of the compounds on 
the chemosensitivity in ABCG2-overexpressing MES-SA/Dx5 cells. Compared with 
doxorubicin (IC50 1.55 µM), compounds 87–91 (IC50 0.86, 0.75, 0.80, 0.82 and 0.66 µM, 
respectively, Figure 1-13) significantly reversed the ABCG2-mediated resistance to 
doxorubicin. Compared with the native pentacyclic FTC (82), the new simplified FTC 
analogues developed in these studies retain the tetracyclic core of 82, but were 
accessible in only four steps with high purity of the diastereomers and good yields.90,92 
In 2016, Wiese et al. synthesized and tested 37 tricyclic tetrahydro-ß-carboline 
derivatives. Ko143 (85), FTC (82) and harmine (106) are modulators of ABCG2 and also 
contain a tetrahydro-ß-carboline or ß-carboline moiety.93 Two compounds (92 and 93, 
Figure 1-13) of this series have a comparable inhibitory activity to Ko143 (85) .94 The 
inhibitory effect was investigated in a Hoechst 33342 and a PhA accumulation assay 
using the MDCKII/ABCG2 cell line. Compound 92 had an IC50 value of 0.233 ± 0.044 µM 
in the Hoechst 33342 assay and an IC50 value of 0.237 ± 0.080 µM in the PhA assay, 
respectively. Shifting the methoxy moiety from the 4 to the 3-position (93) resulted in IC50 
values of 0.238 ± 0.044 µM (Hoechst 33342 assay) and 0.206 ± 0.025 µM (PhA assay), 
respectively. Ko143 (85) was used as positive control (IC50 0.221 ± 0.024 µM, Hoechst 
33342 assay). Both compounds were selective for ABCG2 and compared to Ko143 (85) 
easily accessible in a two-step synthesis starting from tryptamine. 
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Figure 1-13 FTC analogues 
 
1.4.5 Natural Product Derivatives 
Natural products and their derivatives are a rich sources of novel therapeutics. The 
majority of current cancer chemotherapeutics was derived from natural products. Many of 
the reported ABCG2 modulators are natural products or natural product related 
compounds.95,96 
1.4.5.1 Antibiotics 
Novobiocin (94, Figure 1-14) is an aminocoumarin prokaryotic enzyme gyrase inhibitor 
produced by the actinomycete Streptomyces niveus.97 In 2004 it was shown that antibiotic 
94 was effective in the reversal of drug resistance in cancer cells with various levels of 
ABCG2 mRNA expression and increased the intracellular accumulation of the ABCG2 
substrate topotecan in non-cytotoxic concentrations. For example, at a concentration of 
60 µM, 94 decreased the degree of topotecan resistance (from 141- to 5.42-fold in PC-
6/SN2-5H2 cells), SN-38 resistance (from 173-to 4-fold) and of mitoxantrone resistance 
(from 57.2- to 1.63-fold). Shiozawa et al. identified 94 as a competitive inhibitor by 
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studying topotecan transport using plasma membrane vesicles derived from ABCG2-
overexpressing cancer cells.97 
Three years later, Sinko et al. demonstrated that 94 significantly inhibits the activity of 
ABCG2, but not of ABCB1.98 They also investigated the influence of 94 (50 mg/kg) on the 
orally-dosed topotecan (2 mg/kg) in vivo pharmacokinetic in rats. Co-administration 
significantly increased the peak plasma concentration of topotecan by 3-fold. 
 
Figure 1-14 Antibiotics 
1.4.5.2 Curcuminoids 
Curcumin (or diferuloylmethane) is a polyphenol found in the rhizomes of the plant 
Curcuma longa (turmeric) and known for its antitumor, antioxidant, antiarthritic, anti-
amyloid and anti-inflammatory properties.99 Curcumin was shown to interact with the 
transporter with very high affinity and reverses ABCG2-mediated drug resistance.100 
Ambudkar et al. evaluated the ability to modulate the function of the ABCG2 transporter in 
the cellular mitoxantrone accumulation of three purified curcuminoids found in turmeric 
powder, which are curcumin (curcumin I, 95), demethoxycurcumin (curcumin II, 96), and 
bisdemethoxycurcumin (curcumin III, 97). The curcuminoids 95-97 (Curcumin I; IC50 
2.2 nM, II IC50 2.5 nM and III IC50 1.9 nM, Figure 1-15) inhibited the transport of the 
substrates from ABCG2-expressing cells and the maximal inhibition was comparable with 
5 µM FTC (82, IC50 2.1 nM). These findings suggest that curcuminoids may play an 
important role in clinical therapy and the simultaneous administration of recommended 
therapeutic doses of curcuminoids with anticancer drugs would probably result in an 
increased bioavailability of the drugs inside the cells. Thus, these curcuminoids (or 
curcumin mixture) might be used as modulators offering clinical benefits to improve the 
effectiveness of chemotherapy in cancer patients.101,102 
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Figure 1-15 Curcuminoids 
1.4.5.3 Fungal Metabolites 
Fungi inhabit a wide range of environments, including extreme environments such as 
hypersaline waters, tropical forests, and deserts. A wide variety of fungal derived 
bioactive compounds have been described, including, a number of antibacterial agents 
(cephalosporins), immunosuppressive drugs (cyclosporins), and anticancer candidates 
(plinabulin and fumagillin).103 
Interactions between immunosuppressants such as cyclosporine A (CsA, 98) and ABCG2 
substrate chemotherapy drugs have already been reported. Mao et al. investigated the 
effect of the immunosuppressants 98, tacrolimus (99, FK-506, fujimycin) and sirolimus 
(100, rapamycin, Figure 1-16) as possible inhibitors of ABCG2.104 The EC50 values for 
inhibition of ABCG2-mediated PhA efflux were 4.3 ± 1.9 µM (98), 3.6 ± 1.8 µM (99) and 
1.9 ± 0.4 µM (100). The reversal capability of CsA, tacrolimus and sirolimus to ABCG2-
mediated topotecan and MX resistance was studied at 2 and 5 µM at which the three 
immunosuppressants showed no apparent toxicity (CsA and tacrolimus) or low toxicity 
(sirolimus) to HEK cells. Upon addition of 2 and 5 µM CsA, the relative resistance (RR) 
values of topotecan were reduced from 16.7 to 5.6 and 3.6 in HEK/482R cells, 
respectively, whereas the reversal capability of tacrolimus and sirolimus to topotecan 
resistance was even greater than that of CsA as topotecan resistance was nearly 
completely reversed. Direct efflux studies performed with immunosuppressants 189–191 
revealed that the intracellular levels of [3H]-CsA, tacrolimus or sirolimus in HEK/482R and 
HEK/vector cells were not significantly different and that the addition of the ABCG2 
modulator FTC (82) did not affect the efflux, suggesting a non-substrate behavior.104 
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Figure 1-16 Fungal metabolites 
1.4.5.4 Miscellaneous Natural Products and their derivatives 
Many unique natural products from marine habitats are used for pharmaceutical and 
biotechnological applications.105 Compounds isolated from marine sources are evalated in 
clinical trials or serve as prototypes for the design and synthesis of new therapeutic 
agents, like vidarabine (for the treatment of a recurrent epithelial keratitis caused by 
herpes simplex virus type 1 and 2 and superficial keratitis), cytarabine (for cancer), 
ziconotide (for the treatment of severe chronic pain in patients with cancer or AIDS), 
trabectedin (for use as an anticancer agent against soft tissue sarcoma) and halaven (for 
metastatic breast cancer).44,106 
The indolocarbazole (ICZ) family of natural products is a source of lead compounds with 
potential therapeutic applications in the treatment of cancer and other diseases. The 
compounds have been isolated from different organisms; from prokaryotes 
(actinomycetes, cyanobacteria, b-proteobacteria) to eukaryotes (myxomycetes, 
basidiomycetes,marine invertebrates).107 Robey et al. examined the ability of 
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indolocarbazole to inhibit ABCG2. At a concentration of 10 µM, all of the tested 
compounds increased the intracellular fluorescence of the ABCG2-specific substrate PhA 
in ABCG2-transfected HEK-293 cells by 1.3 to 6-fold as measured by flow cytometry; 
whereas FTC (82) increased intracellular fluorescence by 6.6-fold. K252c (101, Figure 
1-17) and arcyriaflavin A (102, Figure 1-17) were the most potent compounds, with IC50 
values for inhibition of [125I]-iodoarylazidoprazosin (IAAP) labeling of 0.37 and 0.23 µM, 
respectively. The results show that indolocarbazoles interact with the ABCG2 protein and 
may increase the oral bioavailability of ABCG2 substrates.108 
Tryprostatin A (TPS-A, 103, Figure 1-17) is an Aspergillus fumigatus secondary 
metabolite with a diketopiperazine scaffold structurally similar to FTC (82). This 
compound was evaluated for its ability to reverse of ABCG2-mediated drug resistance in 
MCF-7 cells. At a concentration of 1 µM, 103 gave a dose-dependent sensitization of 
ABCG2-expressing cells to mitoxantrone (IC50 for mitoxantrone without 103: 0.013 ± 
0.006 µM, IC50 for mitoxantrone with 103: 0.021 ± 0.005 µM) while the positive control 
elacridar (129) gave an IC50 of 0.034 ± 0.009 µM at the same concentration. TPS-A (103) 
is of interest as a pharmacologic tool for in vivo studies as well as in functional assays of 
ABCG2-dependent drug efflux activity for individual tailoring of chemotherapeutic 
regiments.38,109 
In 2009, extracts from the marine ascidian Botryllus tyreus were found to be active when 
tested for inhibition of ABCG2-mediated PhA transport. After purification of the extract, ten 
botryllamides (known botryllamides A-H and new botryllamide I and botryllamide J) were 
obtained and evaluated in a PhA accumulation assay with FTC (82, 1 µM, IC50 0.79 µM) 
as reference compound in NCI-H460/MX20 cells. Except botryllamides C and H the 
maximal activity was at least 60% compared to FTC (82). Botryllamide G (104, IC50 
6.9 µM, Imax 123.7%, Figure 1-17) was the most potent botryllamide of this series. The 
activity as modulators of ABCG2 was further confirmed in a flow-cytometry-based assay. 
Inhibition of ABCG2-mediated BODIPY-prazosin efflux from ABCG2-transfected HEK293 
cells was investigated with either 10 µM FTC (82) or 10 µM botryllamide. In presence of 
FTC (82) a 3.4-fold increase of intracellular BODIPY-prazosin fluorescence compared to 
the absence of any modulator was observed. Except botryllamides H and J, all 
botryllamides were able to increase the intracellular fluorescence of the substrate 2.3 to 
3.3-fold. Furthermore, the authors studied the competition of the botryllamides with [125I]-
iodoarylazidoprazosin (IAAP) labelling of the ABCG2 protein and the stimulation of the 
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ATPase activity of ABCG2. Botryllamide G (104) is the most potent and ABCG2-specific 
compound of this series.96 
To explore a SAR study among the botryllamides with regard to ABCG2, additional twelve 
structural analogues were synthesized. ABCG2 inhibitory activity was evaluated by the 
cellular accumulation of the ABCG2 specific substrate PhA in ABCG2-overexpressing 
cells using FTC (82, IC50 0.79 µM) as positive control. Synthetic botryllamide 105 (IC50 
6.4 µM, Figure 1-17) was the most potent and specific ABCG2 modulator of this series. 
The biological activity of synthetic botryllamide analogues implied that the 2-methoxy-p-
coumaric acid portion (C1-C9), and the degree of double bond conjugation within this 
group, were critical for inhibition of ABCG2. This structural studies provide the basis for 
the continued preclinical evaluation of the botryllamides and it may lead to the 
development of more potent and selective ABCG2 modulators as potential therapeutic 
agents.110 
Harmine (7-methoxy-1-methyl-9H-pyrido[3, 4-b]indole, 106, Figure 1-17) is a tricyclic ß-
carboline alkaloid and a monoamine oxidase inhibitor (MAOI) widely distributed in nature. 
This alkaloid was isolated from marine brown alga, some cyanobacteria and marine 
animals. It shows antimicrobial, antiplasmodial, antifungal, antioxidative, antitumor, 
antimutagenic, cytotoxic and hallucinogenic properties.111 In 2010, harmine was identified 
in a screening program as a novel ABCG2 reversal agent; it inhibited ABCG2-mediated 
drug efflux and increased the cytotoxicity of mitoxantrone (1 µM 106, IC50 2.71 µM) and 
camptothecin (5 µM 106, IC50 1.15 µM) in the cancer cell line MDA-MB-231. Moreover, 
harmine did not inhibit ABCB1-mediated drug efflux.93 Similar to FTC (82), the 
neurotoxicity and cytotoxicity of 106 led to an exclusion of this compound from further 
studies. 
A series of naphthopyrones isolated by Mckee et al. from marine crinoids of the 
Comasteridae family were evaluated for their ability to inhibit the multidrug transporter 
ABCG2 by measuring the accumulation of the ABCG2 specific substrate PhA in ABCG2-
overexpressing NCI-H460 MX20 cells. Authors found that in comparison to the positive 
control FTC (82, 1 µM, 100% inhibition), six angular naphthopyrones (107–112, Figure 
1-17) showed moderate activity (Imax 59.3, 46.3, 31.0, 54.3, 27.5, 44.0%, IC50 11.9, 5.9, 
12.8, 9.0, >20, 16.6 µM respectively) while none of the tested linear naphthopyrones 
inhibited ABCG2-mediated transport.112 
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Liao et al. identified a novel nor-neolignan, asperjinone (113, Figure 1-17) isolated from 
Aspergillus terreus, and twelve known compounds from thermophilic A. terreus. Among 
them, terrein (114,  Figure 1-17) was 100-fold more cytotoxic against breast cancer MCF-
7 cells than paclitaxel, which is an antimicrotubule agent. The IC50 value of 114 against 
breast cancer MCF-7 cells was 1.1 nM, whereas for paclitaxel it was 0.1 µM. A reduction 
of the growth rate by 70% was observed upon incubation of MCF-7 cells with 114 (1 nM). 
This suppressive effect was achieved by introducing apoptosis via activation of the 
caspase-7 pathway and inhibition of the Akt signaling pathwayin ABCG2-expressing cells. 
The findings suggest that terrein may serve as a potential ABCG2 modulator for the 
treatment of drug-resistant breast cancer cells.103 
The lamellarins are a group of over 30 naturally occurring pyrrole alkaloids isolated from 
several marine invertebrates such as sponges which show interesting anticancer and 
antiviral activities.44 Their name comes from Lamellaria sp., a prosobranch mollusc (family 
Lamellariidae).113,114 In 2014, Lamellarin O (115, Figure 1-17) was identified as a selective 
modulator of ABCG2 in a flow cytometry based mitoxantrone efflux assay in NCI-
H460/MX20 cells. It was found that compound 115 exhibited an increase in intracellular 
concentration of mitoxantrone (3.05-fold, 94.5%, 20 µM) which was comparable to that of 
FTC (82, 3.17-fold, 100%, 10 µM), indicating 115 as a promising ABCG2 modulator.115 
 
Figure 1-17 Miscellaneous Natural Products and their derivatives 
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1.4.5.5 Metabolites and others 
Ginsenosides are among the active ingredients of Ginseng, a slow-growing perennial 
plant which has been used in traditional herbal remedies/medicine in Eastern Asia for 
over 2000 years.116 In 2006, ginsenosides derived from Panax ginseng were examined as 
potential modulators of ABCG2 on cellular mitoxantrone accumulation using reserpine as 
positive control (5 µM, IC50 1.95 µM). Metabolites PPD (116, IC50 1.13 µM), PPT (117, 
IC50 3.50 µM) and Rh2 (118, IC50 1.62 µM, Figure 1-18) at a concentration of 20 µM 
enhanced MX associated cytotoxicity in MCF-7/MX cells overexpressing ABCG2 and 
inhibited MX efflux in the same cell line. PPD additionally stimulated ATPase activity.117 
All-trans retinoic acid (ATRA, 119, Figure 1-18) is a bioactive metabolite of vitamin A 
involved in many biological functions, e.g. reproduction, vision and immune response. In 
2010, Matsuzaki et al. investigated ATRA as a modulator of ABCG2 by flow cytometry 
with doxorubicin as substrate. KSL cells treated with doxorubicin and ATRA (50 µM) or 
with doxorubicin and reserpine (7 µM) as a reference displayed higher fluorescence than 
without any modulator.118 These results show that ATRA has a novel function as 
modulator of the ABCG2 transporter. 
Falcarinol type polyacetylenes are present in vegetables such as carrots and parsley. 
They display interesting bioactivities and have the potential being health-promoting and 
therapeutic agents.119 In a recent study, falcarinol (120, IC50 41.7 µM), falcarindiol (121, 
IC50 29.7 µM), falcarindiol 3-acetate (122, IC50 36.5 µM, Figure 1-18) and the non-natural 
falcarindiol 3,8-diacetate (123, IC50 19.7 µM, Figure 1-18) were examined for their 
ABCG2-modulating properties using three in vivo models, namely accumulation of the 
ABCG2 substrate MX in HEK293 cells overexpressing ABCG2, a vesicular transport 
assay and an ATPase assay. The mitoxantrone accumulation assay was performed with 
Ko143 (85) as reference compound at a concentration of 5 µM whereby a 1.9-fold MX 
accumulation was observed. Compound 121 (20 µM) was able to produce an 1.5-fold 
accumulation, while the other three polyacetylenes were in the range of 1.2 to 1.3-fold 
accumulation indicating a moderate inhibition effect. In the vesicular transport assay all 
polyacetylenes show a concentration-dependent inhibition of the tritiated methotrexate 
([3H]-MTX) transport. Compound 123 had the lowest IC50 value of 19.7 µM (Ko143, 85, 
0.026 µM). The results indicate a possible role of ABCG2 in the absorption and 
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disposition of the polyacetylenes and suggest a potential application as MDR reversal 
agents.120 
 
Figure 1-18 Metabolites and others 
1.4.5.6 Stilbenes 
The tubers of Bletilla striata (Orchidaceae) have been used as traditional medicine to treat 
pulmonary tuberculosis and as hemostatic agent. In 2005, Morita et al. examined the 
potential of reversal of ABCG2-mediated drug resistance with eight stilbenoids isolated 
from B. striata. Three stilbenoids (compounds 124-126, Figure 1-19) were able to 
increase the cytotoxicity of the ABCG2 substrate SN-38 in K562/ABCG2 cells but not in 
K562 cells. Reversal indices for SN-38 (given as the ratio of IC50 measurements in the 
absence of the reversal agent to levels in the presence of the reversal agent) were 1.7, 
1.8 and 3.0, for compounds 124, 125 and 126, respectively.121,122 
In 2011, a series of eleven methoxylated resveratrol analogues were evaluated as 
ABCG2 modulators. The best compound of this series (127, IC50 0.16 µM, Figure 1-19) 
showed a maximal inhibition of mitoxantrone efflux of 75% measured by flow cytometry, 
using elacridar (129, IC50 0.16 µM) as reference (100% inhibition). Methoxy stilbenes 
were found effective for inhibition without inducing cytotoxicity, suggesting that these 
molecules could be used in combination with other modulators to block ABCG2 drug-
efflux activity and appear to be good candidates for in vivo experiments.123 
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Figure 1-19 Stilbenes 
1.4.6 Other Types of Modulators 
1.4.6.1 Acridones 
Natural and synthetic acridones are well known heterocyclic compounds that exhibit a 
broad spectrum of biological activities and found applications in oncology.124 In 2007, a 
series of acridone derivatives was synthesized and their ABCG2 modulatory activity was 
investigated using human wild-type (R482) ABCG2-transfected cells. One of the 
acridones, namely MBLI-87 (128, IC50 0.56 µM, 112.3% inhibition, Figure 1-20) was as 
potent as the reference compound elacridar, which is an acridone-derived compound 
(129, IC50 0.41 µM, 100% inhibition, Figure 1-20) inhibiting mitoxantrone efflux. The 
camptothecin analogue irinotecan and its active metabolite SN-38 are both substrates of 
ABCG2. By addition of MBLI-87 (128) a significant sensitization to irinotecan and SN-38 
was observed, although the doses remained below the maximum tolerated dose due to 
the limited solubility of 128.125-127 
 
Figure 1-20 Acridones 
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1.4.6.2 Anthelmintics 
Barrera et al. identified the anthelmintic triclabendazole (TCBZ, 130, Figure 1-21) and its 
main plasma metabolites triclabendazole sulfoxide (TCBZSO, 131, Figure 1-21) and 
triclabendazole sulfone (TCBZSO2, 132, Figure 1-21) as modulators of ABCG2 in vitro 
and in vivo with different assays and substrates. For example, an accumulation assays 
with mitoxantrone as substrate and murine Abcg2- and human ABCG2-transduced 
MDCKII cells confirmed that TCBZSO and TCBZSO2 are ABCG2 modulators. TCBZ as 
parent drug is not detected in plasma, and in mitoxantrone accumulation assays with a 
concentration range from 5 to 25 µM, both metabolites (TCBZSO and TCBZSO2) showed 
inhibitory potencies between 40 and 55% for murine Abcg2/human ABCG2. These results 
support the potential of TCBZSO and TCBZSO2 to participate in drug interactions and 
modulate ABCG2-mediated pharmacokinetic processes.128-130 
 
Figure 1-21 Anthelmintics 
1.4.6.3 Hormones 
New strategies to circumvent ABCG2 mediated MDR in the central nervous system (CNS) 
are required. One major approach to increase brain drug levels is to manipulate signaling 
mechanisms that control transporter expression and function. In 2010 the long-term effect 
of 17β-estradiol on ABCG2 was investigated in an ex vivo model for the blood-brain 
barrier (BBB).131 Concomitantly, levels of ABCG2 mRNA were reduced by 17β-estradiol 
(133) suggesting a down-regulation of the ABCG2 transporter via a genomic pathway. 
Mahringer et al. identified the estrogen receptor beta (ER β) being linked to the function of 
ABCG2 upon stimulation with 133.132 
Masereeuw et al. investigated the interaction between ABCG2 activity and twelve steroid 
hormones using membrane vesicles of HEK293/ABCG2 cells. Estradiol (133, 40.4%, 
Figure 1-22), testosterone (134, 20.1%, Figure 1-22), progesterone (28.7%) and 
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androstenedione (135, 42.4%, Figure 1-22) were the most efficient compounds of this 
series inhibiting tritiated estrone-sulphate (E1S) uptake in a concentration-dependent 
manner. The vesicular E1S uptake is expressed as a percentage of maximum uptake after 
incubation with 250 nM E1S with or without 50 µM of the steroid. The efficient inhibition 
implies a clear interaction between the steroids and the efflux pump.133 
 
Figure 1-22 Hormones 
1.4.6.4 Kinases 
Cyclin-dependent kinases (CDKs) are protein kinases, which are involved in many diverse 
biological processes. Their regulation by small-molecule inhibitors, e.g. purine cyclin-
dependent kinase inhibitors (CDKi), opens an opportunity for the treatment of cancer. In 
2012, five purine CDKi were investigated for their inhibitory effect on ABCG2 transport 
activity in vitro using accumulation assays in ABCG2-transduced MCDKII cells and 
Hoechst 33342, glyburide as substrate and FTC (82) as reference. Four of the five CDKi 
inhibited ABCG2 significantly in the following order: purvalanol A (136, Figure 1-23) > 
olomoucine II (137, Figure 1-23) ≈ FTC > roscovitine (138, Figure 1-23) ≈ bohemine (139, 
Figure 1-23). Compounds 136 and 137 are comparable to FTC (82). The same order of 
potency was found in dually perfused rat placenta expressing Abcg2, but the associated 
mechanism is not clear.134,135 
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Figure 1-23 Kinases 
1.4.6.5 Xanthines 
Methylxanthines and other xanthine derivatives are adenosine receptor (AR) antagonists, 
which are used for treatment of asthma, chronic bronchitis, emphysema and neural 
degenerative diseases.136 Furthermore, the AR antagonist 1,3,7-metyxanthine (140, also 
known as caffeine, Figure 1-24) has been shown to downregulate the expression of 
ABCG2 in cancer cell lines in a time- and dose-dependent and reversible way.137 
Also theophylline and dyphylline decreased ABCG2 expression significantly in MCF-
7/MX100 cells in a time-dependent, dose-dependent and reversible manner. Caffeine 
treatment was shown to increase the retention of mitoxantrone. Combination treatment 
with MX and 140 (IC50 81.4 µM) decreased the IC50 of MX tenfold and induced a greater 
degree of apoptotic cell death than MX treatment alone (IC50 946.5 µM). These results 
unveil xanthines as potential chemosensitizers.137,138 
 
Figure 1-24 Caffeine 
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1.4.7 Tariquidar-like Compounds 
Compound XR9576 (141, tariquidar, Figure 1-25) is an anthranilamide derivative, which 
was developed as a modulator of ABCB1 undergoing clinical trial III studies. 
Unfortunately, the outcome of the clinical trials was disappointing due to inefficiency and 
toxic effects. However, appropriate dosing, considering altered pharmacokinetics and a 
proper selection of the patient cohort may had produced different results.139 Later, it has 
been shown that 141 inhibits both ABCB1 and ABCG2 transport function similarly to 
elacridar (129), and was now used as a scaffold for designing ABCG2-specific modulators 
by structural modifications.140 
Wiese et al. investigated 30 compounds, which are structurally related to 141 in vitro and 
also with 3D-QSAR models in order to identify the main structural features determining 
the interaction with ABCB1 or ABCG2. Elimination of the methoxy groups in positions 6 
and 7 of the tetrahydroisoquinoline substructure, the addition of a second amide linker, a 
shift of the hetarylcarboxamido group from the ortho to the meta position and the 
introduction of an ester group to the central aromatic core were shown to increase the 
interaction with ABCG2.141,142 
Kühnle et al. synthesized a series of selective ABCG2 modulators by minimal structural 
modification, replacing the 3,4-dimethoxy-2-(quinoline-3-carbonylamino)benzoyl moiety in 
tariquidar (141) with a 4-methoxycarbonylbenzoyl moiety bearing a hetarylcarboxamide 
group in 3-position. This resulted in a drastic shift in favor of ABCG2 inhibition. A 
quinoline-3-carboxamide (142, IC50 0.119 µM, Figure 1-25) or quinoline-2-carboxamide 
group (143, IC50 0.060 µM, flow cytometric mitoxantrone efflux assay, topotecan-resistant 
MCF7 breast cancer cells, using Ko143 (85) as positive control with an IC50 value of 
0.225 µM, Figure 1-25) gave the most potent compounds of the series. Furthermore, the 
selectivity for ABCG2 over ABCB1 was about 100 to 500-fold and the compounds were 
inactive at ABCC2. Chemosensitivity assays against MCF-7/Topo cells revealed that the 
non-toxic modulator 143 completely reverted ABCG2-mediated topotecan resistance at 
concentrations higher than 100 nM, whereas 142 showed ABCG2 independent 
cytotoxicity.143 
Interestingly, compounds bearing triethylene glycol ether groups at the 
tetrahydroisoquinoline moiety (144 and 145, Figure 1-25) were comparable to compound 
143 in potency, but considerably more efficient (Imax 83% and 88% vs 60%, FTC, 82, as 
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reference was set to 100%). These results support the hypothesis that solubility of the 
new ABCG2 modulators and of the reference compounds tariquidar (141) and elacridar 
(129) is the efficacy limiting factor in aqueous media. Unfortunately, the compounds were 
unstable in mouse plasma due to rapid enzymatic cleavage of the benzamide bond. 
Replacing of the labile benzanilide core was considered as a promising bioisosteric 
approach to solve the stability problem.144 
In search for more stable analogues, according to a bioisosteric approach, a series of N-
(biphenyl-3-yl)quinoline carboxamides were prepared both by solid phase and solution 
phase synthesis. Inhibition of ABCG2 was determined in a Hoechst 33342 accumulation 
assay. Most synthesized compounds inhibited the ABCG2 transporter selectively at 
submicromolar concentrations with a maximal inhibitory effect (Imax) over 90%, (compound 
146, IC50 0.591 µM, Imax 109%; 147, IC50 0.544 µM, Imax 112%, Figure 1-25). The biphenyl 
analogues 146 and 147 are considerably more stable and show that the benzanilide core 
is not a crucial structural element of quinoline carboxamide-type ABCG2 modulators.145 
In modulators 148 and 149 (Figure 1-25) the labile benzamide unit was replaced by 
quinolyl (148) and indolyl moieties (149). The compounds were investigated together with 
the reference compounds FTC (82, IC50 731 ± 92 nM, 10 µM as 100% ABCG2 inhibition), 
Ko143 (85, IC50 117 ± 53 nM) and tariquidar (141, 1 µM as 100% ABCB1 inhibition, 
ABCB1: IC50 223 ± 8 nM, Imax 103 ± 2%, ABCG2: IC50 526 ± 85 nM, Imax 69 ± 5%) in a 
calcein-AM and a Hoechst 33342 microplate assay using ABCB1-overexpressing Kb-V1 
and ABCG2-overexpressing MCF-7/Topo cells. The quinoline analogue 148 (IC50 602 ± 
44 nM, Imax 60%) was inactive at ABCB1 and ABCG2. However, the compound is poorly 
soluble and therefore inferior to compound 149 (ABCG2: IC50 46 ± 1 nM, Imax 111 ± 9%, 
ABCB1: IC50 3570 ± 640 nM, Imax 36 ± 4%), which is superior to tariquidar (141), FTC (82) 
and even Ko143 (85). Moreover, compound 149 had no effect on the cell proliferation 
even at a high concentration of 1 µM, whereas a strong cytostatic effect was observed in 
combination with topotecan (100 nM).146 
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Figure 1-25 Tariquidar analogues 
Subsequently, the labile amide and ester groups were replaced by a triazole and a ketone 
moiety in a bioisosteric approach147,148 resulting in a 24 h plasma-stable, ABCG2-selective 
quinoline-carboxamide type series of very potent modulators. Compound 150 (Figure 
1-26) inhibited the ABCG2 transporter to 95% with an IC50 value of 64 nM without 
affecting ABCB1 or ABCC1 (FTC, 82, as reference for 100% ABCG2 inhibition, IC50 731 
nM). Combining selective and potent ABCG2 modulation with high plasma stability, the 
modulators are promising candidates for in vivo investigations. Studies on the bio-
distribution of the modulators and their effect on the pharmacokinetics and enhancement 
of cytostatic concentration of co-administered topotecan are subject of ongoing work 
(unpublished data). 
 
Figure 1-26 Triazolic tariquidar analogue 
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1.4.8 Tyrosine Kinase Inhibitor-Based Compounds 
Various tyrosine kinase inhibitors (TKIs) were designed as anticancer agents with high 
specificity and selectivity. However, as most TKIs are targeting intracellular parts and 
therefore have to cross cell membranes, their therapeutic potential may be drastically 
affected by certain ABC membrane transporters. Recently, it was demonstrated that 
several human multidrug transporter ABC proteins interact with specific TKIs. In 
particular, the ABCG2 transporter has a high affinity for some of the TKIs.149 In the 
following, we discus first TKIs as inhibitors of epidermal growth factor receptor (EGFR) 
and followed by other TKIs. 
1.4.8.1 Epidermal Growth Factor Receptor (EGFR) Inhibitors 
Mutations of the epidermal growth factor receptor (EGFR) are correlated with tumor 
proliferation. Inhibition of EGFR by small molecule inhibitors, such as gefitinib (151), 
pelitinib (152), neratinib (153), vandetanib (154) and telatinib (155) is therefore a 
promising therapeutic option.9 
Gefitinib (151, “Iressa”, ZD1839, Figure 1-27) is an orally active, selective EGFR-TKI used 
for the treatment of certain cancer types. Gefitinib was already reported to act as 
chemosensitizer combined with various cytotoxic agents in vitro. However, the underlying 
mechanism was not described. In 2005, Nakamura et al. investigated the mode of action 
of gefitinib (151) in multidrug-resistant MCF-7 cells overexpressing ABCG2 by monitoring 
the intracellular topotecan accumulation. No effects of 151 were observed in the parental 
cells. Reversal of drug resistance in MCF-7/MX cells was observed with gefitinib (151, 
2 µM) in combination with topotecan (IC50 716 ± 118 nM), SN-38 (IC50 116 ± 18.2 nM), 
and mitoxantrone resistance (IC50 178 ± 16.3 nM) in comparison to topotecan (4143 ± 161 
nM), SN-38 (1139 ± 79.3 nM) and mitoxantrone (1210 ± 289 nM) alone. The results show 
that gefitinib (151) effectively reversed drug resistance through inhibition of drug efflux in 
three multidrug-resistant cancer cell lines overexpressing ABCG2 and was not 
transported itself.150 
If local drug concentrations are low, ABCG2 can confer gefitinib (151) or pelitinib (152, 
Figure 1-27) resistance. However, anti-cancer efficiency of neratinib (153, Figure 1-27) 
and vandetanib (154, “Caprelsa”, Figure 1-27) will most probably not be restricted. 
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Conformational changes of ABCG2 can be monitored with the anti-ABCG2 5D3 antibody, 
and drugs, which increase 5D3 immunoreactivity of ABCG2 similar to 1 µM Ko143 (85, 
100% 5D3 binding) are likely to inhibit ABCG2 function as well. The most pronounced 
increase in 5D3 binding was obtained when 10 µM EGFR inhibitors were applied. 5D3 
binding in A431/ABCG2 cells was observed for gefitinib (71.3%), pelitinib (41.9%), 
vandetanib (9.3%) and neratinib (26.0%) relative to Ko143 (85). The finding that these 
EGFR inhibitors efficiently block ABCG2 function may help to design novel therapeutic 
drug-combination strategies.9 
Telatinib (155, Figure 1-27) is a small molecule TKI inhibiting vascular endothelial growth 
factor receptor (VEGFR), platelet-derived growth factor receptor-ß (PDGFR-ß) and stem 
cell growth factor receptor (c-KIT). Chen et al. examined telatinib in 2014 as a reversal 
agent for ABCG2-mediated MDR in H460/MX20 and HEK293 cells overexpressing 
ABCG2 in vitro and in vivo. In the cell viability assay the cytotoxicity of ABCG2 substrate 
anticancer drugs was enhanced in ABCG2-transfected cells and drug selected ABCG2-
overexpressing cancer cells, whereas it has no effect on the parental cells lacking the 
ABCG2 transporter. Also, no effect was observed on ABCB1-, ABCC1- and ABCC10-
mediated MDR. Compound 155 at 1 µM (IC50 0.0468 µM) significantly enhanced the 
intracellular accumulation of mitoxantrone (MX) in ABCG2-overexpressing cell lines (FTC, 
82, IC50 0.0442 µM as positive control). These results showed that telatinib (155) 
selectively inhibits ABCG2, potentiates the ABCG2 substrate anticancer drugs and 
induces cell cytotoxicity in cells overexpressing ABCG2 in vitro and in vivo at clinically 
achievable concentrations. The ATPase activity of ABCG2 was stimulated by telatinib in a 
concentration-dependent manner, indicating a substrate behavior. Co-administration of 
telatinib and doxorubicin significantly decreased the size of ABCG2-expressing tumor 
xenografts compared to the vehicle control or the group treated with doxorubicin only. The 
results indicate that telatinib has the potential to be used in combination with conventional 
ABCG2 substrate anticancer drugs to reduce the MDR-mediated by ABCG2. 
Nevertheless, further clinical studies are required to prove its usefulness.151 
The same year, the EGFR inhibitor AST1306 (156, Figure 1-27) was evaluated on the 
reversal of ABCG2-mediated MDR. A significant increase of intracellular accumulation of 
tritiated mitoxantrone (1 µM 156, IC50 15.03 nM, FTC, 82, 15.41 µM as positive control) in 
ABCG2-overexpressing HEK293 cells was observed. AST1306 (156) was shown to 
directly inhibit the function of the ABCG2 protein at non-toxic concentrations, thus 
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increasing the intracellular concentration of substrate anti-cancer drugs without affecting 
the expression or localization of ABCG2. AST1306 (156) might be considered as a novel 
reversal agent of the ABCG2 transporter with a potential to improve the clinical response 
when combined with conventional chemotherapeutic agents.152 
In 2012, Pick et al. determined the inhibitory potencies of seven TKIs against ABCB1, 
ABCC1 and ABCG2 with different fluorescence based accumulation assays. Among 
them, AG1428 (157) and PD158780 (158) (Figure 1-27), were found to be selective for 
ABCG2 as determined by a Hoechst 33342 assay (157: IC50 5.50 ± 0.38 µM, 158: IC50 
0.36 ± 0.07 µM) and a pheophorbide A assay using MDCK/ABCG2 cells (157: IC50 2.40 ± 
0.85 µM, 158: IC50 0.25 ± 0.09 µM). However, no effect up to 10 µM was observed in the 
calcein-AM assay using MDCK/MDR1 cells for ABCB1 and 2008/MRP1 cells for 
ABCC1.153 
The quinazolinic alpha-adrenergic blocker prazosin has been found to be a substrate of 
ABCG2.154 Also the ABCG2 inhibitory potential of quinazoline based TKIs such as 
PD153035 (159, Figure 1-27) has been reported.155 
Imatinib mesylate (160, “Gleevec”, STI571, Figure 1-27), is a potent kinase inhibitor used 
in the treatment of various cancers. The ATP competitor acts similar as many other 4-
anilinoquinazolinic TKIs. The compounds potently reverse ABCG2-mediated resistance 
and significantly increase the accumulation of topotecan in the human osteosarcoma cell 
line Saos2. With an increasing concentration of 160, the concentration of topotecan 
required to inhibit cell growth by half decreased from 257 nM to 10 nM. Reversal of 
topotecan resistance by half was achieved at a concentration of 170 nM of compound 
160. However, overexpression of ABCG2 does not confer resistance to 160. These 
results suggest that 160 is a potent inhibitor, but not a substrate of the ABCG2 
transporter.156,157 
Juvale et al. investigated several 4-substituted analogues of 2-phenylquinazoline for their 
ABCG2 inhibition, using the Hoechst 33342 assay with MDCK/ABCG2-overexpressing 
cells. It was observed that quinazoline compounds bearing a phenyl substitution at 
position 2 of the quinazoline moiety were potent modulators. From the SAR analysis, it 
was observed that a meta-substituted aniline group at position 4 of the quinazoline 
produced higher inhibitory effects in comparison to an ortho- or para-substituted aniline 
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ring. Nitro, nitrile or trifluoromethyl substituents on the aniline ring were most suitable for 
the inhibition of the ABCG2 transporter. Compounds 161 (IC50 0.130 µM, Figure 1-27) and 
162 (IC50 0.076 µM, Figure 1-27), both bearing an NO2-substituent were the most active 
compounds among all investigated quinazolines, having even lower IC50 values than 
Ko143 (85, 0.25 µM) as reference. After investigating the compounds for their intrinsic 
cytotoxicity, it was found that compound 161 has twice the therapeutic ratio of 162, 
indicating its higher usability in future in vivo studies. These findings can be the basis for 
further development of quinazolines as potent ABCG2 modulators.155,158 
Varlitinib/ARRY-334543 (163) is a small molecule ATP-competitive TKI, which was 
studied for its ability to interact with ABC transporters to enhance the efficacy of 
conventional anticancer drugs. NCI-H460 ABCG2-overexpressing cells were used for the 
reversal study. Compound 163 (1.0 µM, IC50 0.0272 µM; FTC, 82, 5 µM, IC50 0.0243 µM 
as positive control, Figure 1-27) directly inhibited the drug efflux transporter, thereby 
elevating the intracellular amount of the ABCG2 substrate mitoxantrone. The cytotoxicity 
of 167 was screened by an MTT assay and the IC50 value of 163 alone was shown to be 
> 10 µM. At a concentration of 1 µM 163 only slightly reversed ABCB1- and partially 
reversed ABCC10-mediated MDR is observed. Moreover, 163 did not affect the 
expression of the ABCG2 protein or cause its translocation. The TKI 163 inhibited the 
photoaffinity labeling of ABCG2 with [125I]-IAAP and is therefore directly interacting with 
ABCG2 at the drug-binding pocket, which is consistent with findings for other TKIs.159 
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Figure 1-27 EGFR inhibitors 
1.4.8.2 Other TKIs 
Tyrosine kinase inhibitors (TKIs) compete with ATP for the binding at the catalytic domain 
of tyrosine kinases. In vitro studies with biochemical and cell-based assays showed that 
TKIs also interact as substrates or as modulators with the function of the ABC 
transporters such as ABCG2, ABCB1 and ABCC1.160 
Sunitinib (164, “Sutent”, Figure 1-28) is an ATP-competitive multi-targeted small molecule 
TKI of platelet-derived growth factor (PDGFRß), vascular endothelial growth factor 
(VEGFR2) and Fms-like tyrosine kinase 3 (FLT3). In 2009 the possible interaction of 
sunitinib (164) with ABCB1, ABCC1, ABCG2 and lung-resistance protein (LRP) was 
evaluated in vitro. The effect of sunitinib on the ABCG2 reversal is given as the ratio of 
the IC50 for S1-M1-80 cells with the anticancer drug (topotecan and doxorubicin, 
respectively) in the absence of 164 to the IC50 value obtained in the presence of 164. The 
results showed that 164 gave a 56.4-fold MDR reversal for topotecan at a non-toxic 
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concentration of 2.5 µM of 164 (IC50 for topotecan with 2.5 µM 164: 0.091 µM, IC50 for 
topotecan: 5.132 µM) and a 37.8-fold reversal for doxorubicin (IC50 for doxorubicin with 
2.5 µM 164: 0.181 µM, IC50 for doxorubicin: 6.845 µM). No significant reversal effect of 
164 on ABCB1-, ABCC1- and LRP-mediated drug resistance was observed.160 
Although the ABCG2 transporter appears to be a promising target to overcome MDR, to 
date no modulator has successfully passed through the clinical trials. Toxicity and safety 
issues are major obstacles in testing novel chemical structures. An appealing strategy is 
the use of already described compounds (where sudden side effects are unlikely) as 
ABCG2 modulators. This might be the case for sorafenib (165, “Nexavar”), an orally 
active multikinase inhibitor, which was found to induce ABCG2 degradation in lysosome in 
addition to act as modulator of ABCG2. The study may facilitate the rediscovery of new 
functions of structurally diverse FDA-approved compounds, which are ready for clinical 
testing and provide a safe way of reversing MDR in cancer chemotherapy. Sorafenib 
(165, Figure 1-28) serves as a substrate of the ABCG2 transporter at a low concentration. 
While saturating all binding sites, it can inhibit the transporter at high concentrations 
(2.5 µM, IC50 1.31 µM, 2.1 µM MX accumulation) producing a significant increase of 
mitoxantrone accumulation in HEK293/ABCG2 cells (Ko143, 85, 2.9 µM MX 
accumulation). The successful identification of sorafenib (165) as ABCG2 modulator 
through a pharmacophore-based evaluation process indicates that this is a valuable 
approach to rediscover novel uses for known drugs in the reversal of ABCG2-mediated 
drug transport and resistance.161-163 
Tandutinib (166, Figure 1-28) is a novel small molecule multi-targeted TKI. In 2013 the 
capability of tandutinib to reverse ABC transporter-mediated multidrug resistance was 
investigated. Tandutinib potentiated the cytotoxicity of ABCG2 substrate drugs, such as 
topotecan (3 µM, IC50 5.175 µM; FTC, 82, 2.5 µM, IC50 1.041 µM as positive control) in 
the S1-M1-80 ABCG2-overexpressing cell line. Tandutinib significantly reverses ABCG2-
mediated drug resistance by inhibiting the drug efflux function of ABCG2 and increasing 
intracellular accumulation of cytotoxic agents in ABCG2-overexpressing cells. Moreover, 
tandutinib (166) was able to restore the sensitivity of side population (SP) cells to 
chemotherapeutic agents and exerts a positive effect on reversing ABCG2-mediated 
MDR.164 
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OSI-930 (167, Figure 1-28) is a heterocyclic anthranilamide analogue currently used as a 
potent multikinase inhibitor. The quinoline core of 167 was modified with either pyridyl or 
phenyl substituents to obtain a series of fifteen compounds, from which the nitropyridyl 
and ortho-nitrophenyl analogues (168, VKJP1 and 169, VKJP3, Figure 1-28) were 
effective in the reversal of MDR mediated by ABCG2, but unable to reverse ABCB1- or 
ABCC1-mediated MDR indicating a selectivity for ABCG2. At a concentration of 1, 3 and 
10 mM, the two OSI-930 analogues 168 and 169 decreased the IC50 values of ABCG2 
substrates mitoxantrone, SN-38 and doxorubicin in transfected wild-type (R2) or mutant 
(T7) ABCG2-overexpressing cells. The IC50 value for the non-ABCG2 substrate cisplatin 
was not affected. As an example, in the ABCG2-482-R2 cell line the IC50 value for 
mitoxantrone was 278 nM and  significantly lowered to 17 nM in presence of 10 µM 168 
or to 53 nM in presence of 169, respectively (positive control FTC, 82 at a concentration 
of 2.5 µM, IC50 for mitoxantrone 9.03 nM). The sensitization of cells treated with 168 
(10 µM) was the same as with FTC (82, 2.5 µM). These results suggest that the 
compounds specifically inhibit the function of ABCG2 through direct interaction with its 
substrate binding site.165 
 
Figure 1-28 Other TKIs 
1.4.9 Conclusion 
In contrast to the prominent P-glycoprotein (ABCB1) very few suitable inhibitors for 
ABCG2/BCRP have been reported, possibly due to its recent discovery in the late 90s. 
The most remarkable modulator is the non-toxic FTC derivative Ko143, but recently 
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published data reported that this compound is unstable in rat plasma and even unspecific 
at higher concentrations. This inevitably will require further investigations before Ko143 
can be clinically applied. 
The second promising class of ABCG2 modulators is based on the chromone skeleton. 
The most active compound of the series was shown to be highly potent, selective for 
ABCG2 and not cytotoxic. The compound is a good candidate for future in vivo studies. 
Literature research reveals an increasing number of reports on certain phytochemicals 
being ABC modulators, substrates and inhibitors – depending on their structure. However, 
the authors are aware that polyhydroxylated compounds like curcumin as well as their 
analogues and similar natural products are typical pan-assay interference compounds 
(PAINS).166-169 PAINS are frequent hitters in high throughput assays, which may be 
artifacts as the compounds show unspecific binding to various proteins. Moreover, recent 
findings170,171 indicate the interaction of certain phytochemicals, which were also reported 
as modulators of ABC transporters, with membranes causing a promiscuous behavior. 
The last highly active class of compounds is comprised of the anthranilic acid core. The 
structural element is found in tariquidar (XR9576), an ABCB1 modulator, which reached 
clinical trial phase III. Minimal structural modifications resulted in a series of highly active 
and non-toxic modulators selective for ABCG2. However, to the best of knowledge, 
clinical trials to prove reversal of ABCG2-mediated MDR in vivo have not been published. 
Well characterized and clinically useful ABCG2 modulators are highly desired and will 
constitute an active field of research in the future. It will be important to assess the 
performance of the most promising candidates in comprehensive clinical trials. Even if a 
translation into the clinical oncology remains challenging due to several reasons,172 the 
development of potent, specific and non-toxic modulators offers the possibility to study the 
ABCG2 transporter at a molecular level and to gain detailed knowledge of its regulation, 
function and its role in certain diseases. Therefore, the investigation and development of 
compounds acting as modulators is not only of importance for clinical use, but is also 
useful for basic research serving as molecular tools for studying transporter function. 
Apart from that, the research focus may be extended from generating novel modulators in 
the laboratory to proofing their usefulness for drug accumulation in vivo. 
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1.5 Aims and Scope 
ABCG2 overexpression causes resistance to treatment in two types of cancer with high 
incidence and mortality around the world. Prostate cancer (second most common in men 
in Colombia) reported 9564 cases in Colombia on 2012, of which over 30% were fatal and 
it is estimated that by 2017 the incidence will increase more than three times. Breast 
cancer (fifth leading cause of death in the country) claimed the lives of 31% of 8686 cases 
reported on 2012 in Colombia, and it is estimated that in 2017 the incidence would 
increase almost fourfold (Figure 1-29).173,174 With these elements we decided to start a 
pioneering study in our country related to the ABCG2. 
 
Figure 1-29 Main types of Cancer in Colombia and in the world 
 
Previously, a series of new tariquidar analogs was synthesized (Figure 1-30, compounds 
143 and 145), which were identified as a new class of potents and selectives ABCG2 
modulators, compound UR-ME22-1 was the most promising representative.143 Further 
studies tried to improve water solubility of these compounds by adding  triethylenglycol 
chains (UR-COP78),144 the maximal inhibitory effect of these new modulators class clearly 
increased, but unfortunately, in mouse plasma the compounds were enzymatically 
cleaved at the central core structure within 10 minutes. 
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In continuation with these previous works, a bioisosteric approach of the amide bond 
located in the central core of the structure is proposed to increase the stability against 
enzymatic hydrolysis. Also, the addition of ethylene and triethylene glycol chains in the 
tetrahydroisoquinoline moiety would improve the hydrophilicity of the synthesized 
compounds. 
 
Figure 1-30 Some ABCG2 modulators. Tariquidar (141), UR-ME22-1 (143), UR-COP78 
(145) 
General objective 
Synthesize and characterize new tariquidar analogs with improved stability against 
enzymatic hydrolysis and evaluate their inhibitory activity against breast cancer resistance 
protein (ABCG2). 
Specific objectives 
 Synthesize and characterize two series of new compounds with possible inhibitory 
activity against ABCG2, in which a rigid fragment is included to increase the 
stability of the compounds against enzymatic hydrolysis. 
 
 Evaluate the biological activity of the synthesized compounds determining the half 
maximal inhibitory concentration (IC50) as well as their percentage of maximum 
inhibition (Imax). 
 
 Evaluate the stability of the compounds with highest activity against enzymatic 
degradation. 
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2 Tariquidar-like Ketones as Breast Cancer 
Resistance Protein (ABCG2) modulators
2
 
 
Some studies have identified selective tariquidar analogs as ABCG2 inhibitors, which 
were among the most potent representatives reported so far, but these compounds were 
seriously affected by enzymatic hydrolysis which limited any further testing. In search for 
more stable tariquidar analogues a new series of Tariquidar-like ketones were 
investigated, fully characterized and tested for their ABCG2 inhibitory activity; in addition 
their selectivity and stability against enzymatic hydrolysis were determinated. The 
synthesized ketones were active against ABC transporters and exhibited selectivity over 
ABCG2. Some compounds of the series exhibited a maximum inhibition between 85-
110% based on fumitremorgin C as reference compound (100%), and with a remarkable 
chemical stability against the hydrolysis after incubation for 24 hours at 37°C.  
                                               
 
2
All synthesis, purification and characterization of the compounds were carried out by Diana 
Catherine Peña. Inhibition assays (ABCG2, ABCB1, ABCC1), stability and solubility tests were 
carried out by Diana Catherine Peña at the University of Regensburg, Germany. Cell cultures, 
chemosensitive assay and reference compounds were provided by Matthias Scholler, a doctoral 
student at the University of Regensburg. 
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2.1 Introduction 
ATP-binding cassette transporters use the energy of ATP-hydrolysis to transport a broad 
variety of substrates across the cell membrane. Under physiological conditions, these 
efflux pumps, including ABCB1 (p-glycoprotein, P-gp), ABCC1 (multidrug resistance 
related protein 1) and ABCG2 (ABCP, BCRP, MXR), appear to play a protective role in 
several tissues.1 ABC transporters play also an important role in conjunction with multi-
drug resistance (MDR). According to estimations, multi-drug resistant tumors account for 
up to half of all cancer-related deaths. Hence, in many respects, the manipulation of the 
ABCG2 transporter might be a promising approach in cancer chemotherapy. 
Predominantly, inhibition of the efflux pump by potent and selective modulators might be a 
conceivable application to reverse ABCG2-mediated multidrug resistance or to specifically 
target the cancer-stem cells. Long-term survival of these cells, due to resistance against 
cytostatics, that are ABCG2 substrates, might be overcome by a specific ABCG2 inhibitor 
in combination with the pharmacologically active compound.2 
In search for more stable analogs, the replacement of the labile benzanilide moiety in UR-
ME22-1 and UR-COP78 (Figure 1-30) by ketones and the substitution of the hydrolysis-
sensitive ester by hydrogen and methyl group may improve their chemical stability. It is 
known that several aromatic and aliphatic ketones possess antibacterial, antimicrobial 
activity and antifungal properties.3-6 Considering the different properties of the ketones; 
we designed and synthesized a new series derived from tariquidar. All compounds were 
fully characterized and tested for their ABCG2 inhibitory activity and ABC transporters 
selectivity. In addition, the solubility and stability against enzymatic hydrolysis was also 
evaluated. The synthesized ketones showed activity against ABC transporters and 
exhibited a marked preference for ABCG2 inhibition. 
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2.2 Results and discussion 
2.2.1 Synthesis. Synthesis of compounds 176a-f is shown in scheme 2-1. 
 
 
Scheme 2-1 Synthesis of compounds 176a-f. Reagents and conditions: (i) Quinaldic 
acid, Ts-Cl, TEA, 50ºC, overnight; (ii) NBS, MeOH, reflux; (iii) 2-methoxyethyl 4-
methylbenzenesulfonate or 2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate, KOH, THF, N2, 6h; (iv) K2CO3, acetonitrile, 90°C, overnight 
 
Amines 170a-b were prepared from commercially available acetophenone and 4-
methylacetophenone through an electrophilic aromatic substitution with a HNO3/H2SO4 
mixture, followed by a Bechamp reduction with iron powder and a catalytic amount of 
concentrated hydrochloric acid. The amides 171a-b were obtained by reaction between 
quinaldic acid, p-toluenesulfonyl chloride (Ts-Cl) and the amines (170a-b) in presence of 
triethylamine (TEA), using DCM as solvent. Compounds 172a-b were obtained by a 
bromination with N-bromosuccinimide. Tetrahydroisoquinoline 174 is commercially 
available as a hydrochloride salt. The protected tetrahydroisoquinoline 173 reacted with 2-
methoxyethyl 4-methylbenzenesulfonate or 2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate in presence of potassium hydroxide, subsequently  they were 
deprotected with trifluoroacetic acid to produce the desired compounds as a trifluoroacetic 
salts (175a-b). Finally, a nucleophilic substitution between the brominated compounds 
(172a-b) and the respective tetrahydroisoquinolines (174, 175a-b) in presence of 
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potassium carbonate and using acetonitrile as solvent led the target ketones (176a-f, 
Scheme 2-1) in good yields (75-92%, Scheme 3-1). All synthesized compounds were 
characterized by nuclear magnetic resonance (NMR), infrared spectroscopy (IR), high 
resolution mass spectrometry (HR-MS) and the purity was confirmed by analytical high 
performance liquid chromatography (HPLC). 
2.2.2 Inhibitory activity evaluation 
2.2.2.1 Inhibitory activity evaluation on breast cancer resistance 
protein (ABCG2) 
Synthesized ketones 176a-f and reference compounds fumitremorgin C (FTC) nd 
tariquidar were investigated for inhibition of ABCG2 in a Hoechst 33342 microplate assay 
using ABCG2-overexpressing MCF-7/Topo cells, obtaining inhibitory effects and IC50 
values as summarized in Table 2.1. Concentration response curves of selected 
compounds obtained in the Hoechst 33342 assay are shown in Figure 2-1. 
All ketones exhibited maximal inhibitory activities between 46-103%, which means that 
they were active against ABCG2 transporter. Compounds 176d-f, had the best maximal 
inhibitory effect of the whole series (90%, 103% and 95% respectively) in comparison with 
Tariquidar (69%) as reference compound, compound 176e  was even superior to FTC 
(100%). 
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Figure 2-1 Concentration dependent inhibition of the ABCG2 transporter in MCF-7/Topo 
cells (Hoechst 33342 assay) by ketones 176a-f. The inhibition is expressed as % relative 
to the maximal inhibition of ABCG2 by 10 μM of fumitremorgin C (100%) 
 
Compound 176c (IC50 1.13 µM,) was comparable in potency to reference compound 
(FTC, IC50 0.731 µM) and the efficacy was improved with the incorporation of a methyl 
group (R1 in the structure, Table 2-1) at the amino ketone moiety in case of 176e and 
176f  (Imax 103 and 95% respectively, Table 2-1), but at the same time these compounds 
had IC50 values that exceeded 31 and 9 times the IC50 value of FTC and 44 and 13 times 
for Tariquidar respectively (Table 2-1).  
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Table 2-1 Inhibitory activity evaluation on ABCG2 by reference compound and ketones 
176a-f  
 
   ABCG2a  
Compound R1 R2 IC50 (µM)
b Imax (%)
c Log P 
Fumitremorgin C   0.731 ± 0.092 100  
Tariquidar   0.526± 0.085 69 ± 5  
176a H CH3 6.73 ± 1.02 88 ± 6 4.45 
176b H CH2CH2OCH3 14.39 ±11.8 73 ± 4 4.12 
176c H (CH2CH2O)3CH3 1.13 ± 0.27 46 ± 2 3.40 
176d CH3 CH3 8.76 ± 1.59 90 ± 1 4.91 
176e CH3 CH2CH2OCH3 23.24 ± 4.36 103 ± 6 4.58 
176f CH3 (CH2CH2O)3CH3 6.65 ± 1.27 95 ± 6 3.86 
a
Hoechst 33342 microplate assay using ABCG2-overexpressing MCF-7/Topo cells. 
b
Mean values ± 
SEM from three independent experiments performed in triplicate. 
c
Maximal inhibitory effects [%] are 
expressed as inhibition caused by the highest concentration of the compound tested relative to the 
inhibitory effect caused by 10 μM FTC (100% inhibition). 
d
 Calculated values using ACD/Labs I-Lab 
2.0  ilab.acdlabs.com, Algorithm Version: v5.0.0.184 
 
Synthesized ketones were more hydrophilic than the chalcone series (Chapter 3, Table 
3-1). Calculated partition coefficients for the ketones serie were between 3.40 and 4.91 
(lipinski rules, Log P < 5), while this value for the chalcone series was between 5.92 and 
6.97. As shown in the Table 2-1, ketone 176d has the largest partition coefficient (Log P) 
among all the synthesized compounds and its potency was comparable with the FTC 
(100%) and higher than Tariquidar (69%). Compounds 176d and 176e have a large value 
of Log P for the whole series and the highest maximum inhibition (90 and 103% 
respectively, Table 2-1). Compound 176e showed a considerable increase in the maximal 
inhibitory effect (103%) in comparison with compound 176b (73%).  
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2.2.2.2 Selectivity evaluation. Inhibitory activity evaluation on 
ABCB1 and ABCC1 
All synthesized compounds were additionally screened for their inhibition of ABCB1 and 
ABCC1 utilizing the calcein accumulation assay. The screening was conducted at a fixed 
concentration of 1 and 10 μM using Kb-V1 cells (ABCB1) and MDCKII (ABCC1) cell lines. 
Tariquidar (10 μM) was used as standard inhibitor for ABCB1 and Reversan (30 μM) was 
used as standard inhibitor for ABCC1. Figure 2-2 illustrates the effects of the 6 ketones on 
the accumulation of calcein and it exemplifies that the studied substances possess low 
affinity for ABCB1 (Figure 2-2A) and ABCC1 (Figure 2-2B).  
 
Figure 2-2 Effects of ketones 176a-f at 1 and 10 μM concentration on the accumulation of 
calcein in ABCB1 (A) and ABCC1 (B) overexpressing Kb-V1 and MDCKII cells 
respectively. Data were normalized by defining the inhibition caused by 10 μM Tariquidar 
and of 30 μM Reversan as 100 % and are presented as mean ± SD of two independent 
experiments 
All compounds showed lowest affinity at ABCC1, but some compounds presented 
inhibitory activity against ABCB1 above 15%, as compounds 176b, 176c and 176f. 
Concentration-response curves were not generated for the synthesized ketones since 
none of them showed more than 25% inhibition at 10 μM (Table 2-2). 
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Compounds did not show a clear trend based on the substituents (Table 2-2), either the 
presence of methyl in R1, but as shown in Table 2-2, the results for the ABCB1 
transporter the first three compounds showed an increase in the maximal inhibitory effect 
when was added ethylene and triethylenglicol chains in substituent R2 (Table 2-2¡Error! 
No se encuentra el origen de la referencia.). 
Table 2-2 Inhibitory activity evaluation on ABCB1 and ABCC1 by reference compounds 
and ketones 176a-f 
 
 ABCB1a ABCC1b 
Compound Imax (%)
c Imax (%)
d 
Tariquidar  100 n.de 
Reversan n.de 100 
176a 16 ± 1 3± 1 
176b 18± 1 3± 1 
176c 19± 1 5± 1 
176d 14± 2 3± 1 
176e 7± 1 2± 1 
176f 18± 1 3± 1 
a
Calcein-AM microplate assay using ABCB1-
overexpressing Kb-V1 cells. 
b
Calcein-AM 
microplate assay using ABCC1-overexpressing 
MDCKII cells.
 c
Maximal inhibitory effect (Imax) 
relative to the response to tariquidar at a 
concentration of 10 μM (100% inhibition). 
d
Maximal inhibitory effect (Imax) relative to the 
response to reversan at a concentration of 30 μM 
(100% inhibition). 
e
n.d.: not determinated 
 
The maximal inhibitory effect values for the ketones 176a-f over ABCB1 and ABCC1 were 
not significant for these transporters, but, according to what is shown in the Table 2-2, all 
compounds show a preference for ABCB1 than for ABCC1. 
According to the results obtained, the synthesized ketones were selective against ABCG2 
instead of the other transporters here studied. 
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2.2.3 Chemical stability test in Eagle’s Minimum Essential 
Medium (EMEM) 
The metabolism of drugs occurs through basic chemical reactions as soon as the 
administered compound comes into contact with enzymes that are capable of altering its 
chemical structure. Conversely, a drug’s stability after administration is due mainly to its 
lack of transformation by the body’s enzymes. However, many drugs are susceptible to 
some form of chemical decomposition, be it through the interaction with enzymes or 
through improper storage and use, and such degradation often leads to a loss of potency. 
Hydrolysis is the more common pathway for drug breakdown and is the mechanism that 
we will concentrate on here with regard to both chemical stability and metabolism. 
Hydrolysis means the reaction of a molecule with water resulting in the cleavage of a 
chemical bond within that molecule. Although there are a large number of functional 
groups that are susceptible to hydrolysis, esters and amides are the most common ones 
found in drugs prone to hydrolysis.7 
The bioisosteric approach and the replacement of the hydrolysis-sensitive amide bond 
bearing the phenethyl tetrahydroisoquinoline fragment (previously reported ABCG2 
modulators, Figure 1-30, compounds 143 and 145), by ketones moieties resulted in stable 
compounds after incubation in EMEM. As shown in Figure 2-3, synthesized chalcones 
were incubated in EMEM at a temperature of 37°C and aliquots were analyzed by HPLC 
over a period of 24 hours, products of cleavage or degradation of compounds were not 
detected, compounds were not affected by the components present in the incubation 
medium (EMEM) during the assay. 
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Figure 2-3 Chemical stability of compounds 176a-f incubated in EMEM for 24 h (HPLC 
analysis, UV detection at 220 nm). 
2.2.4 Solubility in Eagle’s Minimum Essential Medium (EMEM) 
The solubility in EMEM for ketones was evaluated; aliquots were taken for three different 
concentrations for each compound at three times, the results showed that all chalcones 
were soluble. As shown in Figure 2-4, the concentration found for ketones 176a-f was 
similar in all analyzed aliquots, which means that after 2 h of incubation all compound was 
acting in the assay, and these were not affected by the physiological pH, temperature or 
the substances present in the medium (salts, amino acids or vitamins). Then, the results 
for the inhibition correspond to the entire concentration used in the assay.  
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Figure 2-4 Solubility for ketones in Eagle’s Minimum Essential Medium (EMEM)  
2.2.5 Chemosensitivity assay 
To confirm ABCG2 transporter inhibition, resulting in a reversal of ABCG2 mediated drug 
resistance; the effect of the compound 176a on the proliferation of one cell line was 
investigated using a kinetic crystal violet chemosensitivity assay (Figure 2-5). ABCG2-
overexpressing MCF-7/Topo cells show resistance against the cytostatic drug topotecan, 
a known ABCG2 substrate. The cells were incubated with topotecan alone and in 
combination with different concentrations of the new modulator and the cytostatic drug 
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vinblastine as positive control.8 The modulator was well tolerated up to a concentration of 
3 μM.  
The combination of topotecan at a nontoxic concentration of 100 nM with compound 
176a, resulted in a cytotoxic drug effect, even at a low modulator concentration of 1 µM. A 
higher concentration of the modulator the cyctotoxicity increases. 
 
Figure 2-5 Effect of compound 176a in combination with topotecan on proliferating MCF-
7/Topo cells: vehicle (filled black circles, untreated cells), positive control vinblastine [100 
nM] (filled blue squares), 176a at concentrations of 10 μM (filled red triangles), 3 μM (filled 
green diamonds), 1 μM (filled orange stars) and topotecan alone at 100 nM (filled purple 
circles) 
 
2.3 Conclusion 
In summary, we presented the synthesis and characterization of a series of ketones 
combining quinoline and isoquinoline moieties as ABCG2 modulators. All tested 
compounds showed weak inhibitory activity over ABCB1 and ABCC1 transporter but good 
inhibitory activity towards ABCG2. Compounds with methyl group as substituent in R1 
(176d-f) has the best results for maximal inhibitory effect (Imax) in comparison with 
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reference compound and tariquidar. Compound 176c was the most potent ABCG2 
modulator; with the best IC50 value (1.13 μM) in the Hoechst assay, compound 176e had 
the higher maximal inhibitory effect (103 %) compared to the standard ABCG2 modulator 
Fumitremorgin C and Tariquidar. The unstable benzamide moiety was replaced in a 
bioisosteric approach with a ketone system as central core structure; chemical stability 
tests in EMEM revealed that these compounds (176a-f) are stable to degradation over a 
period of 24 hours of incubation. The hidrophilicity was improved with the addition of 
ethylene and ethylene glycol chains in substituent R2 (Scheme 3-1) as shown in the 
calculated partition coefficient (Table 3-1), in addition, the efficacy for compounds 
increased (Imax 90-103%). The synthesized ketones were more hydrophilic than the 
chalcones series, as can be seen in the calculated partition coefficient, but their IC50 is 
higher that the value for the reference compound, even when their maximal inhibitory 
effect was much higher than the synthesized chalcones and the reference compound. 
2.4 Experimental section 
2.4.1 Synthesis and characterization 
 
General procedure for the preparation of nitro compounds: compounds were 
prepared according to known procedures.9  
1-(3-Nitrophenyl)ethan-1-one  
 
Light yellow solid (1.8 g, yield 50%, Rf PE/EA 1:1 0.67). mp 75-78°C (76-78ºC lit).
9 1H 
NMR (CDCl3, 400 MHz): δ= 8.81 (d, 
4J=1.9 Hz, 1H, ArH), 8.46 (ddd, 3J=8.2, 4J=2.2, 
4J=1.1 Hz, 1H, ArH), 8.32 (d, 3J=7.8 Hz, 1H, ArH), 7.72 (s, 1H, ArH), 2.72 (s, 3H, CH3CO).  
13C NMR (CDCl3, 100 MHz): δ= 195.8 (Cquat), 147.0 (Cquat), 138.4 (Cquat), 133.7 (+), 129.9 
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(+), 127.4 (+), 123.2 (+), 26.7 (+). IR (KBr) [cm-1]: ν = 3237, 3090, 1691, 1520, 1428, 
1348, 1250, 970, 821, 587. 
1-(4-methyl-3-nitrophenyl)ethan-1-one  
 
Yellow solid (1.5 g, yield 65%, Rf PE/EA 7:3 0.43). mp 60-62°C (60-61 lit).
10 1H NMR (400 
MHz, CDCl3): δ 8.52 (d, 
3J=1.5 Hz, 1H, ArH), 8.08 (dd, 3J=8.0, 4J=1.5 Hz, 1H, ArH), 7.47 
(s, 1H, ArH), 2.67 (s, 3H, CH3CO), 2.65 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3): δ 
195.5 (Cquat), 149.2 (Cquat), 138.6 Cquat), 136.1 (Cquat), 133.3 (+), 131.9 (+), 124.6 (+), 26.5 
(+), 20.6 (+). IR [cm-1]: ν = 1692, 1617, 1531, 1348, 1282, 1251, 833, 803. 
General procedure for the preparation of amino compounds (170a-b): The respective 
nitro derivative (1 equiv) was dissolved in a mixture of ethanol and water (2:1), iron 
powder (10 equiv) and conc. HCl (0.05 mL) were added and the mixture was refluxed for 
90 min. Ethyl acetate was added and the mixture was filtered over celite, dried over 
sodium sulfate, filtered again and the solvent evaporated, resulted the corresponding 
amino compound. 
1-(3-aminophenyl)ethan-1-one (170a) 
 
Light brown solid (1.2 g, yield 85%, Rf Pentane:EA 1:1 0.55). mp 93-95°C (94-98ºC).
11 1H 
NMR (CDCl3, 400 MHz): δ= 6.97 (t, 
3J=7.7 Hz, 1H, ArH), 6.90 (m, 1H, ArH), 6.85 (m, 1H, 
ArH) 6.50 (dd, 3J=7.8, 4J=1.7 Hz, 1H, ArH), 2.19 (s, 3H, CH3CO). 
13C NMR (CDCl3, 100 
MHz): δ= 198.6 (Cquat), 146.7 (Cquat), 138.1 (Cquat), 129.4 (+), 119.7 (+), 118.9 (+), 114.0 
(+), 26.7 (+). IR (KBr) [cm-1]: ν =3550, 3473, 3415, 3236, 2925, 2810, 1639, 1618, 1458, 
1384, 1358, 1323, 1238, 870, 621. 
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1-(3-amino-4-methylphenyl)ethan-1-one (170b) 
 
Brown solid (1.4 g, yield 93%, Rf Hex/EA 4:1 0.24). mp 78-80ºC (80-81ºC lit).
10  1H NMR 
(400 MHz, CDCl3): δ 7.28 (dd, 
3J=7.5, 4J=2.0 Hz, 1H, ArH), 7.27 (d, 3J=7.3, 1H, ArH), 
7.12 (d, 3J=7.5, 1H, ArH), 2.54 (s, 3H, COCH3), 2.21 (s, 3H, CH3). 
13C NMR (100 MHz, 
CDCl3): δ 198.3 (Cquat), 144.8 (Cquat), 136.2 (Cquat), 130.4 (Cquat), 128.0 (+), 119.1 (+), 
113.8 (+), 26.5 (+), 17.5 (+). IR [cm-1]: ν = 3367, 1672, 1573, 1422, 1356, 1291, 1237, 
1199. 
 
General procedure for the amide formation (171a-b)12: TsCl (1.2 equiv) and amine 
(170a-b) were added, in that order, at 0 °C under N2 to a flask containing quinaldic acid 
(1.2 equiv), triethylamine (2 equiv), and CH2Cl2, and the mixture was stirred at 40-50°C 
overnight. AcOH (5% aq.) was added to quench the reaction, the organic phase was 
separated and washed three times with water, dried over sodium sulfate, filtered again 
and the solvent evaporated.The obtained solid was washed with ether furnishing the 
desired product. 
N-(3-Acetylphenyl)quinoline-2-carboxamide (171a) 
 
White solid (0.500 g, yield quant, Rf PE:EA 2:1 0.40).
1H NMR (CDCl3, 400 MHz): δ= 8.43 
(s, 2H, quinol), 8.39 (t, 3J=1.9 Hz, 1H, quinol), 8.25 (m, 2H, ArH), 7.96 (d, 3J=8.2 Hz, 1H, 
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quinol), 7.87 (t, 3J=8.3 Hz, 1H, ArH), 7.79 (d, 3J=7.9 Hz, 1H, ArH), 7.71 (t, 3J=7.5 Hz, 1H, 
quinol), 7.56 (t, 3J=7.9 Hz, 1H, quinol), 2.70 (s, 3H, CH3). 
13C NMR (CDCl3, 100 MHz): δ= 
197.8 (Cquat), 162.3 (Cquat), 149.1 (Cquat), 146.1 (Cquat), 138.3 (Cquat), 138.1 (Cquat), 137.9 
(Cquat), 130.5 (+), 129.5 (+), 129.5 (+), 129.4 (+), 128.4 (+), 127.8 (+), 124.2 (+), 124.1 (+), 
119.3 (+), 118.7 (+), 26.7 (+). IR (KBr) [cm-1]: ν =3483, 3416, 3341, 3082, 2923, 1687, 
1591, 1530, 1504, 1442, 1365, 1295, 1126, 955, 846, 774, 686, 584. HRMS (EI-MS) 
calcd. For C18H15N2O2 [M+H]
+: 291.1089; found [M+H]+: 291.1128. 
N-(5-Acetyl-2-methylphenyl)quinoline-2-carboxamide (171b) 
 
Light yellow solid (0.700 g, yield quant, Rf PE/EA 2:1 0.52). 
1H NMR (400 MHz, CDCl3): δ 
8.95 (d, 3J=7.7 Hz, 1H, quinol), 8.40 (s, 2H, ArH quinol), 8.17 (d, 3J=8.5 Hz, 1H, ArH), 
7.93 (d, 3J=9.0 Hz, 1H, quinol), 7.82 (ddd, 3J=8.4, 3J=6.9 Hz, 1H, quinol), 7.73 (dd, 3J=7.9, 
1H, ArH), 7.67 (ddd, 3J= 8.1, 3J=6.9 Hz, 1H, quinol), 7.35 (d, 3J=7.9 Hz, 1H, quinol), 2.65 
(s, 3H, CH3), 2.55 (s, 3H, COCH3).
  13C NMR (100 MHz, CDCl3): δ= 197.8 (Cquat), 162.2 
(Cquat), 149.5 (Cquat), 146.2 (Cquat), 138.0 (Cquat), 136.2 (Cquat), 133.5 (Cquat), 130.7 (Cquat), 
130.4 (+), 129.8 (+), 129.5 (+), 128.3 (+), 127.8 (+), 124.1 (+), 121.5 (+), 118.6 (+), 26.7 
(+), 18.0 (+). IR [cm-1]: ν = 3420, 3050, 2910, 1670, 1580, 1410, 1350, 1220, 1080, 760. 
HRMS (EI-MS) calcd. For C19H17N2O2 [M+H]
+: 305.1245; found [M+H]+: 305.1285. 
 
General procedure for the bromination of ketones 172a-b:13 To a solution of 
acetophenone (10 mmol) in methanol at reflux conditions were added 10% (w/w) silica gel 
and  slowly N-bromosuccinimide (12 mmol), the progress of the reaction was monitored 
by TLC until the disappearance of the substrate. The reaction was filtered after the 
completion of the reaction. The filtrate was concentrated under vacuum and the solid was 
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washed twice with distilled water, then aqueous sodium thiosulfate was added to quench 
the reaction and the product was extracted with dichloromethane, organic layers were 
collected and washed thrice with water, dried over anhydrous Na2SO4, filtered and 
concentrated to give the desired product. 
N-(3-(2-Bromoacetyl)phenyl)quinoline-2-carboxamide (172a) 
  
White solid (0.500 g, yield 84%, Rf PE:EA 2:1 0.67). 
1H NMR (CDCl3, 400 MHz): δ 8.46 (t, 
3J=7.9 Hz, 1H, quinol), 8.42 (s, 1H, quinol), 8.27 (d, 3J=8.5 Hz, 1H, ArH), 8.22 (d, 3J=7.7 
Hz, 1H, quinol), 7.95 (d, 3J=8.2 Hz, 1H, quinol), 7.86 (ddd, 3J=8.4, 3J=6.9 Hz, 1H, ArH), 
7.81 (m, 1H, quinol), 7.72 (m, 2H, ArH), 7.56 (t, 3J=7.9 Hz, 1H, quinol), 4.54 (s, 2H, 
CH2Br).
13C NMR (CDCl3, 100 MHz): δ 191.0 (Cquat), 162.2 (Cquat), 148.9 (Cquat), 145.9 
(Cquat), 138.5 (Cquat), 138.4 (Cquat), 134.8 (+), 130.8 (+), 129.7 (+), 128.6 (+), 127.9 (+), 
125.0 (+), 124.7 (+), 119.8 (+), 118.8 (+), 31.1 (-). IR (KBr) [cm-1]: ν =3483, 3416, 3341, 
3082, 2923, 1687, 1591, 1530, 1504, 1442, 1365, 1295, 1126, 955, 846, 774, 686, 584. 
HRMS (EI-MS) calcd. For C18H14BrN2O2 [M+H]
 +: 369.0194; found [M+H] +: 369.0233. 
N-(5-(2-Bromoacetyl)-2-methylphenyl)quinoline-2-carboxamide (172b) 
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Light yellow solid (0.720 g, yield 77%, Rf PE:EA 2:1 0.59). 
1H NMR (CDCl3, 400 MHz): δ 
9.02 (d, 3J=1.7 Hz, 1H, quinol), 8.41 (s, 1H, quinol), 8.18 (d, 3J=8.5 Hz, 1H, ArH), 7.94 (d, 
3J=8.2 Hz, 1H, quinol), 7.86  (m, 1H, quinol), 7.77 (d, 3J=7.9 Hz, 2H, ArH), 7.68 (dd, 
3J=8.1, 3J=7.0 Hz, 1H, quinol), 7.39 (d, 3J=7.9 Hz, 1H, quinol), 4.54 (s, 2H, CH2Br), 2.57 
(s, 3H, CH3). 
13C NMR (CDCl3, 100 MHz): δ 192.6 (Cquat), 162.3 (Cquat), 149.6 (Cquat), 
146.6 (Cquat), 138.1 (Cquat), 136.4 (Cquat), 134.8 (Cquat), 133.3 (+), 131.1 (+), 130.5 (+), 
129.8 (+), 129.6 (+), 128.4 (+), 127.9 (+), 124.8 (+), 121.9 (+), 118.7 (+), 31.4 (-), 20.6 (+). 
IR (KBr) [cm-1]: ν 3483, 3416, 3341, 3082, 2923, 1687, 1591, 1530, 1504, 1442, 1365, 
1295, 1126, 955, 846, 774, 686, 584. HRMS (EI-MS) calcd. For C19H16BrN2O2 [M+H]
 +: 
383.0350; found [M+H]+: 383.0396. 
tert-Butyl 7-hydroxy-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (173) 
 
 
6-Methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol hydrochloride (1 mmol) and triethylamine 
(2.5 equiv) were dissolved in 10 mL of dry DCM, the mixture was cooled in an ice bath 
and di-tert-butyl dicarbonate (1 equiv) was added slowly. The mixture was stirred at room 
temperature overnight, and then washed with water and brine, dried over magnesium 
sulphate, filtered and the solvent evaporated. The compound was purified by column 
chromatography (PE:EA 2:1), white solid (3.0 g, yield 89%, Rf PE:EA 1:1 0.55). mp 124-
126 ºC (123.6-124.2ºC lit).14 1H NMR (CDCl3, 400 MHz): δ= 6.85 (s, 1H, ArH), 6.70 (s, 
1H, ArH), 4.47 (s, 2H, NCH2), 3.81 (s, 3H, OCH3), 3.60 (m, 2H, NCH2CH2), 2.75 (t, 
3J=5.6 
Hz, 2H, NCH2CH2), 1.48 (s, 9H, C(CH3)3). 
13C NMR (CDCl3, 100 MHz): δ= 154.8 (Cquat), 
151.7 (Cquat), 149.5 (Cquat), 138.5 (Cquat), 133.1 (Cquat), 120.1 (+), 112.5 (+), 83.4 (Cquat), 
56.0 (+), 45.1 (-), 40.4 (-), 28.9 (-), 28.4 (+). IR (KBr) [cm-1]: ν = 3024, 2976, 1685. 
 
2-Methoxyethyl 4-methylbenzenesulfonate15 
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A solution of 4-toluenesulfonyl chloride (0.06 mol) in dichloromethane was added drop-
wise to a solution of (2-methoxyethoxy)ethanol (0.057 mol) and triethylamine (0.114 mol) 
in dichloromethane at 0°C under a nitrogen atmosphere. The formation of a white 
precipitate was observed. The reaction mixture was stirred at room temperature for 18h 
and then poured into water (50 mL). The aqueous layer was extracted with 
dichloromethane. The organic layers were combined and washed with 3M HCl (50 mL), 
saturated solution of sodium bicarbonate (50 mL), and water (50 mL). The organic phase 
was dried over magnesium sulfate, filtered and the solvent was removed in vacuo. Pale 
yellow oil (1.45 g, yield 100%). 1H NMR (CD3OD, 400 MHz): δ= 7.82 (d, 
3J=8.3 Hz, 2H, 
ArH), 7.36 (d, 3J=8.0 Hz, 2H, ArH), 4.17 (d, 3J=1.2 Hz, 2H, OCH2CH2), 3.60 (s, 2H, 
CH2OCH3), 3.32 (s, 3H, CH3), 2.46 (s, 3H, OCH3).
13C NMR (CD3OD, 100 MHz): δ= 
140.87 (Cquat), 129.12 (Cquat), 125.87 (+), 124.03 (+), 65.99 (-), 65.11 (-), 55.06 (+), 17.68 
(+). IR (KBr) [cm-1]: ν =3070, 2928, 2822, 1598, 1495, 1356, 1311, 1018, 817, 689. 
2-(2-(2-Methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 
 
 
 
2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate was prepared according 
to known procedures.15 Pale yellow oil (2.0 g, yield 100%). 1H NMR (CD3OD, 400 MHz): 
δ= 7.77 (d, 3J=8.3, 2H, tosyl), 7.32 (d, 3J=8.2, 2H, tosyl), 4.13 (t, 3J=4.8, 2H, CH2 PEG), 
3.66 (t, 4J=4.8, 2H, CH2 PEG), 3.55 (m, 6H, 3CH2 PEG), 3.48 (m, 2H, CH2 PEG), 3.36 (s, 
3H, OCH3), 2.43 (s, 3H, CH3 tosyl). 
6-Methoxy-7-(2-methoxyethoxy)-1,2,3,4-tetrahydroisoquinoline-2,2,2-trifluoroacetate 
(175a) 
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Compound 175a was prepared according to known procedures with slight modifications.14 
(quantitative yield, Rf DCM:MeOH 19:1 0.50). 
1H NMR (CD3OD, 400 MHz): δ= 6.81 (s, 
1H, ArH), 6.79 (s, 1H, ArH), 4.25 (s, 2H, CH2), 4.12 (m, 2H, CH2), 3.82 (s, 3H, CH3), 3.76 
(m, 2H, CH2), 3.46 (t, 
3J=6.4 Hz, 2H, CH2), 3.41 (s, 3H, CH3), 3.04 (t, 
3J=6.3 Hz, 2H, CH2). 
13C NMR (CD3OD, 100 MHz): δ= 149.6 (Cquat), 147.6 (Cquat), 124.0 (Cquat), 119.6 (Cquat), 
111.6 (+), 70.7 (-), 68.4 (-), 57.8 (+), 55.0 (+), 44.0 (-), 41.5 (-), 24.2 (-).HRMS (EI-MS) 
calcd. For C15H21F3NO5 [M+H]
 +: 352.1327; found [M+H] +: 352.1347. 
6-Methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1,2,3,4-tetrahydroisoquinoline-
2,2,2-trifluoroacetate (175b)  
 
 
Compound 175b was prepared according to known procedures with slight modifications.14 
Sticky brown solid (Yield 79%, Rf DCM:MeOH 19:1 0.46). 
1H NMR (CDCl3, 400 MHz): δ= 
6.60 (s, 1H, CH THIQ), 6.57 (s, 1H, CH THIQ), 4.39 (s, 2H, NCH2 THIQ), 4.06 (t, 
3J=5.04 
Hz, 4H, CH2 PEG), 3.77 (t, 
3J=5.1 Hz, 4H, 2CH2 PEG), 3.65 (m, 4H, 2CH2 PEG), 3.56 (m, 
8H, 4CH2 PEG), 3.51 (m, 2H, CH2 THIQ), 3.46 (m, 4H, CH2 PEG), 3.30 (s, 6H, 2OCH3), 
2.65 (t, 3J=5.3 Hz, 2H, CH2 THIQ). 
13C NMR (CDCl3, 100 MHz): δ= 154.8 (+), 147.5 
(Cquat), 147.4 (Cquat), 127.5 (Cquat), 126.2 (Cquat), 115.0 (+), 112.7 (+), 79.7 (Cquat), 71.9 (-
),70.78 (-), 70.6 (-), 70.5 (-), 69.6 (-), 69.0 (-), 69.0 (-), 59.0 (+), 45.5 (-), 44.8 (+), 41.9 (-), 
40.6 (-), 28.4 (+), 28.4 (-). IR (KBr) [cm-1]: ν = 2920, 2875, 1670. 
 
General procedure for the synthesis of compounds 176a-f A mixture of the 
tretrahydroisoquinoline derivative 174, 175a-b (1 equiv), 172a-b (1 mol) and potassium 
carbonate (3 equiv) was refluxed during 18 h in CH3CN, the solvent was evaporated, the 
residue taken up in water and extracted with DCM. The solution was dried over MgSO4, 
filtered and concentrated to give the crude product. Compounds were purified by column 
chromatography (PE:EA) and reverse column chromatography or preparative HPLC. 
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N-(3-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)phenyl)quinoline-2-
carboxamide (176a) 
 
Light yellow solid. (0.025 g, yield 75%, Rf PE:EA 2 : 1 0.36). 
1H-NMR (400 MHz, CDCl3): 
δ 8.38 (m, 1H, quinol), 8.30 (dd, 3J=7.6, 3J=8.4 Hz, 2H, quinol), 8.12 (dd, 3J=8.3, 3J=7.9 
Hz, 2H, ArH), 7.87 (d, 3J=8.1 Hz, 1H, quinol), 7.78 (t, 3J=7.4 Hz, 1H, quinol), 7.69 (m, 2H, 
ArH), 7.47 (t, 3J=6.2 Hz, 1H, quinol), 6.62 (s, 1H, CH THIQ), 6.52 (s, 1H, CH THIQ), 4.90 
(s, 2H, COCH2), 4.56 (m, 2H, CH2 THIQ), 3.83 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.13 
(m, 4H, 2CH2 THIQ). 
13C-NMR (100 MHz, CDCl3): δ 194.5 (Cquat), 169.7 (Cquat), 149.2 
(Cquat), 148.8 (Cquat), 148.5 (Cquat), 146.6 (Cquat), 138.6 (Cquat), 138.0 (Cquat), 136.2 (Cquat), 
134.4 (Cquat), 130.5 (+), 129.9 (+), 129.7 (+), 128.4 (+), 127.8 (+), 125.8 (+), 123.7 (+), 
122.3 (+), 118.5 (+), 111.2 (+), 55.9 (-), 52.8 (+), 50.0 (-), 45.7 (-), 24.1 (-). IR (KBr) [cm-
1]: ν = 2880, 1689, 1635, 1425, 1150, 753, 726. HRMS (EI-MS) calcd. For C29H28N3O4 
[M+H]+: 482.2035; found [M+H]+: 482.2048 
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N-(3-(2-(6-Methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176b) 
 
Light yellow solid. (0.030 g, yield 90%, Rf PE:EA 2:1 0.31). 
1H-NMR (400 MHz, CDCl3): δ 
8.38 (m, 2H, quinol), 8.33 (s, 2H, quinol), 8.21 (d, 3J=8.5 Hz, 2H, ArH), 7.93 (d, 3J=8.3 Hz, 
2H, quinol), 7.83 (dd, 3J=8.4, 3J=7.0 Hz, 2H, ArH), 7.67 (t, 3J=7.9 Hz, 2H, quinol), 6.80 (s, 
1H, CH THIQ), 6.62 (s, 1H, CH THIQ), 5.28 (s, 2H, COCH2), 4.19 (s, 2H, CH2 THIQ), 3.87 
(d, 3J=5.4 Hz, 2H, CH2 PEG), 3.83 (s, 3H, OCH3), 3.80 (d, 
3J=4.7 Hz, 2H, CH2 PEG), 3.47 
(s, 3H, CH2OCH3), 3.14 (m, 2H, CH2 THIQ), 2.86 (t, 
3J=5.7 Hz, 2H, CH2 THIQ). 
13C-NMR 
(100 MHz, CDCl3): δ 187.0 (Cquat), 163.4 (Cquat), 146.3 (Cquat), 138.6 (Cquat), 138.0 (Cquat), 
134.3 (Cquat), 130.5 (Cquat), 129.8 (Cquat), 129.7 (Cquat), 129.5 (+), 128.4 (+), 127.8 (+), 
125.8 (+), 125.6 (+), 125.6 (+), 122.8 (+), 120.6 (+), 118.7 (+), 111.8 (+), 111.6 (+), 71.0 (-
), 68.7 (-), 59.6 (-), 55.8 (+), 49.5 (+), 49.3 (-), 45.8 (-), 29.7 (-). IR (KBr) [cm-1]: ν = 2903, 
1673, 1645, 1402, 1189, 764, 731. HRMS (EI-MS) calcd. For C31H32N3O5 [M+H]
 +: 
526.2297; found [M+H]+: 526.2315 
 
 
 
 
 
 
Ketones as ABCG2 Modulators 23 
 
N-(3-(2-(6,7-bis(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176c) 
 
Light yellow solid. (0.026 g, yield 85%, Rf PE:EA 2:1 0.20). 
1H-NMR (400 MHz, CDCl3): δ 
8.38 (m, 2H, quinol), 8.33 (s, 2H, quinol), 8.20 (d, 3J=8.5 Hz, 1H, ArH), 7.91 (s, 1H, ArH 
quinol), 7.84 (m, 1H, quinol), 7.67 (t, 3J=7.2 Hz, 1H, ArH), 7.53 (m, 2H, ArH), 6.81 (s, 1H, 
CH THIQ), 6.62 (s, 1H, CH THIQ), 5.27 (s, 2H, COCH2), 4.21 (s, 2H, CH2 THIQ), 3.91 
(dd, 3J=5.7, 4.3 Hz, 2H, CH2 THIQ), 3.82 (s, 3H, OCH3), 3.81 (s, 4H, CH2 PEG), 3.78 (m, 
4H, CH2 PEG), 3.59 (m, 4H, CH2 PEG), 3.39 (s, 3H, CH2OCH3), 3.32 (d, 
3J=3.6 Hz, 2H, 
CH2 THIQ). 
13C-NMR (100 MHz, CDCl3): δ 195.0 (Cquat), 162.3 (Cquat), 149.0 (Cquat), 148.6 
(Cquat), 146.3 (Cquat), 138.3 (Cquat), 137.8 (Cquat), 134.1 (Cquat), 130.5 (Cquat), 129.8 (Cquat), 
129.7 (Cquat), 129.6 (+), 128.3 (+), 127.6 (+), 125.8 (+), 125.6 (+), 122.7 (+), 120.6 (+), 
118.6 (+), 111.7 (+), 111.6 (+), 71.9 (-), 70.6 (-), 70.5 (-), 69.4 (-), 68.7 (-), 68.5 (-), 58.8 
(+), 55.8 (+), 49.6 (-), 49.2 (-), 28.6 (-). IR (KBr) [cm-1]: ν = 2892, 1705, 1687, 1412, 
1126, 749, 731. HRMS (EI-MS) calcd. For C35H40N3O7 [M+H]
+: 614.2822; found [M+H]+: 
614.2851 
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N-(5-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-2-
methylphenyl)quinoline-2-carboxamide (176d) 
 
Light yellow solid. (0.024 g, yield 82%, Rf PE:EA 2:1 0.40). 
1H-NMR (400 MHz, CDCl3): δ  
8.61 (m, 2H, quinol), 8.32 (t, 3J=7.5 Hz, 2H, quinol), 8.16 (m, 1H, ArH), 7.87 (s, 1H, ArH), 
7.75 (t, 3J=8.4 Hz, 1H, ArH), 7.61 (t, 3J=7.0 Hz, 1H, quinol), 7.46 (d, 3J=8.3 Hz, 1H, 
quinol), 6.51 (s, 1H, CH THIQ), 6.44 (s, 1H, CH THIQ), 5.23 (s, 2H, COCH2), 3.91 (s, 2H, 
CH2 THIQ), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.09 (t, 
3J=5.5 Hz, 2H, CH2 THIQ), 
2.68 (t, 3J=5.7 Hz, 2H, CH2 THIQ). 
13C-NMR (100 MHz, CDCl3): δ 200.2 (Cquat), 162.2 
(Cquat), 149.2 (Cquat), 146.2 (Cquat), 138.9 (Cquat), 138.1 (Cquat), 135.6 (Cquat), 132.2 (Cquat), 
130.5 (Cquat), 129.7 (Cquat), 128.4 (+), 127.8 (+), 121.4 (+), 119.6 (+), 118.6 (+), 113.6 (+), 
111.9 (+), 110.4 (+), 109.1 (+), 56.0 (+), 55.2 (-), 53.4 (-), 47.2 (-), 29.7 (-), 17.3 (+). IR 
(KBr) [cm-1]: ν = 2873, 1712, 1696, 1402, 1127, 762, 734. HRMS (EI-MS) calcd. For 
C30H30N3O4 [M+H]
 +: 496.2192; found [M+H]+: 496.2224 
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N-(3-(2-(6-Methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176e) 
 
Light yellow solid. (0.032 g, yield 88%, Rf PE:EA 2:1 0.33). 
1H-NMR (400 MHz, CDCl3): δ 
8.95 (d, 3J=7.7 Hz, 1H, quinol), 8.40 (s, 1H, quinol), 8.16 (d, 3J=8.4 Hz, 1H, ArH), 7.93 (d, 
3J=8.2 Hz, 1H, quinol), 7.84 (m, 1H, quinol), 7.73 (d, 3J=9.7 Hz, 2H, ArH), 7.67 (t, 3J=7.5 
Hz, 1H, quinol), 7.35 (d, 3J=8.0 Hz, 1H, quinol), 6.57 (s, 1H, CH THIQ), 6.55 (s, 1H, CH 
THIQ), 4.94 (s, 2H, COCH2) 4.12 (s, 2H, CH2 THIQ), 3.88 (s, 3H, OCH3), 3.60 (t, 
3J=5.6 
Hz, 2H, CH2 THIQ), 3.37 (s, 3H, CH2OCH3), 2.76 (t, 
3J=5.6 Hz, 2H, CH2 THIQ), 2.55 (s, 
3H, CH3). 
13C-NMR (100 MHz, CDCl3): δ 200.2 (Cquat), 162.19 (Cquat), 149.2 (Cquat), 146.2 
(Cquat), 138.9 (Cquat), 138.1 (Cquat), 135.6 (Cquat), 135.5 (Cquat), 132.2 (Cquat), 130.5 (Cquat), 
129.8 (Cquat), 129.6 (Cquat), 128.4 (+), 127.8 (+), 127.6 (+), 127.0 (+), 121.4 (+), 118.5 (+), 
113.6 (+), 76.7 (-), 70.9 (-), 68.6 (-), 59.1 (+), 56.0 (+), 55.6 (-), 51.2 (-), 30.9 (-), 17.3 (+). 
IR (KBr) [cm-1]: ν = 2905, 1652, 1624, 1423, 1151, 739, 725. HRMS (EI-MS) calcd. For 
C32H34N3O5 [M+H]
+: 540.2454; found [M+H]+: 540.2487 
 
 
 
 
 
 
26 New Analogs of tariquidar 
 
 
 
N-(5-(2-(6,7-bis(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)-2-methylphenyl)quinoline-2-carboxamide (176f) 
 
Light yellow solid. (0.031 g, yield 82%, Rf PE:EA 2:1 0.28). 
1H-NMR (400 MHz, CDCl3): δ 
8.67 (m, 1H, quinol), 8.38 (d, 3J=3.9 Hz, 1H, quinol), 8.15 (d, 3J=8.5 Hz, 2H, ArH), 7.93 (d, 
3J=8.1 Hz, 1H, quinol), 7.74 (m, 1H, ArH), 7.84 (m, 1H, quinol), 7.69 (m, 1H, quinol), 7.52 
(s, 1H, quinol), 6.87 (s, 1H, CH THIQ), 6.65 (s, 1H, CH THIQ), 5.29 (s, 2H, COCH2), 4.20 
(s, 2H, CH2 THIQ), 4.14 (m, 16H, 4CH2 PEG), 3.87 (s, 3H, OCH3), 3.72 (t, 
3J=5.2 Hz, 4H, 
2CH2 PEG), 3.65 (d, 
3J=4.8 Hz, 4H, 2CH2 PEG), 3.55 (s, 3H, CH2OCH3), 2.50 (s, 3H, 
CH3). 
13C-NMR (100 MHz, CDCl3): δ 199.7 (Cquat), 161.6 (Cquat), 148.7 (Cquat), 147.6 
(Cquat), 146.1 (Cquat), 145.7 (Cquat), 138.4 (Cquat), 137.6 (Cquat), 136.4 (Cquat), 135.1 (Cquat), 
131.7 (Cquat), 130.0 (Cquat), 129.2 (+), 127.9 (+), 127.3 (+), 120.9 (+), 118.1 (+), 113.1 (+), 
112.8 (+), 112.0 (+), 111.4 (+), 110.2 (+), 71.4 (-), 70.3 (-), 70.1 (-), 70.0 (-), 69.1 (-), 68.4 
(-), 68.2 (-), 58.5 (+), 55.5 (+), 46.7 (-), 29.2 (-), 16.8 (+). IR (KBr) [cm-1]: ν = 2873, 1675, 
1649, 1392, 1129, 741, 716. HRMS (EI-MS) calcd. For C36H42N3O7 [M+H]
 +: 628.2978; 
found [M+H]+: 628.2994. 
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2.4.2 Biological investigations 
2.4.2.1 Drugs and Chemicals 
Hoechst 33342 (Invitrogen, Karlsruhe, Germany) was dissolved in sterile water to produce 
a 0.8 mM working solution. Calcein-AM (4 mM in anhydrous DMSO) and pluronic F127 
were obtained from Biotium (Hayward, CA, USA) and diluted to 100 μM. Bovine serum 
albumin (BSA) was purchased from Serva (Heidelberg, Germany). Fumitremorgin C 
(FTC; Merck, Darmstadt, Germany) was also dissolved in DMSO and diluted to a 
concentration of 1 mM. Reversan was purchased from Tocris Bioscience (Bristol, UK) and 
diluted to a 3 mM working solution in DMSO. Topotecan and vinblastine for cell culture 
supplementation were purchased from Sigma (Munich, Germany). Loading buffer 
(calcein-AM assay) was made of 120 mM NaCl, 5 mM KCl, 2 mM MgCl2.6H2O, 1.5 mM 
CaCl2.2H2O, 25 mM HEPES, 10 mM glucose, pH 7.4. PBS (phosphate buffered saline) 
was made of 8.0 g/L NaCl, 1.0 g/L Na2HPO4.2H2O, 0.20 g/L KCl, 0.20 g/L KH2PO4 and 
0.15 g/L NaH2PO4.H2O. The pH value was adjusted to 7.3 - 7.4. A solution of 4% (m/m) 
paraformaldeyde (PFA) in PBS was made by stirring 2 g of PFA per 50 g total solution 
while heating on a magnetic stirrer for approximately 30 min. The test compounds were 
dissolved in DMSO at a concentration of 10 mM if possible, depending on the solubility of 
the compounds. All stock solutions were stored at −20 °C. If not otherwise stated, 
chemicals (p.a. quality) were obtained from Merck (Darmstadt, Germany). Purified water 
(Milli-Q system, Millipore, Eschborn, Germany) was used throughout. 
2.4.2.2 Cell lines and culture conditions 
MCF-7/Topo cells, an ABCG2-overexpressing subclone of MCF-7 cells (ATCC® HTB-
22™, American Type Culture Collection, Manassas, VA), were obtained as described16 
and cultured in water-saturated atmosphere (95% air, 5% CO2) at 37 °C in 75 cm2 culture 
flasks from Nunc (Wiesbaden,Germany) in Eagle’s minimum essential medium (EMEM; 
Sigma, Munich, Germany) containing l-glutamine, 2.2 g/L NaHCO3 and 110 mg/L sodium 
pyruvate supplemented with 10% fetal calf serum (FCS; Biochrom, Berlin, Germany) and 
550 nm topotecan to induce overexpression of the ABCG2 transporter. Human Kb-V1 
cells, an ABCB1-overexpressing subclone of Kb cells (ATCC® CCL-17™), were obtained 
and cultured as described.16 MDCKII-MRP1 cells: MDCKII cells (Madin-Darby Canine 
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Kidney cells, strain II; a dog epithelial cell line; ATCC® CRL-2936™), transfected with 
human ABCC1, 17,18 were a kind gift from Prof. Dr. P. Borst from the Netherland Cancer 
Institute (Amsterdam, NL). The cells were cultured in DMEM supplemented with 10% 
FCS, 3.7 g/L NaHCO3 and 110 mg/L sodium pyruvate. Trypsinization was performed at 37 
°C (95% air, 5% CO2) for 20-30 min using 0.1% trypsin / 0.04% EDTA. All cells were 
routinely monitored for mycoplasma contamination by PCR (Venor GeM, Minerva Biolabs, 
Berlin, Germany) and only mycoplasma-negative cultures were used. 
2.4.2.3 Calcelin-AM microplate assay for the determination of 
ABCB1 inhibition 
Kb-V1 cells were seeded into flat-bottomed 96-well plates (Greiner, Frickenhausen, 
Germany) at a density of 20,000 cells per well. On the following day, cells were washed 
with loading buffer (120 mM NaCl, 5 mM KCl, 2 mM MgCl2.6H2O, 1.5 mM CaCl2.2H2O, 25 
mM HEPES, 10 mM glucose, pH 7.4) in order to remove unspecific serum esterases. 
Afterwards, cells were incubated with loading suspension (loading buffer, 5 mg/mL BSA, 
1.25 μL/mL pluronic F127 (20% in DMS )) containing 0.5 μM calcein-AM and the test 
compounds at increasing concentrations (10 nM – 100 μM) for 10 min (37 °C / 5% C 2) 
to construct concentration-response curves. Tariquidar served as positive control at a final 
concentration of 1 μM corresponding to 100% 3 inhibition of calcein-AM efflux. 
Subsequently, the loading suspension was discarded and cells were fixed with 4% PFA 
solution in PBS for 30 min. After three washing steps, fixed cells were overlaid with 
loading buffer and relative fluorescence intensities were determined with a GENios Pro 
microplate reader (Tecan Deutschland, Crailsheim, Germany). Measurement mode: 
fluorescence top; excitation filter (calcein-AM): 485/20; emission filter (calcein-AM): 
535/25; number of reads: 10; integration time: 40 μs; lag time: 0 μs; mirror selection: 
Dichroic 3; plate definition file: GRE96ft.pdf; multiple reads per well (Circle): 3x3; time 
between move and flash: 100 ms. On each plate, the optimal gain was calculated by 
determination of the fluorescence intensity in the presence of the reference substance, 
tariquidar. IC50 values were calculated using SIGMA PLOT 11.0 (Systat Software, Erkrath, 
Germany), “Four parameter logistic curve” fitting. Errors were expressed as standard error 
of the mean (SEM). 
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2.4.2.4 Calcelin-AM microplate assay for the determination of 
ABCC1 inhibition 
MDCKII cells were seeded into flat-bottomed 96-well plates at a density of about 20,000 
cells/well. On the following day, cells were washed with loading buffer in order to remove 
unspecific serum esterases. Afterwards, cells were incubated with loading suspension 
(loading buffer, 5 mg/mL BSA, 1.25 μL/mL pluronic F127 (20% (m/v) in DMS )) 
containing 0.5 μM calcein-AM and the test compound at increasing concentrations (10 
nM-100 μM) for 60 min (37 °C / 5% C 2). Reversan served as positive control at a final 
concentration of 30 μM corresponding to 100% ABCC1 inhibition. In general, test 
compounds were investigated as triplicates, controls as sextuplicates, respectively. 
Subsequently, the loading suspension was discarded, and the cells were fixed with 4% 
PFA solution for 30 min. After three washing circles (loading buffer), fixed cells were 
overlaid with loading buffer, and relative fluorescence intensities were determined at 
535/25 nm at the GENios Pro microplate reader after excitation at 485/20 nm. The 
following cell quantification procedure was performed by analogy with the H33342 assay. 
The obtained mean fluorescence intensities were related to the controls and plotted 
against the various concentrations of test compounds. TECAN instrument settings: 
Measurement mode: fluorescence top; number of reads: 10; integration time: 40 μs; lag 
time: 0 μs; mirror selection: Dichroic 3 (e.g. Fl.); plate definition file: GRE96ft.pdf; multiple 
reads per well (Circle): 3x3; time between move and flash: 100 ms. 
2.4.2.5 Hoechst 33342 microplate assay for the determination of 
ABCG2 inhibition 
Optimal conditions of the assay were systematically determined as described elsewhere19 
with slight modifications. MCF-7/Topo cells were seeded into 96-well plates at a density of 
20,000 cells/well (total volume: 100 mL) and allowed to attach to the surface of the 
microplates overnight in a water-saturated atmosphere (95% air, 5% CO2) at 37 °C. The 
next day, the culture medium was removed, and the cells were incubated with loading 
suspension (EMEM, supplemented as described above, and 0.8 μM Hoechst 33342) in 
combination with the test compound at increasing concentrations (10 nM-100 μM) for 2 h 
(37 °C, 5% CO2). FTC at a final concentration of 10 μM served as reference compound; 
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under these conditions the response was defined as 100% inhibition of Hoechst 33342 
efflux. The supernatants were drained and the cells were fixed for 30 min under light 
protection using 100 mL per well of a 4% PFA solution. Finally, MCF-7/Topo cells were 
washed with PBS (2x250 mL per well) to remove residual dye. Cells were overlaid with 
PBS (100 mL), and the fluorescence intensities were determined using a GENios Pro 
microplate reader (TECAN Deutschland GmbH, Crailsheim, Germany). Measurement 
mode: fluorescence top; excitation filter: 340/35 nm; emission filter: 485/20 nm; number of 
reads: 10; integration time: 40 ms; lag time: 0 ms; mirror selection: automatic; plate 
definition file: GRE96ft.pdf; multiple reads per well (circle, 3x3); time between move and 
flash: 50 ms. On each plate, the optimal gain was calculated by determination of the 
fluorescence intensity in the presence of the reference compound FTC. IC50 values were 
calculated using SIGMA PL T 11.0, “four parameter logistic curve” fitting. Errors are 
expressed as standard error of the mean (SEM). 
2.4.2.6 Chemical Stability in Eagle’s minimum essential medium 
(EMEM) 
Stock solutions of the test compounds (3 mM) were prepared in DMSO. A 1:50 dilution of 
the substances in EMEM was prepared in 1.5-mL polypropylene reaction vessels 
(Eppendorf, Hamburg, Germany). The samples were shortly vortexed and incubated at 37 
°C. At different periods of time, aliquots were taken, and the samples were mixing with 
two parts of ice-cold acetonitrile. For quantitative precipitation, the samples were vortexed 
and stored at 4 °C for 30 min. Finally, samples were centrifuged for 5 min at 14,000 g, 
using an Eppendorf MiniSpin plus centrifuge, and the supernatants were transferred into 
new reaction vessels. Prior to HPLC analysis, the samples were diluted (1:1) with 
acetonitrile and stored at -80 °C. Subsequent RP-HPLC analysis was performed with a 
analytical HPLC (1220 Infinity LC System from Agilent) with a reverse phase 
Phenomenex Luna® 3µ C18(2) 100A column (150 × 2.0 mm, 100 Å) at 30°C. HPLC 
conditions were the following: solvent A = water (Millipore)/TFA (0.05% v/v), solvent B = 
MeCN (Merck, gradient grade); flow rate = 0.3 mL/min; injection volume 100 µL, elution 
with a gradient of 10% to 95% MeCN in 30 min. UV-detection at 220 nm. 
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2.4.2.7 Solubility 
A calibration curve for each compound was made, using solutions 1µM-10nM in DMSO 
and using the analytical HPLC (1220 Infinity LC System from Agilent) with a reverse 
phase Phenomenex Luna® 3µ C18(2) 100A column (150 × 2.0 mm, 100 Å) at 30°C. 
HPLC conditions were the following: solvent A = water (Millipore)/TFA (0.05% v/v), 
solvent B = MeCN (Merck, gradient grade); flow rate = 0.3 mL/min; injection volume 0.2 
µL, elution with a gradient of 10% to 95% MeCN in 30 min. UV-detection at 220 nm. Stock 
solutions of the test compounds (70 µM, 3 mM and 10 mM) were used for this assay, 
aliquots at 5, 60 and 120 minutes were taken and processed with the same protocol used 
in the stability assay. The area found in the HPLC chromatogram for each aliquot was 
introduced in the calibration curve equation and compared with the areas found in 
different periods of time. 
2.4.2.8 Chemosensitivity assay 
The assays were performed as described previously8 with slight modifications. Briefly, 
100 mL/well of a tumor cell suspension, yielding a density of 10-20 cells per microscopic 
field (Olympus, CK2, 320x), were seeded into 96-well plates and incubated overnight at 
37 °C and 5% CO2. The next day, 100 mL/well of fresh medium was added containing the 
test compounds in various concentrations or vehicle. In general, test compounds were 
added as 1000-fold concentrated feed solutions (16 wells per drug concentration). On 
every plate, untreated cells (solvent DMSO in a dilution of 1:1000) served as growth 
control (vehicle), cells treated with a reference cytostatic (vinblastine) as a positive 
control. Incubation of the cells was stopped after different periods of time by removal of 
medium and fixation with a solution of 2% glutardialdehyde (in PBS). All plates were 
stored at 4 °C until the end of the experiment and afterwards simultaneously stained with 
100 mL/well of a 0.02% aq crystal violet solution for 20 min. The trays were rinsed with 
H2O for 20 min in order to remove residual dye. Crystal violet bound by the fixed cells was 
extracted with 70% EtOH (180 mL/well) while shaking the microplates for 2-3 h. 
Absorbance (a parameter proportional to cell mass) was measured at 580 nm using the 
GENios Pro microplate reader. 
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3 Synthesis and characterization of ABCG2 
modulators combining chalcone, quinoline 
and isoquinoline moieties
3
 
ABC transporters such as ABCG2 have been associated with the resistance of cancer 
cells to a variety of structurally and functionally non-related anticancer drugs. To date, 
several  ABCG2 modulators including acridone derivatives, chalcones and 
benzochalcones, indoles and quinolines, among others have been reported in the 
literature. However, the efficiency of these modulators varies regarding potency, 
selectivity profile, interaction with the transporter as substrate or inhibitor, toxicity and 
physicochemical properties. Some studies have shown several tariquidar analogs as a 
new class of potent and selective inhibitors of ABCG2, but the structural stability of these 
compounds is seriously affected by enzymatic hydrolysis of the amide bond attached to 
the anthranilic ring in the structure. In search for more stable tariquidar analogues, a new 
series of chalcones combined with quinoline and isoquinoline moieties were investigated, 
fully characterized and tested for their ABCG2 inhibitory activity, ABC transporters 
selectivity and stability against enzymatic hydrolysis. The synthesized chalcones were 
active against ABC transporters and showed preference over ABCG2. Some compounds 
of the series exhibited a maximum inhibition between 85-110% based on fumitremorgin C 
as reference compound (100% inhibition), and have a remarkable chemical stability 
against the enzymatic hydrolysis after incubation for 24 hours at 37°C. 
                                               
 
3 All synthesis, purification and characterization of the compounds were carried out by 
Diana Catherine Peña. Inhibition assays (ABCG2, ABCB1, ABCC1), stability and solubility 
tests were carried out by Diana Catherine Peña at Regensburg University, Germany. Cell 
cultures, reference compounds and chemosensitive assay were provided by Matthias 
Scholler, a doctoral student at Regensburg University. 
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3.1 Introduction 
Natural products such as flavonoids are becoming interesting in anticancer therapy. More 
than 6000 naturally occurring flavonoids have been identified to date.1 Chalcone or (E)-
1,3-diphenyl-2-propene-1-one, the synthetic precursor of flavonoids and isoflavonoids and 
the open chain intermediates in aurones synthesis of flavones,2  is an important 
chemotype that has attracted great research interest for decades due to the high natural 
abundance of chalcone compounds, their easy synthesis, and most importantly, their 
diverse biological activities. Indeed, many natural chalcones demonstrated a wide variety 
of bioactivities, including anti-cancer, anti-inflammatory, anti-diabetic, cancer 
chemopreventive, anti-oxidant, and anti-microbial activities (Figure 3-1).3,4 Effective drug 
development will depend on multidisciplinary collaboration embracing natural product lead 
discovery and optimization through the application of total and diversity oriented 
synthesis.5 
 
Figure 3-1 Structure scaffold of chalcone and bioactivities (adapted from Zhou et.al3) 
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Taking into account the broad spectrum of action of chalcones, we designed and 
synthesized a new series based on that structure. All compounds were fully characterized 
and tested for their ABCG2 inhibitory activity and ABC transporters selectivity, solubility 
and stability against enzymatic hydrolysis. The synthesized chalcones were active against 
ABC transporters and showed a marked preference for ABCG2 inhibition. 
3.2 Results and discussion 
3.2.1 Synthesis. Synthesis of compounds 179a-f is shown in Scheme 3-1 
 
 
Scheme 3-1 Synthesis of compounds 179a-f. Reagents and conditions: (i) Quinaldic 
acid, Ts-Cl, TEA, 50ºC, overnight; (ii) NaOH 30%, rt, 24h; (iii) a) 2-methoxyethyl 4-
methylbenzenesulfonate or 2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate, KOH, THF, N2, 6h; b) DCM, trifluoroacetic acid, rt, overnight;  
(iv) K2CO3, acetonitrile, 90°C, overnight 
The syntheses of compounds 170a-b, 171a-b and tetrahydroisoquinolines 174, 175a-b 
were already explained in chapter 2. Compound 177 was prepared according to known 
procedures,6,7 A Claisen-Schmidt condensation of the ketones 171a-b with the aldehyde 
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177 with NaOH 30% resulted in the desired chalcones 178a-b. Finally, a nucleophilic 
substitution between the tosylated compounds (178a-b) and the respective 
tetrahydroisoquinolines (174, 175a-b) in presence of potassium carbonate and using 
acetonitrile as solvent led the target chalcones (179a-f, Scheme 3-1) in moderate yields 
(54-68%, Scheme 3-1). All synthesized compounds were characterized by nuclear 
magnetic resonance (NMR), infrared spectroscopy (IR), high resolution mass 
spectrometry (HR-MS) and the purity was confirmed by analytical high performance liquid 
chromatography (HPLC). 
3.2.2 Inhibitory activity evaluation 
3.2.2.1 Inhibitory activity evaluation on breast cancer resistance 
protein (ABCG2) 
The synthesized chalcones 179a-f and reference compounds fumitremorgin C (FTC) and 
tariquidar were investigated for inhibition of ABCG2 in a Hoechst 33342 microplate assay 
using ABCG2-overexpressing MCF-7/Topo cells, obtaining inhibitory effects and IC50 
values as summarized in Table 3-1. Concentration response curves of selected 
compounds obtained in the Hoechst 33342 assay are shown in Figure 3-2. 
All chalcones exhibited maximal inhibitory activities between 72-111%, which means that 
they were active against ABCG2 transporter. Compounds bearing a methyl substituent at 
the amino chalcone core (179d-f) were most active in the series with the lowest IC50 
values and they are superior with respect to the maximal inhibitory effect. Compound 
179d was almost equipotent with the reference compound FTC while compounds 179e 
and 179f  were two to four fold less potent. However, the maximal inhibitory effects (86%, 
97% and 111% respectively) were significantly higher to that of tariquidar or even 
surpassing that of FTC (Figure 3-2, compound 179f). 
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Figure 3-2 Concentration dependent inhibition of the ABCG2 transporter in MCF-7/Topo 
cells (Hoechst 33342 assay) by chalcones 179a-f. The inhibition is expressed as % 
relative to the maximal inhibition of ABCG2 by 10 μM of fumitremorgin C (100%) 
 
The addition of ethylene and triethylene glycol chains (R2 in the structure, Scheme 3-1) at 
the tetrahydroisoquinoline moiety in compounds 179a-c did not have a tendency in the 
IC50 values or Imax effect (Table 3-1). On the other hand the maximal inhibitory effect in 
compounds 179d-f increased from 86 until 111% (Table 3-1). 
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Table 3-1 Inhibitory activity evaluation on ABCG2 by reference compound and chalcones 
179a-f  
 
   ABCG2a  
Compound R1 R2 IC50 (µM)
b Imax (%)
c Log Pd 
FTC   0.731 ± 0.092 100  
Tariquidar   0.526 ± 0.085 69 ± 5  
179a H CH3 4.08 ± 0.29 79 ± 4 6.51 
179b H CH2CH2OCH3 2.13 ± 0.47 72 ± 8 6.18 
179c H (CH2CH2O)3CH3 2.83 ± 0.30 81 ± 5 5.46 
179d CH3 CH3 0.88 ± 0.02 86 ± 10 6.97 
179e CH3 CH2CH2OCH3 1.55 ± 0.36 97 ± 3 6.64 
179f CH3 (CH2CH2O)3CH3 2.72 ± 0.54 111 ± 4 5.92 
a
Hoechst 33342 microplate assay using ABCG2-overexpressing MCF-7/Topo cells. 
b
Mean 
values ± SEM from three independent experiments performed in triplicate. 
c
Maximal 
inhibitory effects [%] are expressed as inhibition caused by the highest concentration of the 
compound tested relative to the inhibitory effect caused by 10 μM FTC (100% inhibition). 
d
Calculated values using ACD/Labs I-Lab 2.0 ilab.acdlabs, Algorithm Version: v5.0.0.184  
 
The partition coefficient (Log P) is a measure of differential solubility of a compound in a 
hydrophobic solvent (octanol) and a hydrophilic solvent (water). The logarithm of these 
two values enables compounds to be ranked in terms of hydrophilicity (or 
hydrophobicity).8 As shown in Table 3-1, chalcone 179d has the largest partition 
coefficient (Log P) among all the synthesized compounds and it is the most potent and 
similar to the reference compound in the series.  
Compounds bearing a methyl substituent at the amino chalcone core (179d-f) exhibited a 
higher calculated partition coefficient in comparison to compounds with hydrogen as 
substituent at the amino chalcone core (179a-c, Table 3-1). These differences were 
clearer as follows, compounds 179a and 179d differ in substituent R1 (Scheme 3-1), the 
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maximal inhibition was better for most lipophilic compound (179d, 86%) and also the IC50 
values was more than 5 times less (179a 4.08 µM, 179d 0.88 µM, Table 3-1). Compounds 
with ethylene glycol in position R2 (179b and 179e, Scheme 3-1), differ in the presence of 
the methyl group in R1, compound 179e showed a considerable increase in the maximal 
inhibitory effect (97%) in comparison with compound 179b (72%) and also the IC50 value 
is lower (179b 2.13 µM, 179e 1.55 µM, Table 3-1). Compounds 179c and 179f were the 
most hydrophilic compounds of the series, but between them two compound 179f showed 
the best maximal inhibitory effect of the whole series (Table 3-1), the IC50 is similar in this 
case for both compounds (179c 2.83 µM, 179f 2.72 µM, Table 3-1). 
3.2.2.2 Selectivity evaluation. Inhibitory activity evaluation on 
ABCB1 and ABCC1 
Tariquidar is an anthranilic acid derivative and have been reported as a potent and 
specific inhibitor of ABCB1 (P-gp), therefore, it is commonly used as a reference 
compound for these transporter inhibition assays.9,10 Reversan is a lead compound found 
in a pyrazolopyrimidines librarie as a prominent structural class of potent ABCC1 
modulators, has been demonstrated that this compound increase the toxicity of 
chemotherapeutic drug exposure.11,12,13 
All synthesized compounds were additionally screened for their inhibition of ABCB1 and 
ABCC1 with the calcein accumulation assay, Tariquidar and Reversan were used as 
reference compounds. The screening was conducted at a fixed concentration of 1 and 10 
μM using Kb-V1 cells (ABCB1) and MDCKII (ABCC1) cell lines. Tariquidar (10 μM) was 
used as standard inhibitor for ABCB1 and Reversan (30 μM) for ABCC1. Figure 3-3 
illustrates the effects of the 6 synthesized chalcones on the accumulation of calcein and it 
exemplifies that the studied substances possess low affinity for ABCB1 (Figure 3-3A) and 
ABCC1 (Figure 3-3B).  
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Figure 3-3 Effects of chalcones 179a-f at 1 and 10 μM concentration on the accumulation 
of calcein in ABCB1 (A) and ABCC1 (B) overexpressing Kb-V1 and MDCKII cells 
respectively. Data were normalized by defining the inhibition caused by 10 μM Tariquidar 
and of 30 μM Reversan as 100% and are presented as mean ± SD of two independent 
experiments. 
 
Chalcone 179a showed the lowest affinity at both transporters contrary to compound 179c 
which has the largest inhibitory activity against ABCC1, although the only difference 
between these two compounds is a triethylenglycol chain in the tetrahydrisoquinoline 
fragment. When a methyl group to one side of the molecule was added, compounds 179d 
and 179f showed almost the same inhibitory effect against both transporters. Compounds 
179b and 179e contain an ethylenglycol chain in the tetrahydroisoquinoline moiety and 
showed less affinity for both transporters than the compounds with similar characteristics. 
Concentration-response curves were not generated for the synthesized chalcones since 
none of them showed more than 25% inhibition at 10 μM (Table 3-2). 
Compounds did not show a clear trend based on the substituents (Table 3-2), either the 
presence of methyl in R1 (Scheme 3-1) or methoxy substituents, ethylene or triethylene 
glycol chains in R2 (Scheme 3-1). 
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Table 3-2 Inhibitory activity evaluation on ABCB1 and ABCC1 by reference compounds 
and chalcones 179a-f 
 ABCB1a ABCC1b 
Compound Imax (%)
c Imax (%)
d 
Tariquidar  100 n.de 
Reversan n.de 100 
179a 7 ± 2 8 ± 1 
179b 10 ± 3 10 ± 6 
179c 12 ± 3 24 ± 7 
179d 12 ± 3 18 ± 2 
179e 4 ± 2 14 ± 4 
179f 12 ± 3 16 ± 4 
a
Calcein-AM microplate assay using ABCB1-
overexpressing Kb-V1 cells. 
b
Calcein-AM 
microplate assay using ABCC1-overexpressing 
MDCKII cells.
 c
Maximal inhibitory effect (Imax) 
relative to the response to tariquidar at a 
concentration of 10 μM (100% inhibition). 
d
Maximal inhibitory effect (Imax) relative to the 
response to reversan at a concentration of 30 μM 
(100% inhibition). 
e
n.d.: not determinated 
 
The maximal inhibitory effect values for the chalcones 179a-f over ABCB1 and ABCC1 
were not significant for these transporters, but, according to the data shown in the Table 
3-2, all compounds showed more affinity for ABCC1 than for ABCB1. 
According to the results presented in the Table 3-2 for the ABCB1 and ABCC1 
transporters inhibition, we can conclude that the synthesized chalcones showed 
selectivity for the ABCG2 transporter. 
3.2.3 Chemical stability test in Eagle’s Minimum Essential 
Medium (EMEM) 
In aqueous solutions almost all of the drugs are subject to some form of chemical 
degradation and, frequently, the therapeutic activity is impaired by the drug instability, for 
that reason the stability assay is a prerequisite for in vivo studies. The most common 
44 New Analogs of Tariquidar 
 
 
 
consequence of the drug’s degradation is the loss of potency but in some cases harmful 
degradation products may be formed.14 
The bioisosteric approach and the replacement of the hydrolysis-sensitive amide bond 
bearing the phenethyl tetrahydroisoquinoline fragment (previously reported ABCG2 
modulators, Figure 1-30, compounds 143 and 145), by chalcones moieties resulted in 
stable compounds after incubation in EMEM. As shown in Figure 3-4, synthesized 
chalcones were incubated in EMEM at a temperature of 37°C and aliquots were analyzed 
by HPLC over a period of 24 hours, products of cleavage or degradation of compounds 
were not detected, compounds were not affected by the components present in the 
incubation medium (EMEM) during the assay. 
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Figure 3-4 Chemical stability of compounds 179a-f incubated in EMEM for 24 h (HPLC 
analysis, UV detection at 220 nm). 
3.2.4 Solubility in Eagle’s Minimum Essential Medium (EMEM) 
Solubility, the phenomenon of dissolution of solute in solvent to give a homogenous 
system, is one of the important parameters to achieve desired concentration of drug in 
systemic circulation for desired (anticipated) pharmacological response. The most 
frequent causes of low oral bioavailability are attributed to poor solubility and low 
permeability. Poorly water soluble drugs often require high doses in order to reach 
therapeutic plasma concentrations after oral administration. Low aqueous solubility is the 
major problem encountered with formulation development of new chemical entities as well 
as generic development. Any drug to be absorbed must be present in the form of an 
aqueous solution at the site of absorption. Water is the solvent of choice for liquid 
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pharmaceutical formulations. Most of the drugs are either weakly acidic or weakly basic 
having poor aqueous solubility.8  
The improvement of drug solubility thereby its oral bioavailability remains one of the most 
challenging aspects of drug development process especially for oral-drug delivery system. 
There are numerous approaches available and reported in literature to enhance the 
solubility of poorly water-soluble drugs.15 Solubility improvement techniques can be 
categorized in to physical modification: particle size reduction,16 modification of the crystal 
habit,17 cocrystallization,18 solid dispersions,19 solid solutions and cryogenic techniques; 
chemical modifications: change of pH, use of buffer, derivatization,20 complexation,21 and 
salt formation;22 and miscellaneous methods: supercritical fluid process,23 use of 
adjuvant24 and novel excipients.25 
Compound 143 (Figure 1-30) is a tariquidar analog (Figure 1-30, compound 141), in 
which the quinoline-carboxamide residue was shifted to the meta-position at the 
benzamide core and the two methoxy groups were replaced by a methyl carboxylate, was 
highly selective for ABCG2, but when one of the methoxy groups on the 
tetrahydroisoquinoline moiety was replaced by a triethylenglycol chain the maximal 
response increased to about 90% (Figure 1-30, compound 145), indicating that water 
solubility was limiting the efficacy in this class of compounds. 
The solubility in EMEM for all compounds was evaluated; the results showed that all 
chalcones were soluble. As shown in Figure 3-5, the concentration found for chalcones 
179a-e was very similar in all analyzed aliquots at different times, which means that after 
5 h of incubation we will find the same amount of the compound in the assay, and these 
were not affected by the physiological pH, temperature or the substances present in the 
medium (salts, amino acids or vitamins). Then, inhibition results for the transporters 
corresponded to the entire concentration used in the assay. 
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Figure 3-5 Solubility for chalcones 179a-f in Eagle’s Minimum Essential Medium (EMEM)  
 
3.2.5 Chemosensitivity assay 
Cytotoxicity assays are widely used by the pharmaceutical industry to screen for 
cytotoxicity in compound libraries. Researchers can either look for cytotoxic compounds, if 
they are interested in developing a therapeutic that targets rapidly dividing cancer cells, 
for instance; or they can screen "hits" from initial high-throughput drug screens for 
unwanted cytotoxic effects before investing in their development as a pharmaceutical.26 
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The effect of the most potent modulator (179d) on the proliferation of ABCG2-
overexpressing MCF-7/Topo cells was investigated by means of a kinetic 
chemosensitivity assay,26 using the modulators in combination with topotecan (known 
ABCG2 substrate) and the cytostatic drug vinblastine as a positive control (Figure 3-6). 
The modulator was well tolerated up to a concentration of 1 μM. The combination of 
topotecan at a nontoxic concentration of 100 nM with compound 179d resulted in a strong 
cytotoxic drug effect and thus reversal of ABCG2-mediated drug resistance. 
 
Figure 3-6 Effect of compound 179d in combination with topotecan on proliferating MCF-
7/Topo cells: vehicle (filled black circles, untreated cells), positive control vinblastine [100 
nM] (filled blue squares), 179d at concentrations of 10 μM (filled red triangles), 3 μM 
(filled green diamonds), 1 μM (filled orange stars) and topotecan alone at 100 nM (filled 
purple circles) 
3.3 Conclusion 
In summary, we presented the synthesis and characterization of a series of chalcones 
combining quinoline and isoquinoline moieties as ABCG2 modulators. All tested 
compounds showed a marked preference for ABCG2 inhibition, because the maximal 
inhibitory effect values for the chalcones over ABCB1 and ABCC1 were not significant. 
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Compounds bearing a methyl substituent at the amino chalcone core (179d-f) were most 
active in the series with the lowest IC50 values and were superior with respect to the 
maximal inhibitory effect (86%, 97% and 111% respectively) to that tariquidar or even 
surpassing that of FTC (compound 179f). Compound 179d was almost equipotent with 
the referente compound (FTC) with IC50 value of 0.880 μM in the Hoechst assay and 
maximal inhibitory effect of 86%. The replacement of one methoxy group for glycol chains 
in the tetrahydroisoquinoline moiety increased the water solubility of the compounds and 
efficacy as ABCG2 modulators (Imax 72-111%). The unstable benzamide moiety in 
compound 145 (Figure 1-30) was replaced in a bioisosteric approach with a chalcone 
system as central core structure, the stability tests in EMEM revealed that the chalcones 
were stables to degradation after 24 hours of incubation and solubility tests showed that 
the inhibition results corresponded to the entire concentration used in the assay. 
Additionally, chemosensitivity assay showed that compound 179d had a strong cytotoxic 
drug effect in combination with topotecan (chemotherapeutic agent) and thus reversal of 
ABCG2-mediated drug resistance. 
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3.4 Experimental section 
3.4.1 Synthesis and characterization 
 
4-(2-Hydroxyethoxy)benzaldehyde 
 
4-(2-hydroxyethoxy)benzaldehyde has already been described.6 Colorless oil (1.2 g, yield 
85%, Rf Hex:EA 1:1 0.20), 
1H NMR (CDCl3, 400 MHz): δ= 7.45 (d, 
3J=8.9 Hz, 2H, 
OCH2CH2), 6.64 (d, 
3J=8.7 Hz, 2H, OCH2CH2), 3.79 (t, 
3J=9.0 Hz, 2H, OCH2), 3.73 (t, 
3J=9.3 Hz, 2H, CH2OH). 
13C NMR (CDCl3, 100 MHz): δ= 190.99 (Cquat), 163.72 (Cquat), 
131.80 (Cquat), 130.10 (+), 114.82 (+), 69.55 (-), 61.21 (-). IR [cm
-1]: ν = 3443, 3274, 2873, 
2842, 2747, 1690, 1580, 1427, 1044, 916, 653. 
2-(4-Formylphenoxy)ethyl 4-methylbenzenesulfonate (177)  
 
Compound 177 has already been described.7 Light pink solid (0.700 g, yield 84%, Rf Pen: 
EA 1:1 0.62). mp: 102-104ºC (103-105ºC lit).7 1H NMR (CDCl3, 400 MHz): δ= 7.83 (d, 
3J=2.5 Hz, 2H, ArH), 7.81 (d, 3J=7.0 Hz, 2H, ArH), 7.36 (d, 3J=8.1 Hz, 2H, ArH), 6.91 (d, 
3J=8.7 Hz, 2H, ArH), 4,42  (m, 2H, OCH2), 4,25 (m, 2H, CH2OSO2), 2.46 (s, 3H, CH3).  
13C 
NMR (CDCl3, 100 MHz): δ= 190.6 (Cquat), 162.8 (Cquat), 145.1 (Cquat), 127.9 (Cquat), 128.0 
(Cquat), 129.9 (+), 129.9 (+), 130.4 (+), 131.8 (+), 131.9 (+), 132.8 (+), 114.7 (+), 114.7 (+), 
67.6 (-), 65.6 (-), 21.6 (+). IR (KBr) [cm-1]: ν =3254, 2830, 2750, 1698, 1603, 1508, 1271, 
1015, 915, 665. 
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General procedure for the chalcone formation (178a-b): Chalcones were obtained by 
a Claisen-Schmidt condensation. The ketone 171a-b (1equiv) and aldehyde 177 (1.3 
equiv) were mixed and heated for 2 hours at 80ºC, then the mixture was allowed to reach 
room temperature and at 0ºC and 1 mL of NaOH 30% was added slowly. After 24 h at 
room temperature, ice was added to the mixture; the product was filtered and dried. 
 
 (E)-2-(4-(3-oxo-3-(3-(Quinoline-2-carboxamido)phenyl)prop-1-en-1-yl)phenoxy)ethyl 
4-methylbenzenesulfonate (178a) 
 
Pale yellow solid (0.400 g, yield 72%, Rf Hex:EA 2:1 0.47). 
1H NMR (400 MHz, CDCl3): δ 
8.40 (d, 3J=8.3 Hz, 2H, ArH), 8.23 (t, 3J=9.0 Hz, 2H, ArH), 7.93 (d, 3J=8.2 Hz, 1H, ArH), 
7.84 (m, 5H, ArH), 7.67 (t, 3J=7.5 Hz, 1H, quinol), 7.60 (m, 2H, ArH), 7.55 (s, 1H, ArH), 
7.47 (d, 3J=15.6 Hz, 1H, COCH), 7.35 (d, 3J=8.0 Hz, 2H, tosyl), 6.83 (d, 3J=7.7 Hz, 2H, 
ArH), 4.44 (t, 3J=4.0 Hz, 2H, ArOCH2), 4.37 (t, 
3J=4.1 Hz, 2H, CH2OSO2), 2.45 (s, 3H, CH3 
Tosyl). 13C NMR (100 MHz, CDCl3): δ 190.0 (Cquat), 162.4 (Cquat), 160.0 (+), 158.3 (Cquat) 
154.7 (Cquat), 147.6 (Cquat), 145.0 (+), 143.8 (Cquat), 142.1 (Cquat), 141.6 (Cquat), 139.3 
(Cquat), 138.9 (Cquat), 137.8 (+), 132.9 (+), 131.5 (Cquat), 130.5 (+), 130.3 (+), 129.9 (+), 
129.7 (+), 129.5 (+), 128.3 (+), 127.9 (+), 124.4 (+), 114.9 (+), 67.8 (-), 65.5 (-), 21.6 (+). 
IR (KBr) [cm-1]: ν = 1640, 1710, 730. HRMS (EI-MS) calcd. For C34H29N2O6S [M+H]
 +: 
593.1702; found [M+H] +: 593.1729. 
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(E)-2-(4-(3-(4-Methyl-3-(quinoline-2-carboxamido)phenyl)-3-oxoprop-1-en-1-
yl)phenoxy)ethyl 4-methylbenzenesulfonate (178b) 
 
Yellow solid. (0.600 g, yield 80%, Rf Hex:EA 2:1 0.50). 
1H-NMR (400 MHz, CDCl3): δ 9.00 
(s, 1H, quinol), 8.42 (m, 2H, quinol), 8.18 (d, 3J=8.4 Hz, 1H, ArH), 7.94 (d, 3J=8.2 Hz, 1H, 
quinol), 7.89 (m, 2H, ArH), 7.68 (t, 3J=7.6 Hz, 2H, quinol), 7.60 (d, 3J=8.7 Hz, 2H, ArH), 
7.50 (d, 3J=15.6 Hz, 1H, COCH), 7.35 (d, 3J=8.1 Hz, 2H, tosyl), 6.81 (d, 3J=8.7 Hz, 2H, 
ArH), 4.39 (t, 3J=5.5 Hz, 2H, OCH2CH2), 4.20 (t, 
3J=5.6 Hz, 2H, CH2OSO2), 2.58 (s, 3H, 
CH3 tosyl), 2.45 (s, 3H, CH3).  
13C-NMR (101 MHz, CDCl3): δ 190.6 (Cquat), 162.3 (Cquat), 
146.3 (Cquat), 138.0 (Cquat), 136.2 (Cquat), 133.6 (Cquat), 131.9 (Cquat), 130.7 (Cquat), 130.4 
(Cquat), 129.9 (+), 129.8 (Cquat), 129.6 (Cquat), 129.4 (+), 128.3 (+), 128.0 (+), 127.8 (+), 
127.9 (+), 124.1 (+), 121.6 (+), 118.7 (+), 114.7 (+), 67.6 (-), 65.6 (-), 26.7 (+), 21.6 (+). IR 
(KBr) [cm-1]: ν = 1635, 1693, 735. HRMS (EI-MS) calcd. For C34H29N2O6S [M+H]
+: 
607.1858; found [M+H]+: 607.1906. 
 
General procedure for the preparation of compounds 179a-f: A mixture of 178a-b (1 
mol), 1,2,3,4-tetrahydroisoquinoline 174, 175a-b (1.3 equiv) and K2CO3 (3 equiv) was 
refluxed in CH3CN overnight. The solvent was evaporated, water was added and the 
compound was extracted with DCM, organic layer was separated, dried with Na2SO4, 
filtered and the solvent evaporated to give the crude product. Compounds were purified, 
first, with a flash column chromatography (DCM:MeOH) and second, reverse column 
chromatography and in some cases a preparative HPLC. 
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(E)-N-(3-(3-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-carboxamide (179a) 
 
Yellow solid (0.030 g, yield 54%, Rf DCM:MeOH 20:1 0.42). 
1H-NMR (400 MHz, CDCl3): 
δ 8.38 (m, 3H, quinol), 8.24 (m, 2H, ArH), 7.93 (m, 2H, quinol), 7.80 (m, 2H, ArH), 7.69 
(m, 1H, quinol), 7.52 (d, 3J=15.5 Hz, 1H, CqCOCH), 6.96 (d, 
3J=8.5 Hz, 2H, ArH), 6.65 (s, 
1H, CH THIQ), 6.54 (s, 1H, CH THIQ), 4.53 (s, 2H, CH2 THIQ), 3.87 (s, 3H, OCH3), 3.85 
(s, 3H, OCH3), 3.81 (s, 2H, CH2 THIQ), 3.65 (m, 2H, CH2 THIQ), 3.42 (m, 2H, OCH2CH2), 
2.65 (m, 2H, CH2 THIQ). 
13C-NMR (100 MHz, CDCl3): δ 190.0 (Cquat), 162.5 (Cquat), 159.1 
(Cquat), 149.2 (Cquat), 148.6 (Cquat), 146.3 (Cquat), 144.4 (+), 139.1 (Cquat), 138.3 (Cquat), 
138.0 (Cquat), 130.5 (+), 129.6 (+), 129.0 (+), 128.3 (Cquat), 127.8 (+), 124.3 (+), 123.9 
(Cquat), 122.2 (+), 120.5 (+), 119.5 (+), 118.4 (+), 118.2 (+), 115.0 (+), 109.2 (+), 63.2 (-), 
56.0 (+), 53.0 (-), 49.6 (-), 23.8 (-). IR (KBr) [cm-1]: ν = 3137, 2810, 1642, 1689, 1660, 
1140, 693. HRMS (EI-MS) calcd. For C38H36N3O5 [M+H]
+:614.2610; found [M+H]+: 
614.2657. 
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(E)-N-(3-(3-(4-(2-(6-Methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-carboxamide (179b) 
 
Pale yellow solid. (0.032 g, yield 63%, Rf DCM:MeOH 20:1 0.39). 
1H NMR (400 MHz, 
CDCl3): δ 8.43 (m, 2H, quinol), 8.22 (d, 
3J=8.4 Hz, 2H, ArH), 7.92 (d, 3J=8.5 Hz, 1H, 
quinol), 7.87 (m, 2H, ArH), 7.63 (s, 2H, quinol), 7.55 (d, 3J=15.7 Hz, 1H, COCH), 7.46 (t, 
3J=7.5 Hz, 1H, ArH), 6.96 (s, 1H, CH THIQ), 6.58 (s, 1H, CH THIQ), 4.28 (m, 2H, CH2 
PEG), 4.17 (m, 2H, CH2 THIQ), 4.02 (m, 2H, OCH2CH2), 3.80 (s, 3H, OCH3), 3.73 (m, 2H, 
CH2CH2O), 3.60 (m, 2H, CH2 THIQ), 3.44 (s, 3H, CH2OCH3), 2.86 (m, 2H, CH2 PEG), 
2.44 (d, 3J=3.8 Hz, 2H, CH2 THIQ).
13C NMR (100 MHz, CDCl3): δ 190.1 (Cquat), 162.5 
(Cquat), 159.3 (Cquat), 154.5 (Cquat), 149.3 (Cquat), 146.3 (Cquat), 144.9 (+), 140.0 (Cquat), 
139.3 (Cquat), 138.3 (Cquat), 138.0 (+), 132.0 (+), 130.4 (+), 130.2 (Cquat), 128.3 (+), 128.0 
(+), 124.2 (Cquat), 119.8 (+), 119.4 (+), 118.7 (+), 115.0 (+), 71.0 (-), 68.6 (-), 65.7 (-), 59.1 
(+), 58.9 (+), 55.9 (-), 51.3 (-), 29.7 (+). IR (KBr) [cm-1]: ν = 3185, 2836, 1617, 1676, 
1660, 1260, 710. HRMS (EI-MS) calcd. For C40H40N3O6 [M+H]
 +: 658.2872; found [M+H] +: 
658.2920. 
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(E)-N-(3-(3-(4-(2-(6,7-bis(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)-3,4-
dihydroisoquinolin-2(1H)-yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-
carboxamide (179c) 
 
Pale yellow solid. (0.025 g, yield 58%, Rf DCM:MeOH 20:1 0.35). 
1H NMR (400 MHz, 
CDCl3): δ 8.43 (m, 3H, quinol), 8.27 (m, 1H, ArH), 7.94 (d, 
3J=8.2 Hz, 1H, quinol), 7.84 
(dd, 3J=8.2, 3J=6.9, 3H, ArH), 7.68 (t, 3J=7.2 Hz, 2H, quinol), 7.50 (d, 3J=15.6 Hz, 1H, 
COCH), 6.98 (s,1H, CH THIQ), 6.66 (s,1H, CH THIQ), 4.52 (s, 2H, CH2 THIQ), 4.17 (m, 
2H, CH2 THIQ), 3.94 (m, 2H, CH2 THIQ), 3.87 (s, 3H, OCH3), 3.73 (dd, 
3J=5.8, 3J=3.1 Hz, 
4H, 2CH2 PEG), 3.70 (m, 4H, 2CH2 PEG), 3.55 (dd, 
3J=5.7, 3J=3.5 Hz, 4H, 2CH2 PEG), 
3.36 (m, 2H, CH2OCH3), 3.14 (m, 2H, CH2CH2N). 
13C NMR (100 MHz, CDCl3): δ 190.1 
(Cquat), 162.4 (Cquat), 161.0 (Cquat), 149.3 (Cquat), 148.3 (Cquat), 146.8 (Cquat), 145.0 (+), 
139.3 (Cquat), 138.3 (Cquat), 138.0 (Cquat), 132.0 (+), 130.4 (+), 129.6 (+), 128.3 (Cquat), 
127.8 (+), 126.8 (+), 124.2 (Cquat), 119.4 (+), 118.7 (+), 115.0 (+), 112.5 (+), 111.9 (+), 
71.9 (-), 70.9 (-), 70.3 (-), 69.6 (+), 68.7 (-), 59.0 (+), 56.6 (-), 56.0 (-), 28.5 (-). IR (KBr) 
[cm-1]: ν = 3156, 2891, 1672, 1661, 1646, 1040, 682. HRMS (EI-MS) calcd. For 
C44H48N3O8 [M+H]
+: 746.3397; found [M+H]+: 746.3444. 
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(E)-N-(5-(3-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-carboxamide (179d) 
 
 
Brown yellow solid. (0.042 g, yield 68%, Rf DCM:MeOH 20:1 0.47). 
1H NMR (400 MHz, 
CDCl3): δ 8.99 (s, 2H, quinol), 8.41 (s, 2H, ArH), 8.18 (d, 
3J=8.4 Hz, 1H, ArH), 7.93 (d, 
3J=13.6 Hz, 1H, quinol), 7.83 (m, 1H, ArH), 7.65 (d, 3J=8.7 Hz, 3H, quinol), 7.50 (d, 
3J=15.6 Hz, 1H, COCH), 7.38 (d, 3J=8.0 Hz, 1H, ArH), 6.96 (d, 3J=8.7 Hz, 2H, ArH), 6.61 
(s, 1H, CH THIQ), 6.53 (s, 1H, CH THIQ), 4.31 (s, 2H, CH2 THIQ), 3.85 (s, 3H, OCH3), 
3.84 (s, 3H, OCH3), 3.66 (m, 2H, CH2 THIQ), 3.16 (m, 2H, CH2 THIQ), 2.58 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3): δ 189.9 (Cquat), 162.3 (Cquat), 159.8 (Cquat), 154.6 (Cquat), 
149.6 (Cquat), 146.3 (Cquat), 144.4 (Cquat), 142.4 (Cquat), 138.0 (Cquat), 137.4 (Cquat), 136.1 
(+), 133.3 (+), 130.9 (+), 130.4 (+), 129.8 (+), 129.5 (+), 128.3 (Cquat), 127.8 (Cquat), 126.4 
(Cquat) 124.7 (+), 121.4 (+), 118.7 (+), 115.0 (+), 111.3 (+), 109.4 (+), 68.0 (-), 58.1 (+), 
55.9 (-), 51.0 (-), 27.2 (-), 18.0 (+). IR (KBr) [cm-1]: ν = 3185, 2824, 1583, 1653, 1660, 
1047, 698. HRMS (EI-MS) calcd. For C39H38N3O5 [M+H]
 +: 628.2767; found [M+H] +: 
628.2814. 
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(E)-N-(5-(3-(4-(2-(6,7-bis(2-Methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-carboxamide (179e) 
 
Yellow solid. (0.036 g, yield 57%, Rf DCM:MeOH 20:1 0.45). 
1H NMR (400 MHz, CDCl3): 
δ 8.43 (m, 2H, ArH quinol), 8.21 (m, 2H, ArH), 7.93 (d, 3J=8.1 Hz, 2H, ArH quinol), 7.81 (t, 
3J=7.2 Hz, 4H), 7.71 (m, 2H, ArH quinol), 7.57 (m, 1H, ArH), 7.36 (d, 3J=8.3 Hz, 1H, 
COCH), 6.57 (s, 1H, CH THIQ), 6.56 (s, 1H, CH THIQ), 4.13 (m, 4H, OCH2CH2), 3.80 (s, 
3H, OCH3), 3.76 (t, 
3J=7.0 Hz, 2H, CH2 PEG), 3.74 (d, 
3J=4.9 Hz, 2H, CH2 PEG), 3.61 (m, 
2H, CH2 THIQ), 3.52 (m, 2H, CH2 THIQ), 3.41 (m, 2H, CH2 THIQ), 3.38 (s, 3H, 
CH2OCH3), 2.57 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3): δ 191.5 (Cquat), 163.5 (Cquat), 
149.9 (Cquat), 148.3 (Cquat), 146.8 (Cquat), 144.6 (+), 143.5 (+), 141,5 (Cquat), 138.0 (Cquat), 
130.9 (+) 130.4 (+), 129.7 (+), 128.3 (Cquat), 127.9 (+), 126.9 (Cquat), 126.3 (Cquat), 125.3 
(+), 115.0 (+), 112.4 (+), 111.8 (+), 71.0 (-), 70.6 (-), 68.6 (-), 59.1 (+), 58.9 (-), 57.4 (+), 
55.9 (-), 51.3 (-), 29.7 (-), 28.4 (+). IR (KBr) [cm-1]: ν = 3158, 2823, 1631, 1596, 1632, 
976, 683. HRMS (EI-MS) calcd. For C41H42N3O6 [M+H]
+: 672.3029; found [M+H]+: 
672.3072. 
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(E)-N-(5-(3-(4-(2-(6,7-bis(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)-3,4-
dihydroisoquinolin-2(1H)-yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-
carboxamide (179f) 
 
Yellow solid. (0.023 g, yield 61%, Rf DCM:MeOH 20:1 0.44). 
1H NMR (400 MHz, CDCl3): 
δ 8.41 (m, 2H, ArH quinol), 8.24 (m, 1H, ArH), 8.05 (s, 1H, ArH), 7.93 (d, 3J=8.2 Hz, 2H, 
ArH quinol), 7.82 (t, 3J=9.8 Hz, 1H, ArH), 7.66 (m, 2H, ArH quinol), 7.51 (d, 3J=15.6 Hz, 
1H, COCH), 7.35 (d, 3J=8.1 Hz, 2H, ArH), 6.92 (d, 3J=6.0 Hz, 1H, ArH), 6.57 (s, 1H, CH 
THIQ), 6.55 (s, 1H, CH THIQ), 4.19 (m, 4H, 2CH2 PEG), 3.90 (m, 2H, CH2 THIQ), 3.87 
(m, 2H, CH2 PEG), 3.81 (s, 3H, OCH3), 3.68  (m, 2H, CH2 PEG), 3.55 (d, 
3J=5.0 Hz, 2H, 
CH2 PEG), 3.37 (m, 4H, 2CH2 PEG), 3.09 (t, 
3J=5.9 Hz, 2H, CH2 THIQ), 2.69 (t, 
3J=5.8 
Hz, 2H, CH2 THIQ). 
13C NMR (100 MHz, CDCl3): δ 170.7 (Cquat), 162.3 (Cquat), 154.6 
(Cquat), 153.6 (Cquat), 148.0 (Cquat), 146.4 (Cquat), 139.0 (Cquat), 138.0 (Cquat), 128.2 (Cquat), 
127.9 (Cquat), 127.3 (Cquat), 118.7 (+), 115.0 (+), 112.6 (+), 111.9 (+), 71.9 (-), 70.7 (-), 70.6 
(-), 70.5 (-), 69.6 (+), 68.7 (-), 59.0 (+), 56.0 (-), 43.9 (-), 28.7 (-), 18.0 (+). IR (KBr) [cm-
1]: ν = 3217, 2913, 1702, 1692, 1589, 984, 714. HRMS (EI-MS) calcd. For C45H50N3O8 
[M+H] +: 760.3553; found [M+H] +: 760.3606. 
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3.4.2 Biological investigations 
3.4.2.1 Drugs and Chemicals 
Hoechst 33342 (Invitrogen, Karlsruhe, Germany) was dissolved in sterile water to produce 
a 0.8 mM working solution. Calcein-AM (4 mM in anhydrous DMSO) and pluronic F127 
were obtained from Biotium (Hayward, CA, USA) and diluted to 100 μM. Bovine serum 
albumin (BSA) was purchased from Serva (Heidelberg, Germany). Fumitremorgin C 
(FTC; Merck, Darmstadt, Germany) was also dissolved in DMSO and diluted to a 
concentration of 1 mM. Reversan was purchased from Tocris Bioscience (Bristol, UK) and 
diluted to a 3 mM working solution in DMSO. Topotecan and vinblastine for cell culture 
supplementation were purchased from Sigma (Munich, Germany). Loading buffer 
(calcein-AM assay) was made of 120 mM NaCl, 5 mM KCl, 2 mM MgCl2.6H2O, 1.5 mM 
CaCl2.2H2O, 25 mM HEPES, 10 mM glucose, pH 7.4. PBS (phosphate buffered saline) 
was made of 8.0 g/L NaCl, 1.0 g/L Na2HPO4.2H2O, 0.20 g/L KCl, 0.20 g/L KH2PO4 and 
0.15 g/L NaH2PO4.H2O. The pH value was adjusted to 7.3 - 7.4. A solution of 4% (m/m) 
paraformaldeyde (PFA) in PBS was made by stirring 2 g of PFA per 50 g total solution 
while heating on a magnetic stirrer for approximately 30 min. The test compounds were 
dissolved in DMSO at a concentration of 10 mM if possible, depending on the solubility of 
the compounds. All stock solutions were stored at −20 °C. If not otherwise stated, 
chemicals (p.a. quality) were obtained from Merck (Darmstadt, Germany). Purified water 
(Milli-Q system, Millipore, Eschborn, Germany) was used throughout. 
3.4.2.2 Cell lines and culture conditions 
MCF-7/Topo cells, an ABCG2-overexpressing subclone of MCF-7 cells (ATCC® HTB-
22™, American Type Culture Collection, Manassas, VA), were obtained as described27 
and cultured in water-saturated atmosphere (95% air, 5% CO2) at 37 °C in 75 cm2 culture 
flasks from Nunc (Wiesbaden,Germany) in Eagle’s minimum essential medium (EMEM; 
Sigma, Munich, Germany) containing l-glutamine, 2.2 g/L NaHCO3 and 110 mg/L sodium 
pyruvate supplemented with 10% fetal calf serum (FCS; Biochrom, Berlin, Germany) and 
550 nm topotecan to induce overexpression of the ABCG2 transporter. Human Kb-V1 
cells, an ABCB1-overexpressing subclone of Kb cells (ATCC® CCL-17™), were obtained 
and cultured as described.27 MDCKII-MRP1 cells: MDCKII cells (Madin-Darby Canine 
60 New Analogs of Tariquidar 
 
 
 
Kidney cells, strain II; a dog epithelial cell line; ATCC® CRL-2936™), transfected with 
human ABCC1,28,29 were a kind gift from Prof. Dr. P. Borst from the Netherland Cancer 
Institute (Amsterdam, NL). The cells were cultured in DMEM supplemented with 10% 
FCS, 3.7 g/L NaHCO3 and 110 mg/L sodium pyruvate. Trypsinization was performed at 37 
°C (95% air, 5% CO2) for 20-30 min using 0.1% trypsin / 0.04% EDTA. All cells were 
routinely monitored for mycoplasma contamination by PCR (Venor GeM, Minerva Biolabs, 
Berlin, Germany) and only mycoplasma-negative cultures were used. 
3.4.2.3 Calcein-AM microplate assay for the determination of 
ABCB1 inhibition 
Kb-V1 cells were seeded into flat-bottomed 96-well plates (Greiner, Frickenhausen, 
Germany) at a density of 20,000 cells per well. On the following day, cells were washed 
with loading buffer (120 mM NaCl, 5 mM KCl, 2 mM MgCl2.6H2O, 1.5 mM CaCl2.2H2O, 25 
mM HEPES, 10 mM glucose, pH 7.4) in order to remove unspecific serum esterases. 
Afterwards, cells were incubated with loading suspension (loading buffer, 5 mg/mL BSA, 
1.25 μL/mL pluronic F127 (20% in DMS )) containing 0.5 μM calcein-AM and the test 
compounds at increasing concentrations (10 nM – 100 μM) for 10 min (37 °C / 5% C 2) 
to construct concentration-response curves. Tariquidar served as positive control at a final 
concentration of 1 μM corresponding to 100% 3 inhibition of calcein-AM efflux. 
Subsequently, the loading suspension was discarded and cells were fixed with 4% PFA 
solution in PBS for 30 min. After three washing steps, fixed cells were overlaid with 
loading buffer and relative fluorescence intensities were determined with a GENios Pro 
microplate reader (Tecan Deutschland, Crailsheim, Germany). Measurement mode: 
fluorescence top; excitation filter (calcein-AM): 485/20; emission filter (calcein-AM): 
535/25; number of reads: 10; integration time: 40 μs; lag time: 0 μs; mirror selection: 
Dichroic 3; plate definition file: GRE96ft.pdf; multiple reads per well (Circle): 3x3; time 
between move and flash: 100 ms. On each plate, the optimal gain was calculated by 
determination of the fluorescence intensity in the presence of the reference substance, 
tariquidar. IC50 values were calculated using SIGMA PLOT 11.0 (Systat Software, Erkrath, 
Germany), “Four parameter logistic curve” fitting. Errors were expressed as standard error 
of the mean (SEM). 
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3.4.2.4 Calcein-AM microplate assay for the determination of 
ABCC1 inhibition 
MDCKII cells were seeded into flat-bottomed 96-well plates at a density of about 20,000 
cells/well. On the following day, cells were washed with loading buffer in order to remove 
unspecific serum esterases. Afterwards, cells were incubated with loading suspension 
(loading buffer, 5 mg/mL BSA, 1.25 μL/mL pluronic F127 (20% (m/v) in DMS )) 
containing 0.5 μM calcein-AM and the test compound at increasing concentrations (10 
nM-100 μM) for 60 min (37 °C / 5% C 2). Reversan served as positive control at a final 
concentration of 30 μM corresponding to 100% ABCC1 inhibition. In general, test 
compounds were investigated as triplicates, controls as sextuplicates, respectively. 
Subsequently, the loading suspension was discarded, and the cells were fixed with 4% 
PFA solution for 30 min. After three washing circles (loading buffer), fixed cells were 
overlaid with loading buffer, and relative fluorescence intensities were determined at 
535/25 nm at the GENios Pro microplate reader after excitation at 485/20 nm. The 
following cell quantification procedure was performed by analogy with the H33342 assay. 
The obtained mean fluorescence intensities were related to the controls and plotted 
against the various concentrations of test compounds. TECAN instrument settings: 
Measurement mode: fluorescence top; number of reads: 10; integration time: 40 μs; lag 
time: 0 μs; mirror selection: Dichroic 3 (e.g. Fl.); plate definition file: GRE96ft.pdf; multiple 
reads per well (Circle): 3x3; time between move and flash: 100 ms. 
3.4.2.5 Hoechst 33342 microplate assay for the determination of 
ABCG2 inhibition 
Optimal conditions of the assay were systematically determined as described elsewhere30 
with slight modifications. MCF-7/Topo cells were seeded into 96-well plates at a density of 
20,000 cells/well (total volume: 100 mL) and allowed to attach to the surface of the 
microplates overnight in a water-saturated atmosphere (95% air, 5% CO2) at 37 °C. The 
next day, the culture medium was removed, and the cells were incubated with loading 
suspension (EMEM, supplemented as described above, and 0.8 μM Hoechst 33342) in 
combination with the test compound at increasing concentrations (10 nM-100 μM) for 2 h 
(37 °C, 5% CO2). FTC at a final concentration of 10 μM served as reference compound; 
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under these conditions the response was defined as 100% inhibition of Hoechst 33342 
efflux. The supernatants were drained and the cells were fixed for 30 min under light 
protection using 100 mL per well of a 4% PFA solution. Finally, MCF-7/Topo cells were 
washed with PBS (2x250 mL per well) to remove residual dye. Cells were overlaid with 
PBS (100 mL), and the fluorescence intensities were determined using a GENios Pro 
microplate reader (TECAN Deutschland GmbH, Crailsheim, Germany). Measurement 
mode: fluorescence top; excitation filter: 340/35 nm; emission filter: 485/20 nm; number of 
reads: 10; integration time: 40 ms; lag time: 0 ms; mirror selection: automatic; plate 
definition file: GRE96ft.pdf; multiple reads per well (circle, 3x3); time between move and 
flash: 50 ms. On each plate, the optimal gain was calculated by determination of the 
fluorescence intensity in the presence of the reference compound FTC. IC50 values were 
calculated using SIGMA PL T 11.0, “four parameter logistic curve” fitting. Errors are 
expressed as standard error of the mean (SEM). 
3.4.2.6 Chemical Stability in Eagle’s minimum essential medium 
(EMEM) 
Stock solutions of the test compounds (3 mM) were prepared in DMSO. A 1:50 dilution of 
the substances in EMEM was prepared in 1.5-mL polypropylene reaction vessels 
(Eppendorf, Hamburg, Germany). The samples were shortly vortexed and incubated at 37 
°C. At different periods of time, aliquots were taken, and the samples were mixing with 
two parts of ice-cold acetonitrile. For quantitative precipitation, the samples were vortexed 
and stored at 4 °C for 30 min. Finally, samples were centrifuged for 5 min at 14,000 g, 
using an Eppendorf MiniSpin plus centrifuge, and the supernatants were transferred into 
new reaction vessels. Prior to HPLC analysis, the samples were diluted (1:1) with 
acetonitrile and stored at -80 °C. Subsequent RP-HPLC analysis was performed with a 
analytical HPLC (1220 Infinity LC System from Agilent) with a reverse phase 
Phenomenex Luna® 3µ C18(2) 100A column (150 × 2.0 mm, 100 Å) at 30°C. HPLC 
conditions were the following: solvent A = water (Millipore)/TFA (0.05% v/v), solvent B = 
MeCN (Merck, gradient grade); flow rate = 0.3 mL/min; injection volume 100 µL, elution 
with a gradient of 10% to 95% MeCN in 30 min. UV-detection at 220 nm. 
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3.4.2.7 Solubility tests 
A calibration curve for each compound was made using five concentrations solutions 
(1µM-10nM in DMSO) in the analytical HPLC (1220 Infinity LC System from Agilent) with 
a reverse phase Phenomenex Luna® 3µ C18(2) 100A column (150 × 2.0 mm, 100 Å) at 
30°C. HPLC conditions were the following: solvent A = water (Millipore)/TFA (0.05% v/v), 
solvent B = MeCN (Merck, gradient grade); flow rate = 0.3 mL/min; injection volume 0.2 
µL, elution with a gradient of 10% to 95% MeCN in 30 min. UV-detection at 220 nm. Stock 
solution of the test compounds (3 mM) for the stability assay was used for the 
measumerement of the solubility also the results for this solution. The area found in the 
HPLC chromatogram for each aliquot was introduced in the calibration curve equation 
and compared with the areas found in different periods of time. 
3.4.2.8 Chemosensitivity assay 
The assays were performed as described previously26 with slight modifications. Briefly, 
100 mL/well of a tumor cell suspension, yielding a density of 10-20 cells per microscopic 
field (Olympus, CK2, 320x), were seeded into 96-well plates and incubated overnight at 
37 °C and 5% CO2. The next day, 100 mL/well of fresh medium was added containing the 
test compounds in various concentrations or vehicle. In general, test compounds were 
added as 1000-fold concentrated feed solutions (16 wells per drug concentration). On 
every plate, untreated cells (solvent DMSO in a dilution of 1:1000) served as growth 
control (vehicle), cells treated with a reference cytostatic (vinblastine) as a positive 
control. Incubation of the cells was stopped after different periods of time by removal of 
medium and fixation with a solution of 2% glutardialdehyde (in PBS). All plates were 
stored at 4 °C until the end of the experiment and afterwards simultaneously stained with 
100 mL/well of a 0.02% aq crystal violet solution for 20 min. The trays were rinsed with 
H2O for 20 min in order to remove residual dye. Crystal violet bound by the fixed cells was 
extracted with 70% EtOH (180 mL/well) while shaking the microplates for 2-3 h. 
Absorbance (a parameter proportional to cell mass) was measured at 580 nm using the 
GENios Pro microplate reader. 
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4 Resumen 
El primer capítulo describe los moduladores específicos de la ABCG2 reportados hasta la 
fecha, La visión global puede facilitar el diseño racional de nuevos moduladores potentes 
y seguros. La proteína de resistencia al cáncer de mama (BCRP, ABCG2) es un miembro 
de la superfamilia de transportadores ATP-binding cassette (ABC) y fue descubierta 
recientemente. En la fisiología normal actúa como herramienta de desintoxicación en las 
barreras de los tejidos, pero en las células tumorales ABCG2 media la resistencia contra 
los fármacos citotóxicos estructuralmente no relacionados, resultando en resistencia a 
múltiples fármacos (MDR) y una quimioterapia ineficaz. La inhibición selectiva de ABCG2 
podría ser una estrategia atractiva para eludir la resistencia a múltiples fármacos en el 
tratamiento contra el cáncer.  
 
El segundo capítulo describe el diseño, síntesis y evaluación de la actividad inhibitoria de 
nuevas cetonas sobre la proteína de resistencia al cáncer de seno (ABCG2). La síntesis 
se lleva a cabo primero formando el enlace amida entre las acetofenonas y el ácido 
quináldico en presencia de trietilamina y cloruro de p-toluensulfonilo, seguido por una 
bromación en el carbono α a la cetona utilizando N-bromosuccinimida. El último paso es 
entonces una sustitución nucleofílica entre las tetrahidroisoquinolinas previamente 
sintetizadas y las cetonas bromadas para obtener el compuesto final. Esta serie fue 
activa sobre los transportadores ABC, especialmente sobre la ABCG2. El Compuesto 
10c  fue comparable en potencia con la Fumitremorgina C y los compuestos 10e y 10f 
tuvieron los mayores efectos inhibitorios. Las cetonas sintetizadas fueron estables en 
EMEM después de 24 horas de incubación. 
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En el tercer capítulo se reporta la síntesis de una nueva serie de chalconas derivadas del 
tariquidar como moduladores de la proteína de resistencia al cáncer de seno (ABCG2). 
Compuestos reportados recientemente, como el UR-ME22-1 y el UR-COP78 fueron 
identificados como moduladores de la ABCG2 potentes y selectivos, pero bajo 
condiciones fisiológicas son hidrolizados por enzimas en el núcleo central. Para sustituir 
este fragmento lábil, se propone un reemplazo bioisostérico por una chalcona. La 
molécula final fue dividida en cuatro fragmentos para una fácil síntesis. El primer paso es 
obtener el enlace amida entre las aminoacetofenonas y el ácido quinaldico, adicionar las 
cadenas de etilen y trietilenglicol para mejorar la hidrofilicidad de los compuestos en las 
tetrahidroisoquinolinas y por último una condensación de Claisen-Schmidt. La chalcona 
8d fue la más potente de la serie con un potencial desarrollo futuro como modulador 
clínico de ABCG2. 
 
 
 
  
 
5 Appendix: Chapter 2 
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a. Reagents and devices 
Reagents and solvents 
Reagents Commercial reagents were used as provided. Solvents were used in per 
analysis grade for reaction mixtures and industrial grade for chromatography. 
Devices 
Automated Flash chromatography  
Purification by column chromatography was performed with a Biotage® Isolera™ Spektra 
One device. Silica gel 60 M (40-63 µM, Merck) for flash column chromatography was 
used. 
Thin layer chromatography 
Analytical TLC on silica gel coated alumina plates (MN TLC sheets ALUGRAM® Xtra SIL 
G/UV254) was used for monitoring reaction progress and product visualization was 
conducted with UV-light (254 and 366 nm), and staining with potassium permanganate or 
Ehrlich’s reagent.3 
Nuclear magnetic resonance spectroscopy 
NMR spectra were recorded at room temperature on a Bruker Avance 9.4 Tesla (1H: 400 
MHz, 13C: 101 MHz) spectrometer with a Nanobay console and a BBFOPlus broadband 
ATMA probe or a Bruker Avance 600 (1H: 600.1 MHz, 13C: 150 MHz) instrument. The 
chemical shifts were reported in δ [ppm] relative to tetramethylsilane as external standard 
according to IUPAC recommendations. The relative number of protons was determined 
by integration. Coupling constants J were reported in Hertz [Hz]. Abbreviations for the 
characterization of the signals: s=singlet, d=doublet, t=triplet, m=multiplet, dd=doublet of 
doublets, q=quartet. 
Mass spectrometry 
High resolution mass spectra were recorded with an Agilent Tech 6540 UHD Accurate 
Mass Q-TOF LC/MS spectrometer. 
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Infrared spectroscopy 
IR-spectra were recorded with a spectrometer FTIR Nicolete iS 10 (Thermo Fisher 
Scientific). Scans of 50 readings were performed by spectrum; the data were recorded in 
units of transmitance. The accessory ATR (PIKE) was used with a diamond crystal and an 
incidence angle of 45 °; samples were analyzed with the software IRsolution. 
Reversed phase high-performance liquid cromatography 
Purification with preparative HPLC was performed on a system from Knauer (Berlin, 
Germany; 2x K-1800 pump, K-2001 detector @280 nm). Column: Nucleodur 100-5 C18 
ec (250 × 21 mm, 5 µm, Macherey-Nagel, Düren, Germany). Solvents: millipore water 
(with 0.1 % (v/v) TFA) / acetonitrile (gradient grade). Flowrate: 15 mL/min at 26 °C. The 
products were collected manually, the acetonitrile was removed from the eluate under 
reduced pressure, and lyophilization furnished the corresponding TFA salts. 
Analytical high-performance liquid cromatography 
The purity of all final compounds (dissolved in DMSO) was determined by integration of 
the UV signal at 220 nm wavelength of an analytical HPLC (1220 Infinity LC System from 
Agilent) with a reverse phase Phenomenex Luna® 3µ C18(2) 100A column (150 × 2.0 
mm, 100 Å) thermostatted at 40 °C. HPLC conditions were the following: solvent A = 
water (Millipore)/TFA (0.05% v/v), solvent B = MeCN (Merck, gradient grade); flow rate = 
0.3 mL/min; injection volume 0.1 µL, elution with a gradient of 10% to 95% MeCN in 30 
min. 
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a. Synthetic pathways 
N-(3-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)phenyl)quinoline-2-
carboxamide (176a) 
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N-(3-(2-(6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176b) 
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N-(3-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176c) 
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N-(5-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-2-
methylphenyl)quinoline-2-carboxamide (176d) 
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N-(3-(2-(6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176e) 
 
Appendix 77 
 
 
N-(5-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-
2(1H)-yl)acetyl)-2-methylphenyl)quinoline-2-carboxamide (176f) 
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b. NMR spectra 
N-(3-(2-bromoacetyl)phenyl)quinoline-2-carboxamide (172a) 
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N-(5-(2-bromoacetyl)-2-methylphenyl)quinoline-2-carboxamide (172b) 
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N-(3-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)phenyl)quinoline-2-
carboxamide (176a) 
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N-(3-(2-(6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176b) 
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N-(3-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176c) 
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N-(5-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)-2-
methylphenyl)quinoline-2-carboxamide (176d) 
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N-(3-(2-(6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)phenyl)quinoline-2-carboxamide (176e) 
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N-(5-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)acetyl)-2-methylphenyl)quinoline-2-carboxamide (176f) 
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c. HPLC Analysis 
Table 5-1 Purities of key compounds 
 
Compound Purity (%) Retention time (min) 
176a 95 14.069 
176b 97 13.932 
176c 95 13.885 
176d 95 15.142 
176e 97 15.004 
176f 95 14.953 
 
 
Compound 176a in DMSO, 0.1 μL injected; Detector: 220 nm 
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Compound 176b in DMSO, 0.1 μL injected; Detector: 220 nm 
 
 
Compound 176c in DMSO, 0.1 μL injected; Detector: 220 nm 
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Compound 176d in DMSO, 0.1 μL injected; Detector: 220 nm 
 
 
 
Compound 176e in DMSO, 0.1 μL injected; Detector: 220 nm 
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Compound 176f in DMSO, 0.1 μL injected; Detector: 220 nm 
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6 Appendix: Chapter 3 
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b. Synthetic pathways 
(E)-N-(3-(3-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-carboxamide (179a) 
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(E)-N-(3-(3-(4-(2-(6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-carboxamide (179b) 
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 (E)-N-(3-(3-(4-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-
dihydroisoquinolin-2(1H)-yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-
carboxamide (179c) 
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(E)-N-(5-(3-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-carboxamide (179d) 
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(E)-N-(5-(3-(4-(2-(6,7-bis(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-carboxamide (179e) 
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(E)-N-(5-(3-(4-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-
dihydroisoquinolin-2(1H)-yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-
carboxamide (179f) 
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c. NMR spectra 
N-(3-acetylphenyl)quinoline-2-carboxamide (171a) 
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N-(5-acetyl-2-methylphenyl)quinoline-2-carboxamide (171b) 
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6-methoxy-7-(2-methoxyethoxy)-1,2,3,4-tetrahydroisoquinoline 2,2,2- 
Trifluoroacetate (175a) 
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(E)-2-(4-(3-oxo-3-(3-(quinoline-2-carboxamido)phenyl)prop-1-en-1-yl)phenoxy)ethyl 
4-methylbenzenesulfonate (178a) 
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(E)-2-(4-(3-(4-methyl-3-(quinoline-2-carboxamido)phenyl)-3-oxoprop-1-en-1-
yl)phenoxy)ethyl 4-methylbenzenesulfonate (178b) 
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(E)-N-(3-(3-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-carboxamide (179a) 
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(E)-N-(3-(3-(4-(2-(6-methoxy-7-(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-carboxamide (179b) 
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(E)-N-(3-(3-(4-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-
dihydroisoquinolin-2(1H)-yl)ethoxy)phenyl)acryloyl)phenyl)quinoline-2-
carboxamide (179c) 
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(E)-N-(5-(3-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-carboxamide (179d) 
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(E)-N-(5-(3-(4-(2-(6,7-bis(2-methoxyethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-carboxamide (179e) 
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(E)-N-(5-(3-(4-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-
dihydroisoquinolin-2(1H)-yl)ethoxy)phenyl)acryloyl)-2-methylphenyl)quinoline-2-
carboxamide (179f) 
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d. HPLC Analysis 
 
Table 6-1 Purities of key compounds 
Compound Purity (%) Retention time (min) 
179a 96 16.698 
179b 96 16.816 
179c 97 16.781 
179d 95 17.733 
179e 96 17.425 
179f 95 17.370 
 
 
Compound 179a in DMSO, 0.1 μL injected; Detector: 220 nm 
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Compound 179b in DMSO, 0.1 μL injected; Detector: 220 nm 
 
 
 
 
Compound 179c in DMSO, 0.1 μL injected; Detector: 220 nm 
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Compound 179d in DMSO, 0.1 μL injected; Detector: 220 nm 
 
 
 
Compound 179e in DMSO, 0.1 μL injected; Detector: 220 nm 
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Compound 179f in DMSO, 0.1 μL injected; Detector: 220 nm 
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